| Date | Title | | | 02/14/13 | OraQuick(R) In-Home HIV Test Named a "Top Health Breakthrough of 2012" by Men's Health Magazine| BETHLEHEM, Pa., Feb. 14, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that the Company's OraQuick® In-Home HIV Test, the first ever in-home rapid infectious disease test made available directly to consumers, has been named a "Top Health Breakthrough of 2012" by Men's Health magazine. The OraQuick® In-Home HIV Test was listed as the #1 breakthrough on this list for 2012.
The OraQuick® In-Home HIV Test, approved... |
|  | | 02/06/13 | OraSure Announces Full-Year and Fourth Quarter 2012 Financial Results| BETHLEHEM, Pa., Feb. 6, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the full-year and fourth quarter of 2012.
Quarterly Highlights
Consolidated net revenues were $87.8 million for the full-year 2012, a 7% increase from the comparable period of 2011. Net revenues for the current period included $14.3 million from the Company's molecular collection systems subsidiary... |
| | | 02/06/13 | Photo Release -- OraSure Joins Interactive One's HelloBeautiful.com to Promote HIV Testing at a Private Concert and Conversation With Alicia Keys Beginning on February 7th| OraQuick(R) In-Home HIV Test is Exclusive Sponsor of Hello Beautiful Interludes: A Concert and Conversation With Alicia Keys to Air During February in Recognition of National Black HIV/AIDS Awareness Day
BETHLEHEM, Pa., Feb. 6, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that in support of National Black HIV/AIDS Awareness Day (NBHAAD) on February 7th, the Company has joined together with Interactive One and Rad... |
| | | 02/06/13 | DNA Genotek Inc. Announces $10,000 GenoFIND™ Genomic Services Award | | | 01/16/13 | OraSure Technologies Earnings Conference Call Invitation| 2012 Fourth Quarter Earnings Conference Call Wednesday, February 6, 2013, 5:00 p.m. ET
BETHLEHEM, Pa., Jan. 16, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2012 fourth quarter and full year financial results and certain 2013 financial guidance for 5:00 pm ET (2:00 pm PT) Wednesday, February 6, 2013. An update on certain business developments will also be provided.
February 6, 2013 Schedule
... |
| | | 11/28/12 | OraSure Technologies Appoints Senior Vice President and General Manager of Consumer Products Business| Company to Launch National Television Advertising Campaign for OraQuick(R) In-Home HIV Test on World AIDS Day, December 1st
BETHLEHEM, Pa., Nov. 28, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it has appointed Kathleen G. Weber as the Company's Senior Vice President and General Manager, Consumer Products. Her appointment is the culmination of an extensive national search which began this past July following... |
| | | 11/21/12 | OraSure Technologies Praises New Routine HIV Screening Recommendations by U.S. Preventive Services Task Force| New Recommendations Advocate HIV Screening as Part of Routine Medical Care for All People Ages 15 to 65
BETHLEHEM, Pa., Nov. 21, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today its support for the draft recommendations issued yesterday by the U.S. Preventive Services Task Force (USPSTF), calling for routine HIV testing for all people ages 15 to 65.
The new recommendations, entitled Screening for HIV: , are a significant expansion of the USPSTF's previous recom... |
| | | 11/07/12 | OraSure Announces 2012 Third Quarter Financial Results| BETHLEHEM, Pa., Nov. 7, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the third quarter and nine months ended September 30, 2012.
Quarterly Highlights
Consolidated revenues were $22.1 million for the third quarter of 2012, a 2% increase from the comparable quarter of 2011. Revenues for the current quarter included $3.3 million from the Company's molecular collection ... |
| | | 11/07/12 | DNA Genotek Inc. Launches GenoFIND(TM) Genomic Services | | | 11/07/12 | OraSure Technologies to Present at the Stephens, Inc. Fall Investment Conference| BETHLEHEM, Pa., Nov. 7, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Stephens Fall Investment Conference in New York City. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak November 14, 2012, at approximately 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time). Interested investors can access the audio webcast of the pres... |
| | | 11/05/12 | OraQuick(R) In-Home HIV Test Named a "Best Invention of 2012" by TIME Magazine| First and Only In-Home Rapid Oral HIV Test Recognized as a Top Innovation of the Year
BETHLEHEM, Pa., Nov. 5, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the company's OraQuick, the first ever in-home rapid infectious disease test made available directly to consumers, has been named one of the "Best Inventions of 2012" by TIME. The OraQuick® In-Home HIV Test is the only health innovation included on this prestigious list for 2012.
"With just a swab of sali... |
| | | 10/25/12 | OraSure Technologies Earnings Conference Call Invitation| 2012 Third Quarter Earnings Conference Call
Wednesday, November 7, 2012, 5:00 p.m. ET
BETHLEHEM, Pa., Oct. 25, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2012 third quarter financial results and certain 2012 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, November 7, 2012. An update on certain business developments will also be provided.
November 7, 2012 Schedule
4:00 p.... |
| | | 10/15/12 | OraSure Technologies Joins With Actress/Model Dayana Mendoza and the Latino Commission on AIDS to Promote the OraQuick(R) In-Home HIV Test for National Latino AIDS Awareness Day| OraQuick® In-Home HIV Test Now Available in Retail Stores Nationwide
Press Conference at New York City Hall Monday, October 15 @ 10:00 AM
BETHLEHEM, Pa., Oct. 15, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that it will join with actress/model and former Miss Universe Dayana Mendoza and the Latino Commission on AIDS to promote the OraQuick® In-Home HIV test and the importance of knowing your HIV status for National Latino AIDS Awareness Day, taking place ... |
| | | 10/09/12 | First and Only In-Home Rapid Oral HIV Test Now Available to Consumers Across the U.S.|
A Major Breakthrough in the Fight Against HIV – the OraQuick® In-Home HIV Test Now Can Be Purchased at Retailers Nationwide and Online
BETHLEHEM, Pa., Oct. 9, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the availability of the OraQuick® In-Home HIV Test at retailers nationwide and online, making it the first rapid infectious disease test ever to be made available directly to consumers for in-home use. To mark the launch, the Company is collaborating w... |
| | | 09/11/12 | OraSure Technologies to Participate at the UBS Global Life Sciences Conference| BETHLEHEM, Pa., Sept. 11, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the UBS Global Life Sciences Conference in New York City. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak September 19, 2012, at approximately 9:30 am Eastern Time (6:30 am Pacific Time). Interested investors can access the live webca... |
| | | 09/05/12 | OraSure Technologies to Present at ThinkEquity's Ninth Annual Growth Conference| BETHLEHEM, Pa., Sept. 5, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at ThinkEquity's Ninth Annual Growth Conference in New York City. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak September 12, 2012, at approximately 2:00 pm Eastern Time (11:00 am Pacific Time). Interested investors can access the live webcast of the pr... |
| | | 08/22/12 | OraSure Technologies Announces 2013 Annual Meeting Date| BETHLEHEM, Pa., Aug. 22, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2013 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 14, 2013. Further details regarding the meeting will be provided at a later date.
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critica... |
| | | 08/16/12 | OraSure Technologies Applauds New CDC Recommendations That All Baby Boomers be Tested for Hepatitis C| Rapid HCV Testing Expected to Play Critical Role in Implementation of Recommendations
BETHLEHEM, Pa., Aug. 16, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its enthusiastic support for the expanded hepatitis C testing recommendations issued by the Centers for Disease Control and Prevention (CDC), urging that all U.S. baby boomers get a one-time test for the hepatitis C virus (HCV).
Recommendations for the Identi... |
| | | 08/08/12 | OraSure Technologies to Present at Canaccord|Genuity's 32nd Annual Growth Conference| BETHLEHEM, Pa., Aug. 8, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Canaccord|Genuity's 32nd Annual Growth Conference in Boston, MA. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak August 15, 2012, at approximately 11:30 am Eastern Time (8:30 am Pacific Time). Interested investors can access the live webcast of the pres... |
| | | 08/07/12 | OraSure Announces 2012 Second Quarter Financial Results| BETHLEHEM, Pa., Aug. 7, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the second quarter and six months ended June 30, 2012.
Financial Highlights
Consolidated revenues were $22.6 million for the second quarter of 2012, a 19% increase from the comparable quarter of 2011. Revenues for the current quarter included $3.3 million in revenues from the Company's molecular di... |
| | | 08/02/12 | DNA Genotek Inc. and BioServe Biotechnologies, Ltd. to Support Genetic Study of Craniofacial Anomalies in Ethiopia| OTTAWA, ON, August 2, 2012. DNA Genotek, a subsidiary of OraSure Technologies Inc. and a leading provider of products for biological sample collection, and BioServe Biotechnologies, Ltd today announced that they are jointly providing support for a new genomic study into craniofacial anomalies (cleft lip and palate) in Ethiopia. The project, titled "Collaborative study on gene- environment interaction in craniofacial anomalies", will investigate the genetic and environmental causes of craniofacia... |
| | | 07/26/12 | OraSure Technologies Supports Rapid HCV Testing Initiatives for World Hepatitis Day| BETHLEHEM, Pa., July 26, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its support of numerous rapid hepatitis C (HCV) testing initiatives for World Hepatitis Day, taking place on July 28, 2012. These testing initiatives will occur in various cities in the U.S., including Chicago, New York, and Washington, D.C., and in several foreign countries, to help encourage thousands of people to get tested for hepatitis C. O... |
| | | 07/25/12 | OraSure Technologies Earnings Conference Call Invitation| 2012 Second Quarter Earnings Conference Call
Tuesday, August 7, 2012, 5:00 p.m. ET
BETHLEHEM, Pa., July 25, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2012 second quarter financial results and certain 2012 financial guidance for 5:00 pm ET (2:00 pm PT) on Tuesday, August 7, 2012. An update on certain business developments will also be provided.
August 7, 2012 Schedule
4:00 p.m. ET
2... |
| | | 07/16/12 | OraSure Technologies, Inc. Announces Closing of Underwritten Offering of Common Stock| BETHLEHEM, Pa., July 16, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the closing of its previously announced public offering of common stock. As a result, the Company issued a total of 6,100,000 shares in the offering at a price of $12.30 per share.
After the underwriting discounts and estimated offering expenses, OraSure received net proceeds of approximately $70.2 million. Citigroup and Jefferies served as joint book-running managers and Canaccord Genuity... |
| | | 07/10/12 | OraSure Technologies, Inc. Prices Underwritten Offering of Common Stock| BETHLEHEM, Pa., July 10, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the pricing of an underwritten offering of 6,100,000 shares of its common stock at a price of $12.30 per share. After the underwriting discount and estimated offering expenses, OraSure expects to receive net proceeds of approximately $70.2 million. In addition, OraSure has granted the underwriters a 30-day option to purchase up to an additional 915,000 shares of its common stock. The offeri... |
| | | 07/09/12 | OraSure Technologies, Inc. Announces Proposed Public Offering of Common Stock| BETHLEHEM, Pa., July 9, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced it has commenced an underwritten public offering of its common stock in an amount of up to $75.0 million. Citigroup and Jefferies are acting as joint book-running managers. Canaccord Genuity, Stephens Inc., ThinkEquity LLC and JMP Securities are acting as co-managers. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common sto... |
| | | 07/09/12 | OraSure Technologies to Present at the Seventh Annual JMP Securities Healthcare Conference| BETHLEHEM, Pa., July 9, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Seventh Annual JMP Securities Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak July 13, 2012, at approximately 9:00 am Eastern Time (6:00 am Pacific Time). Interested investors can access the live webcast of the p... |
| | | 07/03/12 | OraSure Technologies Conference Call Invitation| BETHLEHEM, Pa., July 3, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that it will hold a conference call covering the recent U.S. Food and Drug Administration approval of the OraQuick® In-Home HIV Test and the Company's plans to commercialize this product, at 8:00 am ET (5:00 am PT) on Thursday, July 5, 2012. To participate in the conference call, dial 877-348-9357 (Domestic) or 970-315-0488 (International) and reference Conference ID #98134091.
The confe... |
| | | 07/03/12 | OraSure Receives FDA Approval of OraQuick(R) In-Home HIV Test| First and Only Rapid HIV Test for Over the Counter Use --- To be Available in October for Purchase Online and at Retail Stores Nationwide
BETHLEHEM, Pa., July 3, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's OraQuick® In-Home HIV Test for sale directly to consumers in the over-the-counter (OTC) market – making it the first and only rapid OTC HIV test approved in the U.S. The OraQuick®... |
| | | 06/27/12 | OraSure Supports Rapid HIV Testing Initiatives in Recognition of 18th Annual National HIV Testing Day| Company Joins Public Health Departments, Community-Based Organizations and Hospitals to Encourage People to Get Tested for HIV
BETHLEHEM, Pa., June 27, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its support of various rapid HIV testing initiatives in recognition of National HIV Testing Day, held each year on June 27th. National HIV Testing Day was founded by the National Association of People with AIDS (NAPWA) ... |
| | | 06/01/12 | DNA Genotek’s Oragene®DNA kit chosen by ScotlandsDNA for ancestry testing | | | 05/29/12 | OraSure Technologies to Present at Jefferies 2012 Global Healthcare Conference| BETHLEHEM, Pa., May 29, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Jefferies 2012 Global Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak June 4, 2012, at approximately 8:00 am Eastern Time (5:00 am Pacific Time). Interested investors can access the live webcast of the presentatio... |
| | | 05/18/12 | OraSure Technologies Applauds CDC Proposed Draft Guidelines for Testing of Baby Boomers for Hepatitis C| Draft Recommendations Call for HCV Testing of All Persons Born Between 1945 and 1965
BETHLEHEM, Pa., May 18, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today issued a statement in strong support of the Center for Disease Control and Prevention (CDC) draft guidelines proposing that all U.S. baby boomers get a one-time test for the hepatitis C virus (HCV). The CDC issued a press release (http://www.cdc.gov/nchhstp/newsroom/HepTestingRecsPressRelease2012.html) earlier today ... |
| | | 05/18/12 | OraSure Technologies Announces Rapid HCV Testing Initiatives for First National Hepatitis Testing Day| OraQuick(R) HCV Tests to be Deployed in New York City Department of Health "Check Hep C NYC" Campaign
BETHLEHEM, Pa., May 18, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced its support of numerous rapid hepatitis C (HCV) testing initiatives for the first National Hepatitis Testing Day, taking place on May 19, 2012. These testing initiatives, happening in more than 20 cities across the country, will help encourage thousands of people across the U.S. to get test... |
| | | 05/15/12 | OraQuick(R) In-Home HIV Test Receives Unanimous Positive Recommendation From FDA Advisory Committee| BETHLEHEM, Pa., May 15, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that the U.S. Food and Drug Administration (FDA) Blood Products Advisory Committee (BPAC) provided a unanimous positive recommendation for the Company's OraQuick® In-Home HIV Test. The BPAC provides advice to the FDA on issues related to the safety and effectiveness of biological products and medical devices seeking FDA approval.
The BPAC voted on two questions posed by FDA:
Do the proje... |
| | | 05/08/12 | OraSure Technologies to Webcast Annual Meeting of Stockholders| BETHLEHEM, Pa., May 8, 2012 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced that it will webcast its 2012 Annual Meeting of Stockholders beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) on Tuesday, May 15, 2012.
In order to access the webcast, interested parties should go to OraSure Technologies' web site, www.orasure.com, and click on the Investor Info link at least ten minutes prior to the start of the... |
| | | 05/03/12 | DNA Genotek Inc. Announces Recipients of the DNA Genotek Grant Program | | | 05/02/12 | OraSure Announces 2012 First Quarter Financial Results| BETHLEHEM, Pa., May 2, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the first quarter of 2012.
Financial Highlights
Consolidated revenues were $20.9 million for the first quarter of 2012, a 20% increase from the comparable quarter of 2011. Revenues for the current quarter included $3.3 million in revenues from the Company's molecular diagnostic collection subsidiary, DNA Geno... |
| | | 04/30/12 | OraSure Technologies to Present at Deutsche Bank's 37th Annual Health Care Conference| BETHLEHEM, Pa., April 30, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Deutsche Bank's 37th Annual Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak May 7, 2012, at approximately 8:40am Eastern Time (5:40 am Pacific Time). Interested investors can access the live webcast of the... |
| | | 04/18/12 | OraSure Technologies Earnings Conference Call Invitation| 2012 First Quarter Earnings Conference Call Wednesday, May 2, 2012, 5:00 p.m. ET
BETHLEHEM, Pa., Apr 18, 2012 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2012 first quarter financial results and certain 2012 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, May 2, 2012. An update on certain business developments will also be provided.
May 2, 2012 Schedule
... |
| | | 04/04/12 | FDA Sets Date for Advisory Committee Review of OraSure Over-the-Counter Rapid HIV Test| Final Phase of Clinical Testing to be Among Agenda Topics for Blood Products Advisory Committee Meeting on May 15th
BETHLEHEM, Pa., April 4, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that the U.S. Food and Drug Administration (FDA) Blood Products Advisory Committee (BPAC) will consider the Company's application for the approval of its OraQuick® Rapid HIV-1/2 test for sale in the U.S. consumer or over-the-counter (OTC) market at a meeting scheduled for May... |
| | | 03/28/12 | OraSure Technologies to Present at the 11th Annual Needham Healthcare Conference| BETHLEHEM, Pa., March 28, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President & CEO, will speak to the investment community at the 11th Annual Needham Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak April 4, 2012, at approximately 10:40 am Eastern Time (7:40 am Pacific Time). Interested investors can access the live webcast of the pre... |
| | | 02/27/12 | OraSure Technologies to Present at the Cowen & Co. 32nd Annual Health Care Conference| BETHLEHEM, Pa., Feb. 27, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Cowen & Co. 32nd Annual Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak March 5, 2012, at approximately 1:30 pm Eastern Time (10:30 am Pacific Time). Interested investors can access the live webc... |
| | | 02/22/12 | OraSure Technologies to Present at the 2012 RBC Capital Markets' Healthcare Conference| BETHLEHEM, Pa., Feb. 22, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Ronald H. Spair, COO & CFO, will speak to the investment community at the 2012 RBC Capital Markets Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet.
Mr. Spair is scheduled to speak February 29, 2012, at approximately 3:30pm Eastern Time (12:30 pm Pacific Time). Interested investors can access the live webcast of the present... |
| | | 02/21/12 | OraSure Technologies to Present at the 2012 Citi Global Healthcare Conference| BETHLEHEM, Pa., Feb. 21, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2012 Citi Global Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak February 28, 2012, at approximately 10:00 am Eastern Time (7:00 am Pacific Time). Interested investors can access the live webcast of the prese... |
| | | 02/08/12 | OraSure Announces Fourth Quarter and Full-Year 2011 Financial Results| Company Reports Record Quarterly Revenues
BETHLEHEM, Pa., Feb. 8, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the fourth quarter and full year of 2011.
Financial Highlights
Consolidated revenues were $23.7 million for the fourth quarter of 2011, a 26% increase from the comparable quarter of 2010. Revenues for the current quarter included $19.5 million from OraSure operati... |
| | | 01/26/12 | OraSure Technologies Earnings Conference Call Invitation| 2011 Fourth Quarter Earnings Conference Call Wednesday, February 8, 2012, 5:00 p.m. ET
BETHLEHEM, Pa., Jan. 26, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2011 fourth quarter financial results and certain 2012 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, February 8, 2012. An update on certain business developments will also be provided.February 8, 2012 Schedule
... |
| | | 01/06/12 | OraSure Technologies to Participate at the Fourteenth Annual Needham Growth Conference| BETHLEHEM, Pa., Jan. 6, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Fourteenth Annual Needham Growth Conference in New York at approximately 8:00 am Eastern Time (5:00 am Pacific Time) on Wednesday, January 11, 2012. The conference will be simultaneously webcast over the Internet.
Interested investors can access the live audio webcast of the discuss... |
| | | 01/03/12 | OraSure Makes Final FDA Submission for Approval of Over-the-Counter Rapid HIV Test| BETHLEHEM, Pa., Jan 3, 2012 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in rapid point-of-care infectious disease diagnostics and biological sample collection, stabilization and preparation products, announced today that it has submitted the final of three modules in its application to the U. S. Food and Drug Administration (FDA) for the approval of the Company's OraQuick(R) Rapid HIV-1/2 test for sale in the U.S. consumer or over-the-counter (OTC) mark... |
| | | 12/08/11 | Photo Release -- OraSure Technologies Subsidiary, DNA Genotek Receives FDA 510(k) Clearance for Oragene(R) Dx Collection Device| First Saliva DNA Collection and Stabilization Device to Receive 510(k) Clearance
OTTAWA, Dec. 8, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies', Inc. (Nasdaq:OSUR) subsidiary, DNA Genotek, a leading provider of products for biological sample collection, stabilization and preparation, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for DNA Genotek's Oragene•Dx collection device. Oragene•Dx is the first and only saliva DNA collection and stabilization... |
| | | 11/29/11 | OraSure Technologies Receives CLIA Waiver for OraQuick(R) HCV Rapid Test| BETHLEHEM, Pa., Nov. 29, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that the U.S. Food and Drug Administration ("FDA") has granted a waiver under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") for its OraQuick® HCV Rapid Antibody Test for use with fingerstick whole blood and venous whole blood specimens.
The OraQuick® HCV Rapid Antibody Test is the first and only FDA-approved rapid test for the detection of antibodies to the hepatitis C... |
| | | 11/10/11 | OraSure Technologies Appoints Veteran Consumer Products Executive to Its Board of Directors| BETHLEHEM, Pa., Nov 10, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the appointment of Gerald M. Ostrov as a member of the Company's Board of Directors. Mr. Ostrov will serve as a Class I Director with an initial term expiring in 2013.
"We are very pleased to welcome Gerald Ostrov, a highly successful and seasoned healthcare executive, to our Board of Directors," said Douglas G. Watson, Chairman of the Board of OraSure Technologies. "Jerry has... |
| | | 11/09/11 | OraSure Technologies to Present at the Stephens, Inc. Fall Investment Conference| BETHLEHEM, Pa, Nov 9, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Stephens Fall Investment Conference in New York City. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak November 16, 2011, at approximately 10:00am Eastern Time (7:00am Pacific Time). Interested investors can access the live webcast of the pr... |
| | | 11/02/11 | OraSure Announces 2011 Third Quarter Consolidated Financial Results| BETHLEHEM, Pa., Nov 2, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the third quarter of 2011.
Quarterly Highlights -- The Company completed the acquisition of DNA Genotek Inc. ("DNAG") on
August 17, 2011.
-- Consolidated revenues totaled $21.7 million for the quarter, a 14%
increase from the comparable period of 2010. Revenues included $19.7... |
| | | 11/01/11 | OraSure Applauds American Academy of Pediatrics Updated Recommendations for Routine HIV Screening for Adolescents| BETHLEHEM, Pa., Nov 1, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) today issued a statement in support of updated recommendations issued by the American Academy of Pediatrics ("AAP") on HIV screening for adolescents. These recommendations, which advocate regular, routine HIV screening for all adolescents 16 to 18 years of age in healthcare settings when the prevalence of HIV in the patient population is more than 0.1%, were included in a policy statement entitled... |
| | | 10/19/11 | OraSure Technologies Earnings Conference Call Invitation| 2011 Third Quarter Earnings Conference Call Wednesday, November 2, 2011, 5:00 p.m. ET
BETHLEHEM, Pa., Oct 19, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2011 third quarter financial results and certain 2011 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, November 2, 2011. An update on certain business developments will also be provided.
Nove... |
| | | 10/11/11 | DNA Genotek Launches Grant Program Aimed at Cancer, Personalized Medicine and Infectious Disease Research| FOR IMMEDIATE RELEASE OTTAWA, ON, October 11, 2011. DNA Genotek, a leading provider of products for biological sample collection, stabilization and preparation, today launched a grant program that encompasses three primary areas of focus – cancer, personalized medicine and infectious disease.
The DNA Genotek Grant Program invites research proposals that showcase innovative and novel use of the company's saliva-based collection and... |
| | | 09/21/11 | OraSure Technologies to Participate at the Sixth Annual JMP Securities Healthcare Conference| BETHLEHEM, Pa., Sep 21, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Sixth Annual JMP Securities Healthcare Conference in New York City at approximately 10:00am Eastern Time (7:00am Pacific Time) on Tuesday, September 27, 2011. The conference will be simultaneously webcast over the Internet.
Interested investors can access the live audi... |
| | | 09/13/11 | OraSure Technologies to Participate at the UBS Global Life Sciences Conference| BETHLEHEM, Penn., Sep 13, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the UBS Global Life Sciences Conference in New York City. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak September 19, 2011, at approximately 8:00 am Eastern Time (5:00 am Pacific Time). Interested investors can access ... |
| | | 09/06/11 | OraSure Technologies Announces 2012 Annual Meeting Date| BETHLEHEM, Pa., Sep 6, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2012 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 15, 2012. Further details regarding the meeting will be provided at a later date.
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose ... |
| | | 09/01/11 | OraSure Technologies to Participate at the William Blair 2011 Life Sciences Conference| BETHLEHEM, Pa., Sep 1, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Dr. Stephen R. Lee, Chief Science Officer & EVP R&D, will participate on a panel at the William Blair 2011 Life Sciences Conference in New York City. The panel discussion will be simultaneously webcast over the Internet.
Dr. Lee is scheduled to participate on the Hepatitis C Value Chain panel September 7, 2011, at approximately 3:20 pm Eastern Time (12:20 pm Pacifi... |
| | | 08/18/11 | OraSure Technologies Announces Closing of DNA Genotek Acquisition| BETHLEHEM, Pa., Aug 18, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that it has completed its previously-announced acquisition of DNA Genotek Inc., a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, for 50 million Canadian dollars in cash (approximately US $50.7 million at current exchange rates). The acquisition was funded by OraSure with cash on hand.
The acquisiti... |
| | | 08/09/11 | OraSure Closes Enrollment in Final Clinical Study for Rapid HIV Over-the-Counter Test| BETHLEHEM, Pa., Aug 9, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it has closed enrollment for its multi-site clinical study of the Company's OraQuick(R) Rapid HIV-1/2 test for sale in the U.S. consumer or over-the-counter (OTC) market.
As previously announced, OraSure initiated the final phase of clinical testing for an in-home HIV self-test kit in December 2010. This phase consists of a mul... |
| | | 08/03/11 | OraSure Announces 2011 Second Quarter Financial Results| BETHLEHEM, Pa., Aug 3, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced total revenues of $19.1 million for the three months ended June 30, 2011, compared to $19.2 million recorded for the three months ended June 30, 2010.
Product revenues for the current quarter increased 6% as higher sales of the Company's infectious disease and substance abuse testing products were partially offset by lower sales of it... |
| | | 08/03/11 | OraSure Technologies to Present at Canaccord Genuity's 31st Annual Growth Conference| BETHLEHEM, Pa., Aug 3, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Canaccord|Genuity's 31st Annual Growth Conference in Boston, MA. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak August 9, 2011, at approximately 1:00 pm Eastern Time (10:00 am Pacific Time). Interested investors can access the live webcast of ... |
| | | 07/25/11 | OraSure Technologies to Acquire DNA Genotek Inc.; Acquisition Provides Entry Into Rapidly Growing Molecular Diagnostics Market and Strengthens Company's Leadership in Oral Fluid Diagnostics| BETHLEHEM, Pa., Jul 25, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that it will acquire privately-held DNA Genotek Inc., a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, for approximately US $53 million in cash, subject to certain adjustments. The transaction is anticipated to close in the third quarter of this year. DNA Genotek generated approximately US $14.0 milli... |
| | | 07/20/11 | OraSure Technologies Earnings Conference Call Invitation| 2011 Second Quarter Earnings Conference Call Wednesday, August 3, 2011, 5:00 p.m. ET
BETHLEHEM, Pa., Jul 20, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2011 second quarter financial results and certain 2011 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, August 3, 2011. An update on certain business developments will also be provided.
August 3, 2... |
| | | 06/27/11 | OraSure Technologies Supports 17th Annual National HIV Testing Day| Thousands of People to be Tested With OraQuick ADVANCE(R) Rapid HIV Test
BETHLEHEM, Pa., Jun 27, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its support of numerous rapid HIV testing initiatives in recognition of National HIV Testing Day, held annually on June 27th. Now in its 17th year, National HIV Testing Day is an annual event led by the National Association of People with AIDS (NAPWA) to encoura... |
| | | 06/02/11 | OraSure Technologies to Present at Jefferies 2011 Global Healthcare Conference| BETHLEHEM, Pa., Jun 2, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Jefferies 2011 Global Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak June 6, 2011, at approximately 11:30 am Eastern Time (8:30 am Pacific Time). Interested investors can access the live webcast of the p... |
| | | 05/19/11 | OraSure Technologies to Present At ThinkEquity's 2nd Annual Healthcare Conference| BETHLEHEM, Pa., May 19, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at ThinkEquity's 2nd Annual Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak May 25, 2011, at approximately 12:00 pm Eastern Time (9:00 am Pacific Time). Interested investors can access the live webcast of t... |
| | | 05/10/11 | OraSure Technologies to Webcast Annual Meeting of Stockholders| BETHLEHEM, Pa., May 10, 2011 (GlobeNewswire via COMTEX) --
The webcast will include the formal portion of the meeting and a presentation by the Company's President and CEO, Douglas A. Michels.
In order to access the webcast, interested parties should go to OraSure Technologies' web site, www.orasure.com, and click on the Investor Info link at least ten minutes prior to the start of the webcast to register, download and install any necessary software. A replay of the webcast will be archiv... |
| | | 05/04/11 | OraSure Announces 2011 First Quarter Financial Results| BETHLEHEM, Pa., May 4, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR), a market leader in oral fluid diagnostics, today announced total revenues of $17.4 million for the three months ended March 31, 2011, compared to $17.9 million recorded for the three months ended March 31, 2010.
Product revenues for the quarter increased 3% as higher sales of the Company's infectious disease and substance abuse testing products were partially offset by lower sales of its cryosurgical sys... |
| | | 04/25/11 | OraSure Technologies to Present at Deutsche Bank's 36th Annual Health Care Conference| BETHLEHEM, Pa., Apr 25, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at Deutsche Bank's 36th Annual Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak May 2, 2011, at approximately 11:20 am Eastern Time (8:20 am Pacific Time). Interested investors can access the l... |
| | | 04/20/11 | OraSure Technologies Earnings Conference Call Invitation| 2011 First Quarter Earnings Conference Call Wednesday, May 4, 2011, 5:00 p.m. ET
BETHLEHEM, Pa., Apr 20, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2011 first quarter financial results and certain 2011 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, May 4, 2011. An update on certain business developments will also be provided.
May 4, 2011 Schedule... |
| | | 04/07/11 | OraSure Technologies Appoints Stephen S. Tang, Ph.D. to Its Board of Directors| BETHLEHEM, Pa., Apr 7, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR), today announced the appointment of Stephen S. Tang, Ph.D. as a member of the Company's Board of Directors. Dr. Tang will serve as a Class I Director with an initial term expiring at the Company's 2013 Annual Meeting of Stockholders.
"I am very pleased to welcome Stephen Tang, a seasoned healthcare executive, to our Board of Directors," said Douglas G. Watson, Chairman of the Board of OraSure T... |
| | | 03/28/11 | OraSure Technologies to Present at the 10th Annual Needham Healthcare Conference| BETHLEHEM, Pa., Mar 28, 2011 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President & CEO, will speak to the investment community at the 10th Annual Needham Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak April 5, 2011, at approximately 9:20 am Eastern Time (6:20 am Pacific Time). Interested investors can access the live webcast of ... |
| | | 03/23/11 | OraSure Technologies Submits CLIA Waiver Application for OraQuick(R) HCV Rapid Test| BETHLEHEM, Pa., Mar 23, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that it has submitted to the U.S. Food and Drug Administration ("FDA") an application for a waiver under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") for its OraQuick(R) HCV Rapid Antibody Test for use with venous whole blood and fingerstick whole blood specimens.
The OraQuick(R) HCV Rapid Antibody Test is the first and only FDA-approved rapid test for the d... |
| | | 03/04/11 | OraSure Technologies to Present at the Roth 23rd Annual OC Growth Stock Conference| BETHLEHEM, Pa., Mar 4, 2011 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Ronald H. Spair, COO & CFO, will speak to the investment community at the Roth 23rd Annual OC Growth Stock Conference in Dana Point, California. The conference will be simultaneously webcast over the Internet.
Mr. Spair is scheduled to speak March 14, 2011, at approximately 6:30 pm Eastern Time (3:30 pm Pacific Time). Interested investors can access the live webcast of ... |
| | | 03/03/11 | OraSure Technologies and Roche Announce FDA 510(k) Clearance for Four Fully Automated Oral Fluid Drugs of Abuse Assays| PCP, Cocaine, Opiates and Methamphetamine Assays to be Used Exclusively as Part of OraSure's Intercept(R) Oral Fluid Drug Testing System
BETHLEHEM, Pa., Mar 3, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) and Roche announced today that the U.S. Food and Drug Administration ("FDA") has granted the Companies 510(k) clearance on four homogeneous fully automated oral fluid drugs of abuse assays developed to be used exclusively as part of OraSure's Intercept(R) Oral F... |
| | | 03/01/11 | OraSure Technologies to Present at the Cowen & Co. Health Care Conference| BETHLEHEM, Pa., Mar 1, 2011 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Cowen & Co. Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak March 7, 2011, at approximately 4:00 pm Eastern Time (1:00 pm Pacific Time). Interested investors can access the live webcast o... |
| | | 02/28/11 | OraSure Technologies to Present at the 2011 RBC Capital Markets Healthcare Conference| BETHLEHEM, Pa., Feb 28, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2011 RBC Capital Markets Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak March 3, 2011, at approximately 10:30am Eastern Time (7:30 am Pacific Time). Interested investors can access the live webcast... |
| | | 02/24/11 | OraSure Technologies to Present at the 2011 Citi Global Healthcare Conference| BETHLEHEM, Pa., Feb 24, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2011 Citi Global Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak March 1, 2011, at approximately 10:00 am Eastern Time (7:00 am Pacific Time). Interested investors can access the live webcast of the... |
| | | 02/22/11 | OraSure Technologies Receives FDA Approval for Its OraQuick(R) HCV Rapid Test Using Fingerstick Whole Blood| BETHLEHEM, Pa., Feb 22, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that its OraQuick(R) HCV Rapid Antibody Test has now been approved by the U.S. Food and Drug Administration ("FDA") for use in detecting HCV antibodies with a fingerstick whole blood sample. The fingerstick whole blood claim is the second application to be approved by the FDA for the OraQuick(R) HCV test. The product received an initial approval for use in persons at risk for HCV ... |
| | | 02/09/11 | OraSure Announces Fourth Quarter and Full Year 2010 Financial Results| BETHLEHEM, Pa., Feb 9, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $75.0 million and $18.8 million for the year and quarter ended December 31, 2010, respectively. This compares to revenues of $77.0 million and $20.9 million for the year and quarter ended December 31, 2009.
The Company recorded a net loss of $3.5 million, or $0.08 per share, and $1.0 million, or $0.02 per share, for the ye... |
| | | 01/31/11 | OraSure Technologies Earnings Conference Call Invitation| 2010 Fourth Quarter and Full Year Earnings Conference Call Wednesday, February 9, 2011, 5:00 p.m. ET
BETHLEHEM, Pa., Jan 31, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2010 fourth quarter and full-year financial results and certain 2011 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, February 9, 2011. An update on certain business developments will also be provided.
... |
| | | 01/26/11 | Oral Fluid Drug Testing Reveals More Heroin Use| BETHLEHEM, Pa., Jan 26, 2011 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that Quest Diagnostics Incorporated (NYSE:DGX) released new data indicating that oral fluid revealed approximately five times more heroin use in the general U.S. workforce than previously believed.
In the Quest Diagnostics Drug Testing Index special report, with more than 320,000 oral-fluid samples analyzed from the general U.S. wor... |
| | | 01/11/11 | OraSure Technologies to Launch OraSure QuickFlu(TM) Rapid Flu A+B Test| Test Provides Accurate Rapid Differential Diagnosis for Influenza Virus Type A and Type B
BETHLEHEM, Pa., Jan 11, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) announced today the impending launch of the OraSure QuickFlu(TM) Rapid Flu A+B Test, a U.S. Food and Drug and Administration ("FDA") approved in vitro rapid qualitative test for the detection of influenza (flu) type A and type B, including H1N1 viral infections. The test specimen is collected with a nasal ... |
| | | 01/07/11 | OraSure Technologies to Participate at the Thirteenth Annual Needham Growth Conference| BETHLEHEM, Pa., Jan 7, 2011 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Thirteenth Annual Needham Growth Conference in New York at approximately 10:40 am Eastern Time (7:40 am Pacific Time) on Tuesday, January 11, 2011. The conference will be simultaneously webcast over the Internet.
Interested investors can access the live audio webcast of t... |
| | | 01/04/11 | Accomplished Sales and Marketing Executive Joins OraSure Technologies Management Team| BETHLEHEM, Pa., Jan 4, 2011 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that Tony Zezzo has joined the Company as its new Executive Vice President, Marketing and Sales, effective January 3, 2011.
In this position, Zezzo will have overall responsibility for the Company's global marketing and sales operations, which includes the domestic and international sales teams for our infectious disease and substance abuse businesses, marketing, and client ser... |
| | | 12/13/10 | OraSure Initiates Enrollment in Final Clinical Study for OraQuick(R) Rapid HIV Over-the-Counter Test| FDA Approves 24-Month Shelf Life for OraQuick ADVANCE(R) Rapid HIV-1/2 Test
BETHLEHEM, Pa., Dec 13, 2010 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it has enrolled the first subject in its final phase of clinical studies for United States Food and Drug Administration ("FDA") approval of the Company's OraQuick(R) Rapid HIV-1/2 test for sale in the U.S. consumer or over-the-counter ("OTC") market.
... |
| | | 12/02/10 | OraSure Technologies Announces 2011 Annual Meeting Date| BETHLEHEM, Pa., Dec 2, 2010 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2011 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 17, 2011. A location for the meeting will be announced at a later date.
About OraSure Technologies
OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in ... |
| | | 12/01/10 | OraSure Technologies Supports Rapid HIV Testing Initiatives for World AIDS Day| OraSure to Preside Over NASDAQ Market Open on December 1
BETHLEHEM, Pa., Dec 1, 2010 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its support of more than 150 rapid HIV testing initiatives taking place in more than 25 states in the U.S. and numerous countries globally, in recognition of World AIDS Day, commemorated annually on December 1st. OraSure's support of these initiatives, taking place in Africa, Asi... |
| | | 11/22/10 | OraSure Technologies Receives FDA Approval to Conduct Final Phase of Clinical Studies for OraQuick(R) Over-the-Counter HIV Test| BETHLEHEM, Pa., Nov 22, 2010 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced that the U.S. Food and Drug Administration ("FDA") has granted an investigational device exemption (IDE) for the Company to conduct the final phase of clinical testing for FDA approval of its OraQuick(R) Rapid HIV-1/2 Antibody Test for sale in the consumer or over-the-counter ("OTC") market.
Receipt of the IDE allows the Company to... |
| | | 11/17/10 | Photo Release -- OraSure Technologies Receives Popular Science "Best of What's New" Award for OraQuick(R) HCV Rapid Antibody Test| OraQuick(R) HCV Rapid Antibody Test Named One of the Top 100 Technical Innovations of the Year
BETHLEHEM, Pa., Nov 17, 2010 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced that the editors of Popular Science have named the OraQuick(R) HCV Rapid Antibody Test one of the top technology innovations of 2010. As a winner of a "Best of What's New" Award, the OraQuick HCV Rapid Antibody Test was recognized for its t... |
| | | 11/10/10 | OraSure Technologies to Participate at the Stephens Fall Investment Conference| BETHLEHEM, Pa., Nov 10, 2010 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Stephens Fall Investment Conference in New York City at approximately 10:30am Eastern Time, (7:30am Pacific Time) on Wednesday, November 17, 2010. The conference will be simultaneously webcast over the Internet.
Interested investors can access the live audio webcast of... |
| | | 11/09/10 | OraSure Announces 2010 Third Quarter Financial Results| BETHLEHEM, Pa., Nov 9, 2010 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $19.0 million for the three months ended September 30, 2010, compared to $21.6 million recorded for the three months ended September 30, 2009. Revenues in the third quarter of 2009 were higher primarily because they included the elimination of a $2.2 million backlog for OraQuick(R) HIV orders which existed at June 30, 2009. R... |
| | | 10/27/10 | OraSure Technologies Earnings Conference Call Invitation| 2010 Third Quarter Earnings Conference Call Tuesday, November 9, 2010, 5:00 p.m. ET
BETHLEHEM, Pa., Oct 27, 2010 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2010 third quarter financial results and certain 2010 financial guidance for 5:00 pm ET (2:00 pm PT) on Tuesday, November 9, 2010. An update on certain business developments will also be provided.
November 9, 2010 Schedule
... |
| | | 09/22/10 | OraSure Technologies to Participate at the Fifth Annual JMP Securities Healthcare Conference| BETHLEHEM, Pa., Sep 22, 2010 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Fifth Annual JMP Securities Healthcare Conference in New York City at approximately 3:30pm Eastern Time, (12:30pm Pacific Time) on Tuesday, September 28, 2010. The conference will be simultaneously webcast over the Internet.
Interested investors can access the live aud... |
| | | 09/14/10 | OraSure Technologies to Participate at the UBS Global Life Sciences Conference| BETHLEHEM, Pa., Sep 14, 2010 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the UBS Global Life Sciences Conference in New York City at approximately 4:00pm Eastern Time, (1:00pm Pacific Time) on Monday, September 20, 2010. The conference will be simultaneously webcast over the Internet.
Interested investors can access the live audio webcast of th... |
| | | 08/05/10 | OraSure Technologies to Participate at the Canaccord Adams 30th Annual Global Growth Conference| BETHLEHEM, Pa., Aug 5, 2010 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Canaccord Adams 30th Annual Global Growth Conference in Boston at approximately 4:30 pm Eastern Time (1:30 pm Pacific Time) on Wednesday, August 11, 2010. The conference will be simultaneously webcast over the Internet.
Interested investors can access the live audio web... |
| | | 08/04/10 | OraSure Announces 2010 Second Quarter Financial Results| OraSure Also Provides Update on OraQuick(R) HIV Shelf Life Extension and OraQuick(R) HCV Clinical Program
BETHLEHEM, Pa., Aug 4, 2010 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $19.2 million for the three months ended June 30, 2010, compared to $17.3 million recorded for the three months ended June 30, 2009.
Revenues in the current quarter reflect increases for each of the Company's product... |
| | | 08/03/10 | OraSure Technologies to Participate at the BMO Capital Markets 10th Annual Focus on Healthcare Conference| BETHLEHEM, Pa., Aug 3, 2010 (GlobeNewswire via COMTEX) --
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the BMO Capital Markets 10th Annual Focus on Healthcare Conference in New York at approximately 4:00 pm Eastern Time (1:00 pm Pacific Time) on Thursday, August 5, 2010. The conference will be simultaneously webcast over the Internet.
Interested investors can access the live... |
| | | 07/21/10 | OraSure Technologies Earnings Conference Call Invitation| 2010 Second Quarter Earnings Conference Call Wednesday, August 4, 2010, 5:00 p.m. ET
BETHLEHEM, Pa., Jul 21, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2010 second quarter financial results and certain 2010 financial guidance for 5:00 pm ET (2:00 p.m. PT) on Wednesday, August 4, 2010. An update on certain business developments will also be provided.
August 4, 2010 Schedule
... |
| | | 06/25/10 | OraSure Technologies Receives FDA Approval for OraQuick(R) HCV Rapid Test, the First Rapid HCV Test Approved for Sale in the U.S.| BETHLEHEM, Pa., Jun 25, 2010 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that its OraQuick(R) Hepatitis C ("HCV") Rapid Antibody Test has been approved by the U.S. Food and Drug Administration ("FDA") for use in detecting HCV antibodies in venous whole blood specimens, making it the first rapid HCV test approved by the FDA for use in the United States.
"The OraQuick HCV test efficiently identifies previously undiagnosed HCV infected individuals who are... |
| | | 06/25/10 | OraSure Technologies and the National Association of People With AIDS Launch Sixth Annual "Mayors Campaign Against HIV(TM)" for National HIV Testing Day| More Than 100 U.S. Mayors Unite to Promote HIV Screening
BETHLEHEM, Pa., Jun 25, 2010 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) and the National Association of People with AIDS (NAPWA) announced today the launch of the sixth annual Mayors Campaign Against HIV(TM), a national campaign to encourage testing for HIV and promote the benefits of knowing one's HIV status. The Campaign is part of the annual observance of National HIV Testing Day (NHTD) on Sunday, June 27, 2... |
| | | 06/07/10 | OraSure Technologies to Participate at ThinkEquity's Mid Year Check-Up on Healthcare| BETHLEHEM, Pa., Jun 10, 2010 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at ThinkEquity's Mid-Year Check-Up on Healthcare Conference in New York City at approximately 9:30 am Eastern Time (6:30 am Pacific Time) on Wednesday, June 16, 2010. The conference will be simultaneously webcast over the Internet.
Interested investors can access the live audio w... |
| | | 06/04/10 | OraSure Technologies to Participate at Jefferies 2010 Global Life Sciences Conference| BETHLEHEM, Pa., Jun 4, 2010 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Jefferies 2010 Global Life Sciences Conference in New York City at approximately 12:15 pm Eastern Time (9:15 am Pacific Time) on Friday, June 11, 2010. The conference will be simultaneously webcast over the Internet.
Interested investors can access the live audio webcast of... |
| | | 06/02/10 | OraSure Technologies to Participate at the Ninth Annual Needham Healthcare Conference| BETHLEHEM, Pa., Jun 2, 2010 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Ninth Annual Needham Healthcare Conference in New York at approximately 2:40 pm Eastern Time (11:40 am Pacific Time) on Wednesday, June 9, 2010. The conference will be simultaneously webcast over the Internet.
Interested investors can access the live audio webcast of the di... |
| | | 05/05/10 | OraSure Announces 2010 First Quarter Financial Results| BETHLEHEM, Pa., May 5, 2010 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $17.9 million for the three months ended March 31, 2010, compared to $17.3 million recorded for the three months ended March 31, 2009. Increased sales of cryosurgical systems products and higher licensing and product development revenues were partially offset by lower revenues from the Company's infectious disease testing and in... |
| | | 04/21/10 | OraSure Technologies Earnings Conference Call Invitation| 2010 First Quarter Earnings Conference Call Wednesday, May 5, 2010, 5:00 p.m. ET
BETHLEHEM, Pa., Apr 21, 2010 (GlobeNewswire via COMTEX) --OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2010 first quarter financial results and certain 2010 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, May 5, 2010. An update on certain business developments will also be provided. May 5, 2010 Schedule
4:00 p.m. ... |
| | | 03/03/10 | OraSure Technologies to Present at the Cowen & Co. Health Care Conference| BETHLEHEM, Pa., Mar 3, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Cowen & Co. Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak March 9, 2010, at approximately 2:15 pm Eastern Time (11:15 am Pacific Time). Interested investors can access the live webcast of... |
| | | 02/10/10 | OraSure Announces Fourth Quarter and Full Year 2009 Financial Results| BETHLEHEM, Pa., Feb 10, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $77.0 million and $20.9 million for the year and quarter ended December 31, 2009, respectively. This compares to revenues of $71.1 million and $17.2 million for the year and quarter ended December 31, 2008.
The Company recorded a net loss of $7.8 million or $0.17 per share, and $2.8 million or $0.06 per share, on a GAAP1 bas... |
| | | 02/03/10 | OraSure CEO Appointed to Presidential Advisory Council on HIV/AIDS| BETHLEHEM, Pa., Feb 3, 2010 (GlobeNewswire via COMTEX) -- Douglas A. Michels, President and Chief Executive Officer of OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, was sworn in yesterday by U.S. Health and Human Services Secretary Kathleen Sebelius, as a new member of the Presidential Advisory Council on HIV/AIDS (PACHA).
PACHA provides advice, information, and recommendations to the President of the United States through the Secretary of Health and Huma... |
| | | 01/28/10 | OraSure Technologies Earnings Conference Call Invitation| 2009 Fourth Quarter and Full Year Earnings Conference Call Wednesday, February 10, 2010, 5:00 p.m. ETBETHLEHEM, Pa., Jan 28, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2009 fourth quarter and full‑year financial results and certain 2010 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, February 10, 2010. An update on certain business developments will also be provided.
... |
| | | 01/19/10 | OraSure Technologies and Roche Diagnostics Sign Worldwide Commercialization Agreement for Fully Automated Oral Fluid Drugs of Abuse Assays| BETHLEHEM, Pa., Jan 19, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) and Roche Diagnostics today announced that the companies have signed an agreement for the worldwide commercialization of homogeneous fully automated oral fluid drugs of abuse assays with OraSure's Intercept(R) oral specimen collection device. The oral fluid assays use Roche's KIMS (kinetic interaction of micro-particles in solution) technology and are being jointly developed under an agreement pre... |
| | | 01/07/10 | OraSure Technologies Files Additional Data With FDA in Support of PMA Application for OraQuick Rapid HCV Test| BETHLEHEM, Pa., Jan 7, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today the recent filing of a pre-market approval ("PMA") amendment with the U.S. Food and Drug Administration ("FDA") for the Company's OraQuick(R) Rapid HCV Antibody Test. The amendment contains additional clinical data requested by the FDA for use of the test in detecting antibodies to the Hepatitis C Virus ("HCV") in venous whole blood samples.
When approved for use with venous whole... |
| | | 01/05/10 | OraSure Technologies to Participate at the Twelfth Annual Needham Growth Conference| BETHLEHEM, Pa., Jan 5, 2010 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Twelfth Annual Needham Growth Conference in New York at approximately 10:00 am Eastern Time (7:00 am Pacific Time) on Tuesday, January 12, 2010. The conference will be simultaneously webcast over the Internet.
Interested investors can access the live audio webcast of the d... |
| | | 12/15/09 | OraSure Technologies Receives CE Mark for OraQuick(R) Rapid HCV Antibody Test| First and Only Oral Fluid Rapid HCV Test Bearing a CE Mark
BETHLEHEM, Pa., Dec. 15, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that it has received approval to affix the CE mark to its OraQuick(R) Rapid HCV Antibody Test. A CE mark is required to sell this test in the 27 countries that currently make up the European Union. The OraQuick(R) Rapid HCV Antibody Test is the first and only rapid Hepatitis C test bearing a CE mark that can be used with oral fluid... |
| | | 11/19/09 | OraSure Technologies Announces Settlement of Patent Infringement Lawsuit With Inverness and Church & Dwight| BETHLEHEM, Pa., Nov. 19, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the settlement of the patent infringement lawsuit filed against OraSure by Inverness Medical Innovations, Inc. (NYSE:IMA), Inverness Medical Switzerland GmbH and Church & Dwight, Co., Inc. (NYSE:CHD).
Under the settlement, OraSure has agreed to pay Inverness a sum of $3,000,000 in cash and Inverness has agreed to grant OraSure certain licenses to its lateral flow patents. In addition, ... |
| | | 11/18/09 | OraSure Technologies Participates in BPAC Meeting on HIV Over-the-Counter Test| BETHLEHEM, Pa., Nov. 18, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that it participated in a Blood Products Advisory Committee ("BPAC") meeting held November 17, 2009 in which the BPAC considered, among other topics, the public need and performance characteristics for over-the-counter ("OTC") home use HIV test kits. The BPAC provides advice to the U.S. Food and Drug Administration ("FDA") on issues related to the safety and effectiveness of biological prod... |
| | | 11/04/09 | OraSure Announces 2009 Third Quarter Financial Results| BETHLEHEM, Pa., Nov. 4, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $21.6 million for the three months ended September 30, 2009, compared to $16.9 million recorded for the three months ended September 30, 2008.
The revenue increase for the third quarter reflects double digit growth in sales of the Company's infectious disease testing, cryosurgical systems and insurance risk assessment testing produ... |
| | | 10/22/09 | OraSure Technologies Earnings Conference Call Invitation| 2009 Third Quarter Earnings Conference Call Wednesday, November 4, 2009, 5:00 p.m. ET
BETHLEHEM, Pa., Oct. 22, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2009 third quarter financial results and certain 2009 financial guidance for 5:00 p.m. ET (2:00 p.m. PT) on Wednesday, November 4, 2009. An update on certain business developments will also be provided.
November 4, 2009 Schedule
... |
| | | 09/24/09 | OraSure Technologies Awarded Premier Contract for Its OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test| OraQuick ADVANCE(R) Will Also be Offered Through Premier's ASCEND Program BETHLEHEM, Pa., Sep 24, 2009 (GlobeNewswire via COMTEX) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced that it has been awarded a 36-month contract for its OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test with Premier Purchasing Partners, L.P., the group purchasing unit of Premier, Inc.
The new agreement, effective November 1, 2009, provides Premier's more than... |
| | | 09/17/09 | OraSure Technologies to Participate At the UBS Global Life Sciences Conference| BETHLEHEM, Pa., Sept. 17, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the UBS Global Life Sciences Conference in New York City at approximately 8:30am Eastern Time (5:30am Pacific Time), on Tuesday, September 22, 2009. The conference will be simultaneously webcast over the Internet.
Interested investors can access the live audio webcast of the discu... |
| | | 09/10/09 | OraSure Technologies Appoints Robert A. Gregg, Ph.D. as Vice President, Regulatory Affairs and Quality Assurance| BETHLEHEM, Pa., Sept. 10, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced that Robert A. Gregg, Ph.D., has been appointed as the Company's Vice President, Regulatory Affairs and Quality Assurance, effective September 14, 2009.
In this capacity, Dr. Gregg will have responsibility for the Company's regulatory, quality assurance and clinical affairs functions. Dr. Gregg will report to Douglas A. Michels, OraSure's ... |
| | | 08/27/09 | OraSure Technologies Announces 2010 Annual Meeting Date| BETHLEHEM, Pa., Aug. 27, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2010 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 11, 2010. Stockholder proposals must be received no later than December 2, 2009, in order to be considered for inclusion in the Company's Proxy Statement under relevant Securities and Exchange Commission rules and no later than February 11, 2010, in order to be considered at the Annual Meeting or to nominat... |
| | | 08/05/09 | OraSure Announces 2009 Second Quarter Financial Results and Resumption of Full-Scale OraQuick(r) Production| BETHLEHEM, Pa., Aug. 5, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $17.3 million for the three months ended June 30, 2009, compared to $18.9 million recorded for the three months ended June 30, 2008. The Company also announced the resolution of the previously disclosed manufacturing issue related to its OraQuick(r) rapid HIV-1/2 antibody test and the resumption of full-scale production of that product.... |
| | | 07/27/09 | OraSure Technologies Earnings Conference Call Invitation| 2009 Second Quarter Earnings Conference Call Wednesday, August 5, 2009, 5:00 p.m. ET
BETHLEHEM, Pa., July 27, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2009 second quarter financial results and certain 2009 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, August 5, 2009. An update on certain business developments will also be provided.
August 5, 2009 Schedule
... |
| | | 06/25/09 | OraSure Technologies Provides Update on Clinical Development Programs and OraQuick Manufacturing| BETHLEHEM, Pa.--(BUSINESS WIRE)--Jun. 25, 2009--
OraSure Technologies, Inc. (NASDAQ:OSUR) today announced an update
regarding the status of its application for U.S. Food and Drug
Administration (“FDA”) approval of an OraQuick® Hepatitis C
(“HCV”) test for professional use and its clinical program for an
OraQuick® HIV-1/2 test for sale in the consumer or
over-the-counter (“OTC”) market. In addition, the Company announced its
efforts to address ... |
| | | 05/06/09 | OraSure Announces 2009 First Quarter Financial Results| BETHLEHEM, Pa.--(BUSINESS WIRE)--May. 6, 2009--
OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid
diagnostics, today announced revenues of $17.3 million for the three
months ended March 31, 2009, compared to $18.1 million recorded for the
three months ended March 31, 2008. Increased sales of the Company’s
OraQuick ADVANCE® rapid HIV-1/2 antibody test and
insurance risk assessment products during the first quarter 2009 were
... |
| | | 05/04/09 | OraSure Technologies to Webcast Annual Meeting of Stockholders| BETHLEHEM, Pa.--(BUSINESS WIRE)--May. 4, 2009--
OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral
fluid diagnostics, announced that it will webcast its 2009 Annual
Meeting of Stockholders beginning at 10:00 a.m. Eastern Time (7:00 a.m.
Pacific Time) on Tuesday, May 12, 2009.
The webcast will include the formal portion of the meeting and a
presentation by the Company’s President and CEO, Douglas A. Michels.
In ... |
| | | 04/22/09 | OraSure Technologies Earnings Conference Call Invitation| 2009 First Quarter Earnings Conference Call Wednesday, May 6, 2009, 5:00 p.m. ET
BETHLEHEM, Pa.--(BUSINESS WIRE)--Apr. 22, 2009--
OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular
earnings conference call covering 2009 first quarter financial results
and certain 2009 financial guidance for 5:00 pm ET (2:00 pm PT) on
Wednesday, May 6, 2009. An update on certain business developments will
also be provided.
... |
| | | 02/11/09 | OraSure Announces Fourth Quarter and Full Year 2008 Financial Results| BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 11, 2009--
OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid
diagnostics, today announced revenues of $71.1 million and $17.2 million
for the year and quarter ended December 31, 2008, respectively. This
compares to revenues of $82.7 million and $19.8 million for the year and
quarter ended December 31, 2007, respectively.
The Company recorded a net loss of $31.3 million or $0.67 per s... |
| | | 02/04/09 | OraSure Technologies Earnings Conference Call Invitation| 2008 Fourth Quarter and Full Year Earnings Conference Call Wednesday, February 11, 2009, 5:00 p.m. ET
BETHLEHEM, Pa.--(BUSINESS WIRE)--
OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular
earnings conference call covering 2008 fourth quarter and full-year
financial results and certain 2009 financial guidance for 5:00 pm ET
(2:00 pm PT) on Wednesday, February 11, 2009. An update on certain
business developments will also be provided.
... |
| | | 01/28/09 | U.S. FDA Approves OraQuick ADVANCE(R) 12-Month Shelf Life Dating| BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 28, 2009--OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that the United
States Food and Drug Administration (FDA) has approved its request for
12-month shelf life from the date of manufacture for its OraQuick ADVANCE(R)
Rapid HIV-1/2 Antibody Test.
The FDA approval is based on enhancements made by OraSure to the
manufacturing process and product packaging of its OraQuick ADVANCE(R)
test, and re... |
| | | 01/05/09 | OraSure Technologies to Participate at the Eleventh Annual Needham Growth Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 5, 2009--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the Eleventh Annual Needham Growth Conference in
New York at approximately 10:30 am Eastern Time (7:30 am Pacific Time)
on Wednesday, January 7, 2009. The conference will be simultaneously
webcast over the Internet.
Interested investors... |
| | | 12/01/08 | OraSure Technologies Supports Global and Domestic Rapid HIV Testing Initiatives for World AIDS Day| BETHLEHEM, Pa., Dec 01, 2008 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral
fluid diagnostics, today announced its support of rapid HIV testing
initiatives taking place in more than 20 states in the U.S. and several
countries globally, in recognition of World AIDS Day, commemorated
annually on December 1st. OraSure's support of these
initiatives includes the production of HIV testing promotional
materials, co... |
| | | 11/17/08 | OraSure Technologies to Participate at the Lazard Capital Markets 5th Annual Healthcare Conference| BETHLEHEM, Pa., Nov 17, 2008 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the Lazard Capital Markets Fifth Annual
Healthcare Conference in New York City at approximately 9:30 am Eastern
Time, (6:30 am Pacific Time) on Wednesday, November 19, 2008. The
conference will be simultaneously webcast over the Internet.
Intereste... |
| | | 11/05/08 | OraSure Technologies Announces 2008 Third Quarter Results| BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 5, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid
diagnostics, today announced quarterly revenues of $16.9 million for
the three months ended September 30, 2008, compared to $21.4 million
in revenues for the three months ended September 30, 2007. Sales of
the Company's OraQuick ADVANCE(R) rapid HIV-1/2 antibody test
increased 18% for the third quarter 2008. This increase was offset
primarily by an expected decrease i... |
| | | 11/05/08 | OraSure Technologies to Sell OraQuick ADVANCE Rapid HIV-1/2 Antibody Test Directly to U.S. Hospitals| OraSure Sales Force Expansion will Support Hospital Customers
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 5, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid
diagnostics, today announced that it will begin to sell its OraQuick
ADVANCE(R) Rapid HIV-1/2 Antibody Test directly into the U.S. hospital
market beginning in 2009. In recent years, the U.S. hospital market
has received this product through an exclusive distribution
arrangement with Abbott.
In early... |
| | | 11/04/08 | OraSure's Intercept Oral Fluid Drug Test Results Comparable to Urine Drug Screening According to Landmark Five-Year Analysis|
SAMHSA Sponsored Study of 650,000 Oral Fluid Specimen Drug Test
Results Presented at the Annual Meeting of the Society of Forensic
Toxicologists
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 4, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR) announced today that findings from a
recent large-scale study of laboratory-based oral fluid drug testing
results are comparable to urine drug testing positive rates for the
same classes of drugs. The 650,000 oral flu... |
| | | 10/28/08 | OraSure Technologies Files For FDA Approval of OraQuick Rapid Hepatitis C Test| When Approved, OraQuick(R) HCV is Expected to be the First Rapid HCV Test in U.S.
BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 28, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that it has submitted
a pre-market approval ("PMA") application to the U.S. Food and Drug
Administration ("FDA") for a rapid test for antibodies to the
Hepatitis C virus ("HCV") utilizing OraSure Technologies' OraQuick(R)
technology platform. When approved, the OraQuick(R) HCV test is
expected to be ... |
| | | 10/20/08 | OraSure Technologies Earnings Conference Call Invitation| 2008 Third Quarter Earnings Conference Call Wednesday, November 5, 2008, 5:00 p.m. ET
BETHLEHEM, Pa.--(BUSINESS WIRE)--OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its
regular quarterly earnings conference call covering 2008 third quarter
financial results for 5:00 p.m. ET (2:00 p.m. PT) on Wednesday,
November 5, 2008. An update on certain business developments will also
be provided.
November 5, 2008 Schedule
---------------------------------------... |
| | | 10/13/08 | OraSure Technologies Helps Expand Access to Rapid HIV Testing in Recognition of National Latino AIDS Awareness Day, October 15, 2008| Company Joins the Latino Commission on AIDS in Urging All Latinos to Get Tested and Learn Their HIV Status
BETHLEHEM, Pa.--(BUSINESS WIRE)--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in
oral fluid diagnostics, announced today its support to expand access
to rapid HIV testing in recognition of National Latino AIDS Awareness
Day (NLAAD) taking place on October 15, 2008. The effort to help
increase opportunities for Latinos to learn their HIV status is being
executed in p... |
| | | 09/29/08 | OraSure Applauds Congress for Passing Legislation to Enable Routine HIV Testing Throughout the U.S. Veterans Health Care System| BETHLEHEM, Pa.--(BUSINESS WIRE)--OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in
oral fluid diagnostics, today issued a statement applauding the U.S.
Congress for passage of The Veterans Mental Health and Other Care
Improvements Act of 2008 (S. 2162). The bill includes a provision that
repeals the 1988 Veterans Benefits and Services law which has limited
the implementation of the Centers for Disease Control and Prevention
(CDC) guidelines for routine HIV testing, counsel... |
| | | 09/18/08 | OraSure Technologies to Participate at the 2008 UBS Global Life Sciences Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 18, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the 2008 UBS Global Life Sciences Conference
in New York City at approximately 2:30pm Eastern Time, (11:30am
Pacific Time) on Tuesday, September 23, 2008. The conference will be
simultaneously webcast over the Internet.
Interested investors can access the live audio webcas... |
| | | 09/10/08 | Brian W. Reid to Join OraSure Technologies as Vice President, International Sales| BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 10, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, is pleased to announce that Brian W. Reid will join the
Company as Vice President, International Sales, effective September
22, 2008.
Reid will be responsible for leading OraSure's international sales
efforts for the Company's diagnostic businesses. Reid will report to
Douglas A. Michels, OraSure's President and CEO.
"We are delighted that Br... |
| | | 09/02/08 | Walter Reed Evaluation Concludes OraQuick(R) HCV Test is Preferred Over Other Rapid Tests| OraQuick(R) HCV Test Found to Have Higher Sensitivity and Specificity Than Other Rapid HCV Tests
BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 2, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid
diagnostics, today announced that an evaluation by the Walter Reed
Army Institute of Research of the OraQuick(R) HCV Test, currently in
clinical development by OraSure Technologies, was recently released at
the Advanced Technology Applications for Combat Casualty Care me... |
| | | 08/26/08 | OraSure Technologies Announces 2009 Annual Meeting Date| BETHLEHEM, Pa., Aug 26, 2008 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that its 2009
Annual Meeting of Stockholders is scheduled to be held on Tuesday, May
12, 2009, at the Historic Hotel Bethlehem, Bethlehem, Pennsylvania.
Stockholder proposals must be received no later than December 9, 2008,
in order to be considered for inclusion in the Company's
Proxy Statement under relevant Securities and Exchange Commission rules
... |
| | | 08/05/08 | OraSure Technologies Announces 2008 Second Quarter Results| Significant Milestones Achieved in Clinical Development Programs
BETHLEHEM, Pa.--(BUSINESS WIRE)--Aug. 5, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid
diagnostics, today announced quarterly revenues of $18.9 million for
the three months ended June 30, 2008, compared to $21.4 million in
revenues for the three months ended June 30, 2007. Increased sales of
the Company's OraQuick ADVANCE(R) rapid HIV-1/2 antibody test and
insurance risk assessment pro... |
| | | 08/05/08 | OraSure Technologies Announces $25 Million Share Repurchase Program| BETHLEHEM, Pa.--(BUSINESS WIRE)--Aug. 5, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid
diagnostics, today announced that its Board of Directors has approved
a share repurchase program to acquire up to $25 million of its
outstanding common shares.
Purchases under the program will be made at the Company's
discretion, subject to market conditions, in the open market, in
privately-negotiated transactions or otherwise, including pursuant to
a 10b5-1 pla... |
| | | 07/18/08 | OraSure Technologies Earnings Conference Call Invitation|
2008 Second Quarter Earnings Conference Call
Tuesday, August 5, 2008, 5:00 p.m. ET
BETHLEHEM, Pa.--(BUSINESS WIRE)--July 18, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly
earnings conference call covering 2008 second quarter financial
results for 5:00 pm ET (2:00 pm PT) on Tuesday, August 5, 2008. An
update on certain business developments will also be provided.
August 5, 2008 Schedule
... |
| | | 06/26/08 | OraSure Technologies and the National Association of People with AIDS Will Open the NASDAQ Stock Market on June 27 in Observance of National HIV Testing Day| BETHLEHEM, Pa.--(BUSINESS WIRE)--June 26, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR) and the National Association of
People with AIDS (NAPWA) announced today that OraSure officials will
be joined by Frank Oldham, Jr., President and CEO of NAPWA, and the
Honorable Johnny Ford, Mayor of Tuskegee, Alabama and Director General
of the World Conference of Mayors to preside over the NASDAQ Stock
Market opening on June 27, 2008 in observance of National HIV Testing
Day. This event will sp... |
| | | 06/23/08 | 65 U.S. Mayors to Join OraSure Technologies and the National Association of People with AIDS in Fourth Annual 'Mayors Campaign against HIV(TM)' for National HIV Testing Day| Record Number of U.S. Mayors Unite to Promote HIV Screening on June 27thBETHLEHEM, Pa., Jun 23, 2008 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) and the National
Association of People with AIDS (NAPWA) announced today that more than
65 mayors and/or Department of Health offices in major metropolitan
cities nationwide have committed their participation and support for
the fourth annual Mayors Campaign Against HIV(TM), a national campaign
to encourage testing for HIV and prom... |
| | | 06/16/08 | Nationwide Data Indicate a Very High Degree of Accuracy for OraQuick ADVANCE Rapid HIV-1/2 Antibody Test with Oral Fluid| Nationwide Accuracy for 2007 Through May 2008 of 99.8% Reported From Over 400 Testing Sites and More Than 250,000 Tests
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 16, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that aggregate
nationwide performance data for 2007 and the first five months of 2008
indicate that its widely used rapid HIV-1/2 antibody screening test,
OraQuick ADVANCE(R), has a very high degree of accuracy with oral
fluid - at rates that are within the U.S. ... |
| | | 06/05/08 | OraSure Technologies to Present at the Seventh Annual Needham & Company, LLC Biotechnology & Medical Technology Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--June 5, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and CEO, will speak to the investment community at
the Seventh Annual Needham & Company, LLC Biotechnology & Medical
Technology Conference in New York City. The conference will be
simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak on June 11, 2008, at
approximately 11:00 am Eastern Time (8:00 am Pacific Time). Intereste... |
| | | 05/06/08 | OraSure Technologies Announces 2008 First Quarter Results| BETHLEHEM, Pa., May 06, 2008 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral
fluid diagnostics, today announced quarterly revenues of $18.1 million
for the three months ended March 31, 2008, compared to $20.1 million
in revenues recorded for the three months ended March 31, 2007.
Increased sales of the Company's OraQuick ADVANCE(R) rapid HIV-1/2
antibody test, professional cryosurgical products and insurance risk
assessment products during the first qua... |
| | | 05/01/08 | OraSure Technologies to Webcast Annual Meeting of Stockholders| BETHLEHEM, Pa.--(BUSINESS WIRE)--May 1, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, announced that it will webcast its 2008 Annual Meeting of
Stockholders beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific
Time) on Tuesday, May 13, 2008.
The formal portion of the meeting will be immediately followed by
a management presentation and a question and answer session. Persons
accessing the webcast who desire to ask questions will be ... |
| | | 04/23/08 | OraSure Technologies Earnings Conference Call Invitation|
2008 First Quarter Earnings Conference Call
Tuesday, May 6, 2008, 5:00 p.m. ET
BETHLEHEM, Pa.--(BUSINESS WIRE)--April 23, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly
earnings conference call covering 2008 first quarter financial results
for 5:00 pm ET (2:00 pm PT) on Tuesday, May 6, 2008. An update on
certain business developments will also be provided.
May 6, 2008 Schedule
-----------------... |
| | | 04/17/08 | OraSure Technologies to Defend Patent Infringement Lawsuit| BETHLEHEM, Pa.--(BUSINESS WIRE)--April 17, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR) announced that it has received a
complaint from Inverness Medical Innovations, Inc. (AMEX:IMA),
Inverness Medical Switzerland GmbH and Church & Dwight, Co., Inc.
(NYSE:CHD), filed in the United States District Court for the District
of New Jersey, alleging that the manufacture and sale of the Company's
OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test infringes U.S. Patent
No. 6,485,982. OraSure Te... |
| | | 03/17/08 | OraSure Technologies to Present at the Cowen & Co. Health Care Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--March 17, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Ronald H. Spair,
Chief Operating Officer and Chief Financial Officer, will speak to the
investment community at the Cowen & Co. Health Care Conference in
Boston, Massachusetts. The conference will be simultaneously webcast
over the Internet.
Mr. Spair is scheduled to speak on March 20, 2008, at
approximately 10:15 am Eastern Time (7:15 am Pacific Time). Interested
invest... |
| | | 03/04/08 | OraSure Technologies Expands Distribution of Over-the-Counter Cryosurgical Wart Removal Product in Latin America| Genomma Lab to Distribute Product under the POINTTS TradenameBETHLEHEM, Pa., Mar 04, 2008 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) announced today the
execution of new agreements to expand distribution of OraSure's
cryosurgical wart removal product by Genomma Lab in the
over-the-counter ("OTC") or consumer retail market in Central and
South America. In addition, the parties renewed and extended their
prior distribution arrangement for Mexico and signed a new agreement
to... |
| | | 02/27/08 | OraSure Technologies to Participate at the Susquehanna Financial Group's Second Annual SIGnificant Options in Healthcare Conference| BETHLEHEM, Pa., Feb 27, 2008 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that
Douglas A. Michels, President and Chief Executive Officer, will speak
to the investment community at the Susquehanna Financial Group's
Second Annual SIGnificant Options in Healthcare Conference in New York
City at approximately 9:30 a.m. Eastern Time, (6:30 a.m. Pacific Time)
on Wednesday, March 5, 2008. The conference will be simultaneously
webcast over the Internet.
Interested ... |
| | | 02/12/08 | OraSure Announces Fourth Quarter and Full Year 2007 Financial Results| Annual Revenues Reach Record Level with 21% Growth Over 2006
BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 12, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid
diagnostics, today announced revenues of $82.7 million and $19.8
million for the year and quarter ended December 31, 2007,
respectively. This compares to revenues of $68.2 million and $17.7
million for the year and quarter ended December 31, 2006,
respectively.
The Company reported net income of $2.5... |
| | | 02/11/08 | Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test| New Agreement Provides for Development and Promotion of OraQuick(R) HCV Test Outside the United States
KENILWORTH, N.J. & BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 11,
2008--Schering-Plough Corporation (NYSE:SGP) and OraSure Technologies,
Inc. (NASDAQ:OSUR) today announced an agreement to collaborate on the
development and promotion of a rapid oral hepatitis C virus (HCV) test
utilizing OraSure Technologies' OraQuick(R) technology platform on a
worldwide basis outside the United States.
... |
| | | 02/07/08 | OraSure Technologies Pledges Support for National Black HIV/AIDS Awareness Day| Joins Nationwide Call to Action to Encourage the African American
Community to Learn Their HIV Status
BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 7, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, today announced its support of National Black HIV/AIDS
Awareness Day (NBHAAD), through the distribution of complimentary
OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test kits and educational
materials to more than 25 HIV testing sites ... |
| | | 01/31/08 | OraSure Technologies Earnings Conference Call Invitation| 2007 Fourth-Quarter and Full-Year Earnings Conference Call
Tuesday, February 12, 2008, 5:00 p.m. ET
BETHLEHEM, Pa., Jan 31, 2008 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), has scheduled its
regular quarterly earnings conference call covering 2007
fourth-quarter and full-year financial results and 2008 financial
guidance for 5:00 p.m. ET (2:00 p.m. PT) on Tuesday, February 12,
2008. An update on certain business developments will also be
provided.
... |
| | | 01/04/08 | OraSure Technologies to Participate at the Tenth Annual Needham Growth Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 4, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the Tenth Annual Needham Growth Conference in
New York at approximately 8:30 am Eastern Time, (5:30 am Pacific Time)
on January 9, 2008. The conference will be simultaneously webcast over
the Internet.
Interested investors can access the live audio webcast of the
discussion... |
| | | 01/02/08 | Debra Fraser-Howze to Join OraSure Technologies as Vice President, Government and External Affairs| BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 2, 2008--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, is pleased to announce that Debra Fraser-Howze, current
President/CEO of the National Black Leadership Commission on AIDS
(NBLCA), will join the Company as Vice President, Government and
External Affairs on January 7, 2008.
Fraser-Howze will represent OraSure with government officials
regarding the issues, policies, and laws impacting the Company's
... |
| | | 11/29/07 | OraSure Technologies Supports Global and Domestic Rapid HIV Testing Initiatives for World AIDS Day| OraSure to Participate in NASDAQ Market Open and HIV/AIDS Industry
Panel Discussion on November 30, 2007
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 29, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, today announced its support of more than 150 global and
domestic rapid HIV testing initiatives in recognition of World AIDS
Day, commemorated annually on December 1st. OraSure's support of these
initiatives, taking place in Afri... |
| | | 11/20/07 | OraSure Technologies to Host Analyst Day| BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 20, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid
diagnostics, today announced that it will host an Analyst Day meeting
on Wednesday, November 28, 2007 in New York City, New York, at the
NASDAQ MarketSite at Times Square. Presentations by OraSure's senior
executive team are scheduled to begin at 11:30 a.m. (Eastern Time) and
conclude by 3:00 p.m. (Eastern Time) and will cover product
development, including clinical ... |
| | | 11/19/07 | OraSure Technologies to Participate at the Lazard Capital Markets 4th Annual Healthcare Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 19, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the Lazard Capital Markets Fourth Annual
Healthcare Conference in New York City at approximately 10:30 am
Eastern Time, (7:30 am Pacific Time) on Tuesday, November 27, 2007.
The conference will be simultaneously webcast over the Internet.
Interested investors can access the... |
| | | 11/14/07 | OraSure Technologies and Schering-Plough to Settle Patent Infringement Litigation| BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 14, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that an agreement has
been reached on the principal terms to settle its pending patent
infringement litigation against Schering-Plough Healthcare Products,
Inc. (NYSE:SGP). The settlement is subject to completion and execution
of a final settlement agreement.
Under the terms of the settlement, Schering-Plough will receive a
license to OraSure's patents in the U.S. OTC market an... |
| | | 10/30/07 | OraSure Technologies Announces Third Quarter Financial Results| Quarterly Revenues Increase 21% Over 2006
BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 30, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid
diagnostics, today announced quarterly revenues of $21.4 million for
the three months ended September 30, 2007, a 21% increase over the
$17.6 million in revenues recorded for the three months ended
September 30, 2006. Increased sales of the Company's OraQuick
ADVANCE(R) rapid HIV-1/2 antibody test and over-the-counter ("O... |
| | | 10/23/07 | OraSure Technologies Announces Results of Arbitration With Prestige Brands| Prestige Brands Found To Have Breached Non-Compete Provision
BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 23, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced the results of its
arbitration with Prestige Brands Holdings, Inc (NYSE:PBH). Since April
2003, Prestige has exclusively distributed OraSure's cryosurgical wart
removal product in the United States over-the-counter or retail
("OTC") market under the Compound W Freeze Off(R) tradename. The
arbitration arose after Presti... |
| | | 10/19/07 | OraSure Technologies Quarterly Conference Call Invitation|
2007 Third Quarter Conference Call
Tuesday, October 30, 2007, 5:00 p.m. ET
BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 19, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly
earnings conference call covering 2007 third quarter financial results
and 2007 financial guidance for 5:00 pm ET (2:00 pm PT) on Tuesday,
October 30, 2007.
October 30, 2007 Schedule
------------------------------------------------------... |
| | | 10/10/07 | OraSure Technologies and the Latino Commission on AIDS Launch HIV Testing Initiative in Recognition of National Latino AIDS Awareness Day, October 15, 2007| Congressional Hispanic Caucus Joins Effort to Help Latinos Learn Their HIV Status
BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 10, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, today announced the launch of a Rapid HIV Testing
Initiative in connection with National Latino Awareness Day 2007. This
Initiative is being conducted in partnership with the Latino
Commission on AIDS with support from the Congressional Hispanic
Caucus.
As part of ... |
| | | 09/20/07 | OraSure Technologies to Participate at the 2007 UBS Global Life Sciences Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 20, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the 2007 UBS Global Life Sciences Conference
in New York City at approximately 8:00 am Eastern Time, (5:00 am
Pacific Time) on Wednesday, September 26, 2007. The conference will be
simultaneously webcast over the Internet.
Interested investors can access the live audio web... |
| | | 07/31/07 | OraSure Technologies Announces Record 2007 Second Quarter Results| Increases 2007 Full Year Revenue GuidanceBETHLEHEM, Pa., Jul 31, 2007 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral
fluid diagnostics, today announced record quarterly revenues of $21.4
million for the three months ended June 30, 2007, a 22% increase over
the $17.6 million in revenues recorded for the three months ended June
30, 2006. Increased sales of the Company's OraQuick ADVANCE(R) rapid
HIV-1/2 antibody test, substance abuse testing products and
... |
| | | 07/26/07 | OraSure Technologies Signs Agreement with the Supply Chain Management System for Supply of OraQuick(R) HIV Test to PEPFAR Countries| BETHLEHEM, Pa.--(BUSINESS WIRE)--July 26, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, today announced the execution of an agreement for the
supply of its OraQuick(R) Rapid HIV-1/2 Antibody Test to the Supply
Chain Management System ("SCMS"). Created with funds from the
President's Emergency Plan for AIDS Relief, or PEPFAR, SCMS procures
essential medicines, diagnostic tests and other supplies for the
prevention and treatment of HIV for ... |
| | | 07/19/07 | OraSure Technologies Announces Pre-Clinical Study Results for Prototype Rapid HCV Antibody Test at AACC Annual Meeting| Prototype Test Performance Equivalent to Lab-Based Testing in Pre-clinical Trials of Human SubjectsBETHLEHEM, Pa., Jul 19, 2007 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in
oral fluid diagnostics, today announced pre-clinical study results for
a prototype rapid Hepatitis C ("HCV") antibody test on the Company's
OraQuick(R) test platform, using oral fluid, finger-stick whole blood,
venous whole blood, serum and plasma samples. These results were
reported... |
| | | 07/18/07 | OraSure Technologies Appoints Vice President, Consumer Marketing| BETHLEHEM, Pa., Jul 18, 2007 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in
oral fluid diagnostics, today announced that Kenneth A. Adach will be
appointed as the Company's Vice President, Consumer Marketing.
Mr. Adach joins OraSure with extensive experience in consumer
sales and marketing, including over twenty-five years of relevant
over-the-counter ("OTC") marketing experience. Since 2005, Mr. Adach
has served as Director of Marketing for Bausch & Lomb... |
| | | 07/17/07 | OraSure Technologies Quarterly Conference Call Invitation|
2007 Second Quarter Conference Call
Tuesday, July 31, 2007, 5:00 p.m. ET
BETHLEHEM, Pa.--(BUSINESS WIRE)--July 17, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly
earnings conference call covering 2007 second quarter financial
results and 2007 financial guidance for 5:00 pm ET (2:00 pm PT) on
Tuesday, July 31, 2007.
July 31, 2007 Schedule
----------------------------------------------------------... |
| | | 06/26/07 | OraSure and the National Association of People with AIDS Launch Third Annual ''Mayors Campaign against HIV(TM)'' for National HIV Testing Day|
33 U.S. Mayors Unite to Promote HIV Screening on June 27th,
National HIV Testing Day
OraSure, NAPWA, City, State and Local Agencies to Open NASDAQ
Stock Market
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 26, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR) and the National Association of
People with AIDS (NAPWA) announced today the launch of the third
annual Mayors Campaign Against HIV(TM), a national campaign to
encourage te... |
| | | 06/22/07 | OraSure Technologies Sets 2008 Annual Meeting Date| BETHLEHEM, Pa., Jun 22, 2007 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that its
2008 Annual Meeting of Stockholders is scheduled to be held on
Tuesday, May 13, 2008, at the Historic Hotel Bethlehem, Bethlehem,
Pennsylvania. Stockholder proposals must be received no later than
December 10, 2007, in order to be considered for inclusion in the
Company's Proxy Statement under relevant Securities and Exchange
Commission rules and no later than February 13, 2008... |
| | | 06/11/07 | OraSure Technologies Receives CE Mark for OraQuick ADVANCE(R) Rapid HIV Test| Approval Required for Sales in European Union
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 11, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR) announced today that it has received
approval to affix the CE mark to its OraQuick ADVANCE(R) Rapid HIV-1/2
Antibody Test, which is required to sell this product in the 27
countries that currently make up the European Union. The OraQuick
ADVANCE(R) HIV test is the first and only rapid HIV test bearing a CE
mark that can be used with oral fluid, in add... |
| | | 06/08/07 | OraSure Technologies to Present at the Sixth Annual Needham & Company, LLC Biotechnology & Medical Technology Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--June 8, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Ronald H. Spair,
Chief Operating Officer and Chief Financial Officer, will speak to the
investment community at the Sixth Annual Needham & Company, LLC
Biotechnology & Medical Technology Conference in New York City. The
conference will be simultaneously webcast over the Internet.
Mr. Spair is scheduled to speak on June 13, 2007, at approximately
11:30 am Eastern Time (8:30 ... |
| | | 06/04/07 | OraSure Applauds $35 Million in CDC Funding to Support Increased HIV Testing and Prevention| BETHLEHEM, Pa.--(BUSINESS WIRE)--June 4, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics and the manufacturer of the OraQuick ADVANCE(R) Rapid
HIV-1/2 Antibody Test, today issued a statement in support of the
recent program announcement by the Centers for Disease Control and
Prevention ("CDC") that it has identified $35 million in additional
funding to expand HIV testing and prevention programs. These funds are
expected to be allocated to sp... |
| | | 05/29/07 | OraSure Technologies to Present at the Bank of America 2007 Health Care Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--May 29, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the Bank of America 2007 Health Care
Conference, Four Seasons Hotel in Las Vegas, NV. The conference will
be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak on May 31, 2007, at
approximately 3:40pm EDT (12:40pm PDT). Interested investors can
acce... |
| | | 05/10/07 | OraSure Technologies to Webcast Annual Meeting of Stockholders| BETHLEHEM, Pa., May 10, 2007 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in
oral fluid diagnostics, announced that it will webcast its 2007 Annual
Meeting of Stockholders beginning at 10:00 a.m. Eastern Time (7:00
a.m. Pacific Time) on Tuesday, May 15, 2007.
The formal portion of the meeting will be immediately followed by
a management presentation and a question and answer session. Persons
accessing the webcast who desire to ask questions will be permitt... |
| | | 05/08/07 | OraSure Technologies Announces 2007 First Quarter Results| Record Quarterly Revenues Led by OraQuick ADVANCE(R) SalesBETHLEHEM, Pa., May 08, 2007 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral
fluid diagnostics, today announced record quarterly revenues of $20.1
million for the three months ended March 31, 2007, compared to $15.2
million in revenues recorded for the three months ended March 31,
2006. Increased sales of the Company's OraQuick ADVANCE(R) rapid
HIV-1/2 antibody test, substance abuse testing produ... |
| | | 04/30/07 | OraQuick(R) Rapid HIV Test Chosen for Madagascar National AIDS Control Program| Use of Oral Fluid Key to Selection - Madagascar Estimates Approximately 400,000 Individuals Will Be Tested in 2007
BETHLEHEM, Pa.--(BUSINESS WIRE)--April 30, 2007--OraSure
Technologies, Inc. (NASDAQ: OSUR), the market leader in oral fluid
diagnostics, announced today that it has been selected by the Malagasy
government and its National AIDS Control Program to be the exclusive
first-line provider of rapid HIV screening tests for the country's
outreach program over the next five years.... |
| | | 04/25/07 | OraSure Technologies Quarterly Conference Call Invitation| First Quarter Earnings Conference Call Tuesday, May 08, 2007, 5:00 p.m. ET
BETHLEHEM, Pa.--(BUSINESS WIRE)--April 25, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly
earnings conference call for 5:00 pm ET (2:00 pm PT) on Tuesday, May
8, 2007, covering 2007 first quarter financial results, business
developments and the Company's 2007 outlook.
May 8, 2007 Schedule
--------------------
4:00 p.m. E... |
| | | 04/02/07 | OraSure Technologies Signs Agreement for Development of Counseling and Referral System for Home Use Rapid HIV Test Kit| BETHLEHEM, Pa.--(BUSINESS WIRE)--April 2, 2007--OraSure
Technologies, Inc. (NASDAQ: OSUR), the market leader in oral fluid
diagnostics and the manufacturer of the OraQuick ADVANCE(R) Rapid
HIV-1/2 Antibody Test, announced today that it has signed an agreement
with Constella Group LLC, to design and develop a telephonic and
Internet accessible consumer counseling and referral system for use
with the Company's OraQuick ADVANCE(R) test in the consumer or
over-the-counter (OTC) market. Co... |
| | | 03/09/07 | OraSure Technologies to Present at the Cowen & Co. Health Care Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--March 9, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the Cowen & Co. Health Care Conference in
Boston, Massachusetts. The conference will be simultaneously webcast
over the Internet.
Mr. Michels is scheduled to speak on March 13, 2007, at
approximately 3:15 pm Eastern Time (12:15 pm Pacific Time). Interested
investors can ac... |
| | | 02/28/07 | OraSure Technologies to Launch First Over-the-Counter Cryosurgical Wart Removal Product in Mexico| Genomma Lab to Distribute Product under the POINTTS Tradename
BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 28, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR) announced today the commercial launch
of the first cryosurgical wart removal product in the over-the-counter
("OTC") or consumer retail market in Mexico. The product will be
manufactured by OraSure for its Mexican distributor, Producciones
Infovision, S.A. de C.V. The product will be sold under the POINTTS
tradename by Producciones ... |
| | | 02/13/07 | OraSure Announces 2006 Financial Results| BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 13, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid
diagnostics, today announced revenues of $68.2 million and $17.7
million for the year and quarter ended December 31, 2006,
respectively. This compares to revenues of $69.4 million and $18.0
million for the year and quarter ended December 31, 2005,
respectively.
The Company reported net income of $5.3 million, or $0.11 per
share on a fully-diluted basis, for the ... |
| | | 02/06/07 | OraSure Technologies Quarterly Conference Call Invitation| 2006 Fourth Quarter and Year End Earnings Conference Call Tuesday, February 13, 2007, 5:00 p.m. ET
BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 6, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly
earnings conference call covering 2006 fourth quarter and full-year
financial results and 2007 financial guidance for 5:00 pm ET (2:00 pm
PT) on Tuesday, February 13, 2007.
February 13, 2007 Schedule
-----------------... |
| | | 02/06/07 | OraSure Technologies Donates OraQuick ADVANCE(R) Rapid HIV-1/2 Tests in Honor of National Black HIV/AIDS Awareness Day| BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 6, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, today announced that, in an effort to encourage rapid HIV
testing for National Black HIV/AIDS Awareness Day (NBHAAD), it has
donated OraQuick ADVANCE(R) Rapid HIV-1/2 Tests to more than 20
community-based organizations and testing sites across the country.
The tests will be utilized by these locations to conduct free HIV
testing in observance of NBHAAD ... |
| | | 01/05/07 | OraSure Technologies to Participate at the Ninth Annual Needham Growth Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 5, 2007--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the Ninth Annual Needham Growth Conference in
New York at approximately 1:30 pm Eastern Time, (10:30 am Pacific
Time) on January 11, 2007. The conference will be simultaneously
webcast over the Internet.
Interested investors can access the live audio webcast of the
discussi... |
| | | 01/04/07 | Schering-Plough and OraSure Technologies Sign Agreement for Development and Promotion of Rapid Point-of-Care Oral Hepatitis C Test| Test Will Utilize OraSure's OraQuick(R) Technology Platform
KENILWORTH, N.J. and BETHLEHEM, Pa., Jan. 4 /PRNewswire-FirstCall/ --
Schering-Plough Corporation (NYSE: SGP) and OraSure Technologies, Inc.
(Nasdaq: OSUR) today announced an agreement to collaborate on the development
and promotion of a rapid oral test for the detection of antibodies to the
hepatitis C virus (HCV) utilizing OraSure Technologies' OraQuick(R) technology
platform.
The agreement brings together OraSure - th... |
| | | 12/07/06 | OraQuick ADVANCE(R) to Be Centerpiece of Expanded HIV Testing in Philadelphia| Initial $1.5 Million Funding Increase Approved for the City's
HIV/AIDS Programs
BETHLEHEM, Pa.--(BUSINESS WIRE)--Dec. 7, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR), the leader in oral fluid
diagnostics, announced that its OraQuick ADVANCE(R) Rapid HIV 1/2
Antibody Test will be the centerpiece of a planned initiative in the
City of Philadelphia to provide oral fluid rapid HIV 1/2 testing to
populations that are traditionally underserved and in many inst... |
| | | 12/07/06 | OraSure Technologies to Participate At RBC Capital Markets Healthcare Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--Dec. 7, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will participate in a
panel discussion related to the development of Point-of-Care
Diagnostics on December 14, 2006, at 2:00 pm EST as part of the 2006
RBC Capital Markets Healthcare Conference being held at the Westin New
York at Times Square Hotel in New York City.
Interested investors can access the live audio we... |
| | | 11/30/06 | OraSure Technologies to Participate in NASDAQ Industry Panel Discussion and Market Close in Observance of World AIDS Day on December 1, 2006| Company Will Also Support Local and Global Campaigns to Encourage Individuals to Learn Their HIV Status
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 30, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, today announced it will participate in the NASDAQ's Stock
Market Closing Bell Ceremony and a special industry panel discussion
in observance of World AIDS Day on December 1, 2006. In addition, as
part of this commemorative day, OraSure will actively ... |
| | | 11/01/06 | OraSure Announces Third Quarter Financial Results| BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 1, 2006--OraSure
Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid
diagnostics, today announced revenues of $17.6 million for the quarter
ended September 30, 2006, compared to $18.1 million in revenues
recorded for the comparable period in 2005.
The Company's net income was $2.1 million, or $0.05 per share on a
basic and fully-diluted basis, for the third quarter of 2006, which
includes charges for stock option expense and a pro... |
| | | 10/27/06 | OraSure Technologies Sets 2007 Annual Meeting Date| BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 27, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that its 2007 Annual
Meeting of Stockholders is scheduled to be held on Tuesday, May 15,
2007, at the Historic Hotel Bethlehem, Bethlehem, Pennsylvania.
Stockholder proposals must be received no later than December 9, 2006,
in order to be considered for inclusion in the Company's Proxy
Statement under relevant Securities and Exchange Commission rules and
no later than February 14, ... |
| | | 10/23/06 | OraSure Technologies Quarterly Conference Call Invitation| Third Quarter Earnings Conference Call Wednesday, November 1, 2006, 5:00 p.m. ETBETHLEHEM, Pa., Oct 23, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular
quarterly earnings conference call covering its 2006 third quarter
financial results and an update of business developments and financial
guidance, for 5:00 pm ET (2:00 pm PT) on Wednesday, November 1, 2006.
November 1, 2006 Schedule
4:00 p.m. ET 2006 third quarter finan... |
| | | 10/12/06 | OraSure Technologies Donates OraQuick ADVANCE(R) Tests in Recognition of National Latino AIDS Awareness Day| 4th Annual Awareness Day to Be Held on Oct. 15th Interview Footage and B-Roll Available via Satellite Uplink, Friday, October 13 at 2:00 PM EDTBETHLEHEM, Pa., Oct 12, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in
oral fluid diagnostics, in conjunction with the Latino Commission on
AIDS and the Congressional Hispanic Caucus, announced today the
donation of OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Tests in
recognition of the 4th Annual National Latino... |
| | | 10/05/06 | OraSure Technologies Announces Director Appointments and Organizational Changes| BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 5, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, today announced the appointment of two new members of the
Company's Board of Directors, the promotions of two executive officers
and the addition of a new member to its management team.
Michael Celano has been appointed as a member of the Board of
Directors to serve as a Class III Director with an initial term
expiring at the Company's 2009 Annual M... |
| | | 10/04/06 | Roche Diagnostics and OraSure Technologies Sign Letter of Intent to Develop Fully Automated Oral Fluid Drugs of Abuse Assays| This partnership will enable laboratories to increase efficiencies while offering an improved level of service by providing quicker turnaround times
INDIANAPOLIS, Oct. 4 /PRNewswire/ -- Roche Diagnostics today signed a letter of intent to negotiate an agreement for the joint development and commercialization of homogeneous fully-automated oral fluid drugs of abuse assays that can run on random access chemistry analyzers with OraSure Technologies, Inc. (Nasdaq: OSUR - News). The oral fluid as... |
| | | 09/27/06 | OraSure Technologies Commences Initial Studies for FDA Approval of Home Use Rapid HIV Test Kit| BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 27, 2006--OraSure
Technologies, Inc. (NASDAQ: OSUR), the market leader in oral fluid
diagnostics and the manufacturer of the OraQuick ADVANCE(R) Rapid
HIV-1/2 Antibody Test, announced today that it has commenced several
laboratory-based operational studies as the initial stage of the
process to obtain U.S. Food and Drug Administration ("FDA") approval
of the OraQuick ADVANCE(R) test for use in the consumer or
over-the-counter ("OTC") market in th... |
| | | 09/25/06 | OraSure Technologies Responds to Acquisition of Wartner Cryosurgical Product Line by Prestige Brands| BETHLEHEM, Pa.--(BUSINESS WIRE)--OraSure Technologies, Inc. (NASDAQ: OSUR) today issued a statement
in response to the announcement by Prestige Brands, Inc. that it has
acquired the Wartner cryosurgical wart removal product line, which is
sold in the retail or over the counter ("OTC") market in the United
States. The Wartner product competes directly in the OTC market
against OraSure's cryosurgical wart removal product, which is
distributed by Prestige on an exclusive basis under its Compo... |
| | | 09/21/06 | OraSure Technologies Applauds CDC's Call for Routine HIV Testing; Revised HIV Testing Recommendations Advocate HIV Screening as Routine Part of Medical Care| BETHLEHEM, Pa., Sep 21, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market
leader in oral fluid diagnostics and the manufacturer of the OraQuick
ADVANCE(R) Rapid HIV-1/2 Antibody Test, today issued a statement in
support of "The Revised Recommendations for HIV Testing of Adults,
Adolescents, and Pregnant Women in Health Care Settings," issued today
by the Centers for Disease Control and Prevention ("CDC"). These
recommendations, which advocate routine HIV screenin... |
| | | 09/19/06 | OraSure Technologies to Present at UBS Global Life Sciences Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 19, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the UBS Global Life Sciences Conference 2006
in New York, at approximately 1:00 pm Eastern Time (10:00 am Pacific
Time) on September 27, 2006. The conference will be simultaneously
webcast over the Internet.
Interested investors can access the live audio webcast of the
di... |
| | | 08/28/06 | OraSure Technologies to Present at Thomas Weisel Partners' Healthcare Conference 2006| BETHLEHEM, Pa.--(BUSINESS WIRE)--Aug. 28, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the Thomas Weisel Partners' Healthcare
Conference 2006 in Boston, Massachusetts, at approximately 8:00 am
Eastern Time (5:00 am Pacific Time) on September 7, 2006. The
conference will be simultaneously webcast over the Internet.
Interested investors can access the live audi... |
| | | 08/08/06 | OraSure Announces Second Quarter Financial Results| BETHLEHEM, Pa., Aug 08, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a market
leader in oral fluid diagnostics, today announced revenues of $17.6
million for the quarter ended June 30, 2006, representing a slight
increase over the $17.4 million in revenues recorded for the
comparable period in 2005.
The Company's net income was $1.2 million, or $0.03 per share on a
basic and fully-diluted basis, for the second quarter of 2006, which
includes $953,000 of stock option... |
| | | 07/31/06 | OraSure Technologies Appoints Senior Vice President, Business Development| BETHLEHEM, Pa.--(BUSINESS WIRE)--July 31, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, today announced that Mark Kirtland has been appointed as
the Company's Senior Vice President, Business Development.
Mr. Kirtland has over fourteen years of experience in healthcare
and medical diagnostics, with a particular focus on the assessment and
commercialization of new technologies. He brings to OraSure
Technologies extensive transactional e... |
| | | 07/25/06 | OraSure Technologies Quarterly Conference Call Invitation; Second Quarter Earnings Conference Call Tuesday, August 08, 2006, 5:00 p.m. ET| BETHLEHEM, Pa.--(BUSINESS WIRE)--July 25, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly
earnings conference call covering its 2006 second quarter financial
results and an update of business developments and financial guidance,
for 5:00 pm ET (2:00 pm PT) on Tuesday, August 8, 2006.
August 8, 2006 Schedule
4:00 p.m. ET 2006 second quarter financial results will be
distributed by Business Wire
... |
| | | 06/27/06 | OraSure Technologies Signs Purchase Contract with New York City Department of Mental Health and Hygiene for OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Tests| BETHLEHEM, Pa.--(BUSINESS WIRE)--June 27, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, today announced that it has entered into an approximate
$6 million, multi-year purchase contract with the New York City
Department of Mental Health and Hygiene to expand the use of
OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Tests in the City.
The contract will commence on July 1, 2006, and will extend New
York City's aggressive program of HIV p... |
| | | 06/26/06 | Washington, DC Launches City-Wide HIV Testing and Prevention Campaign with OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test| BETHLEHEM, Pa., Jun 26, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) announced today
that the City of Washington, DC has agreed to purchase OraQuick(R)
ADVANCE(TM) Rapid HIV-1/2 Antibody Tests for use in a city-wide HIV
testing campaign being launched this week on June 27th, National HIV
Testing Day. The campaign, led by Dr. Marsha Martin, Senior Deputy
Director for HIV Policy and Programs and DC Mayor Anthony Williams
will offer increased HIV testing services with OraQ... |
| | | 06/25/06 | OraQuick(R) Advance(TM) to Be Featured as Part of D.C Health Department's City-Wide HIV Testing Campaign Launch on June 27, 2006| --(BUSINESS WIRE)--OraSure Technologies, Inc. (NASDAQ: OSUR):
WHAT: OraSure Technologies, Inc. (NASDAQ: OSUR) will take part in
the official launch of the D.C. Health Department's city-wide
HIV testing campaign on June 27, National HIV Testing Day
(NHTD).
The citywide campaign will encourage all District residents to
learn their HIV status. The D.C. Health Department plans on
distributing tests through a variety of settings includi... |
| | | 06/22/06 | OraSure Technologies, the National Association of People with AIDS and POZ Magazine to Open the NASDAQ Stock Market in Recognition of National HIV Testing Day| BETHLEHEM, Pa., Jun 22, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market
leader in oral fluid diagnostics, today announced it will participate
in The NASDAQ Stock Market Opening Bell Ceremony on June 27th in
recognition of National HIV Testing Day 2006, a national effort that
is commemorated annually. Joining OraSure President and Chief
Executive Officer, Douglas A. Michels, at the NASDAQ Market Open will
be Frank J. Oldham Jr., Executive Director of the Nationa... |
| | | 06/20/06 | OraSure Technologies and the National Association of People with AIDS Launch Second Annual ''Mayors Campaign Against HIV'' for National HIV Testing Day 2006; Mayors Across the U.S. Promote HIV Testing and Prevention| BETHLEHEM, Pa.--(BUSINESS WIRE)--June 20, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR) and the National Association of
People with AIDS (NAPWA) announced today the launch of the second
annual Mayors Campaign Against HIV, a national campaign to encourage
testing for HIV and promote the benefits of individuals knowing their
HIV status. The Campaign is being sponsored by OraSure Technologies,
the manufacturer of the OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody
Test, in observance of ... |
| | | 06/08/06 | OraSure Technologies to Present at Needham Biotechnology and Medical Technology Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--June 8, 2006--OraSure
Technologies, Inc. (NASDAQ: OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the Needham & Company, LLC Biotechnology and
Medical Technology Conference in New York City. The conference will be
simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak on June 15, 2006, at
approximately 2:30 pm Eastern Time (11:30 am Pacific Time). ... |
| | | 06/06/06 | OraSure Technologies to Present at Pacific Growth Equities Life Sciences Growth Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--June 6, 2006--OraSure
Technologies, Inc. (NASDAQ: OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the Pacific Growth Equities Life Sciences
Growth Conference in San Francisco, California. The conference will be
simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak on June 13, 2006, at
approximately 12:30 pm Pacific Time (3:30 pm Eastern Time). Int... |
| | | 05/22/06 | OraSure Technologies Appoints New Director| BETHLEHEM, Pa., May 22, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market
leader in oral fluid diagnostics, today announced the appointment of
Jack Goldstein, Ph.D. as a member of the Company's Board of Directors.
Dr. Goldstein will serve as a Class I Director with an initial term
expiring at the Company's 2007 Annual Meeting of Stockholders.
Dr. Goldstein has enjoyed a distinguished career in the medical
diagnostic and pharmaceutical industries. Since 2002, Dr... |
| | | 05/18/06 | CDC Commits to Bulk Purchase of OraQuick(R) Advance(TM) Tests to Support Continuing HIV Prevention Programs; OraSure Increases 2006 Full Year Guidance| BETHLEHEM, Pa.--(BUSINESS WIRE)--May 18, 2006--OraSure
Technologies, Inc. (NASDAQ: OSUR), the market leader in oral fluid
diagnostics, announced today that The Centers for Disease Control and
Prevention ("CDC") has provided the Company with a purchase order for
the immediate bulk procurement of its OraQuick(R) ADVANCE(TM) Rapid
HIV-1/2 Antibody Test. The CDC placed the order to further support its
prevention initiatives. This order is the fourth bulk purchase of
OraQuick(R) devices ma... |
| | | 05/10/06 | OraSure Technologies to Webcast Annual Meeting of Stockholders| BETHLEHEM, Pa., May 10, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market
leader in oral fluid diagnostics, announced that it will webcast its
2006 Annual Meeting of Stockholders beginning at 10:00 a.m. Eastern
Time (7:00 a.m. Pacific Time) on Tuesday, May 16, 2006.
The formal portion of the meeting will be immediately followed by
a management presentation and a question and answer session. Persons
accessing the webcast who desire to ask questions will be permi... |
| | | 05/08/06 | OraSure Applauds CDC's Expected Call for Routine HIV Testing Nationwide; CDC to Issue Revised HIV Testing Guidelines Recommending Routine HIV Testing| BETHLEHEM, Pa.--(BUSINESS WIRE)--May 8, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics and the manufacturer of the OraQuick(R) ADVANCE(TM) Rapid
HIV-1/2 Antibody Test, today issued a statement in support of the U.S.
Centers for Disease Control and Prevention's (CDC) plans to issue
revised HIV testing guidelines that call for voluntary HIV testing as
part of routine medical care, for all Americans ages 13 to 64 -
regardless of their perceive... |
| | | 05/02/06 | OraSure Technologies Announces 2006 First Quarter Results| BETHLEHEM, Pa., May 02, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a market
leader in oral fluid diagnostics, today announced revenues of $15.2
million for the quarter ended March 31, 2006, compared to $15.8
million in revenues recorded for the quarter ended March 31, 2005.
Increased sales of both the Company's OraQuick(R) ADVANCE(TM) rapid
HIV-1/2 antibody test and substance abuse testing products during the
first quarter of 2006, were offset by decreased sales of t... |
| | | 04/21/06 | OraSure Technologies Quarterly Conference Call Invitation; First Quarter Earnings Conference Call Tuesday, May 2, 2006, 5:00 p.m. ET| BETHLEHEM, Pa.--(BUSINESS WIRE)--April 21, 2006--OraSure
Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular quarterly
earnings conference call covering 2006 first quarter financial results
for 5:00 p.m. ET (2:00 p.m. PT) on Tuesday, May 2, 2006.
May 2, 2006 Schedule
4:00 p.m. ET 2006 first quarter financial results will be
distributed by Business Wire
4:50 p.m. ET To participate in the conference call, dial
888... |
| | | 04/19/06 | Novation Signs Single Source Agreement for OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test| BETHLEHEM, Pa.--(BUSINESS WIRE)--April 19, 2006--OraSure
Technologies, Inc. (NASDAQ: OSUR) today announced that Novation, the
health care contracting services company of VHA, Inc., a health care
provider alliance of more than 2,400 not-for-profit health care
organizations, and the University HealthSystem Consortium (UHC), has
signed an agreement with Abbott Laboratories to make the OraQuick(R)
ADVANCE(TM) Rapid HIV-1/2 Antibody Test available throughout
Novation's network of healthcar... |
| | | 03/13/06 | OraSure Technologies Issues Statement Regarding Proceedings of the Blood Products Advisory Committee Meeting of the FDA; Company Applauds FDA's Recommendations for Proposed Studies To Support Approval of Home-Use HIV Test Kits| BETHLEHEM, Pa.--(BUSINESS WIRE)--March 13, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics and the manufacturer of the OraQuick(R) ADVANCE(TM) Rapid
HIV-1/2 Antibody Test, today issued a statement following a meeting of
the Blood Products Advisory Committee ("BPAC") of the Food and Drug
Administration ("FDA"), held Friday, March 10, 2006, in Gaithersburg,
MD.
The BPAC meeting included a discussion of proposed studies to
support the appr... |
| | | 03/09/06 | ADVISORY/OraSure Technologies to Host Media Briefing Following Blood Products Advisory Committee Meeting of the FDA; March 10th Committee Meeting to Address Proposed Studies to Support Approval of Over-the-Counter HIV Test Kits| --(BUSINESS WIRE)--OraSure Technologies, Inc. (NASDAQ:OSUR):
WHAT: OraSure Technologies, Inc. (NASDAQ:OSUR) CEO and President
Douglas Michels will host an on-site media briefing
following the Blood Products Advisory Committee (BPAC)
meeting on March 10, 2006, to address the outcomes and
next steps resulting from the BPAC discussion, as well as
the potential for an OTC rapid HIV test from OraSure. The
Com... |
| | | 02/22/06 | OraSure Technologies to Present at the Cowen & Co. Health Care Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 22, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the Cowen & Co. Health Care Conference in
Boston, Massachusetts. The conference will be simultaneously webcast
over the Internet.
Mr. Michels is scheduled to speak on March 7, 2006, at
approximately 9:40 am Eastern Time (6:40 am Pacific Time). Interested
investors can acce... |
| | | 02/09/06 | OraSure Announces Record Full Year Financial Results; 2005 Results Include $18.2 Million Tax Benefit| BETHLEHEM, Pa., Feb 09, 2006 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a market
leader in oral fluid diagnostics, today announced revenues of $69.4
million and $18.0 million for the year and quarter ended December 31,
2005, respectively. Full year 2005 revenues represent record revenues
for the Company and a 28% increase over the $54.0 million in revenues
recorded in 2004. Revenues for the quarter ended December 31, 2005
were 27% higher than those for the same period in ... |
| | | 02/02/06 | OraSure Applauds President's Initiative to Prevent, Treat and Defeat HIV/AIDS; President Bush calls for Nation-Wide Deployment of Rapid HIV Tests| BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 2, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics and the manufacturer of the OraQuick(R) ADVANCE(TM) Rapid
HIV-1/2 Antibody Test, today issued a statement in support of the
Administration's recently-announced initiative to increase efforts to
prevent, treat and ultimately defeat HIV/AIDS. The initiative includes
a proposal to distribute rapid HIV test kits in areas of the country
with the highest rates... |
| | | 01/25/06 | OraSure Technologies Quarterly Conference Call Invitation; 2005 Fourth Quarter and Year End Earnings Conference Call Thursday February 09, 2006, 5:00 p.m. ET| BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 25, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly
earnings conference call covering 2005 fourth quarter and full-year
financial results for 5:00 pm ET (2:00 pm PT) on Thursday, February 9,
2006.
February 9, 2006 Schedule
-------------------------
4:00 p.m. ET 2005 fourth quarter and full-year financial
results will be distributed by... |
| | | 01/24/06 | Johns Hopkins Hospital Successfully Implements Routine Oral Fluid HIV Screening Program with OraQuick(R) ADVANCE(TM); OraQuick(R) ADVANCE(TM) Is Most Used Rapid HIV Test in Hospitals| BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 24, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that The Johns
Hopkins Hospital Department of Emergency Medicine has implemented an
oral fluid HIV screening program in the emergency department of The
Johns Hopkins Hospital using the OraQuick(R) ADVANCE(TM) Rapid HIV-1/2
Antibody test. The program, which was initiated in September 2005,
recently completed its start-up phase and is becoming fully
operational. The Johns Hopkins pro... |
| | | 01/09/06 | OraSure Technologies Appoints New Director| BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 9, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, today announced the appointment of Charles W. Patrick as
a member of the Company's Board of Directors. Mr. Patrick has been
appointed to fill a vacancy on the Company's Board and will serve as a
Class III Director with an initial term expiring at the Company's 2006
Annual Meeting of Stockholders.
Mr. Patrick has had extensive experience managing hig... |
| | | 01/04/06 | OraSure Technologies to Present at Needham & Company, LLC Growth Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 4, 2006--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the Needham & Company, LLC Growth Conference
in New York City. The conference will be simultaneously webcast over
the Internet.
Mr. Michels is scheduled to speak on January 10, 2006, at
approximately 11:30 am Eastern Time (8:30 am Pacific Time). Interested
investors can acc... |
| | | 12/20/05 | OraSure Technologies Provides Update Regarding OraQuick(R) ADVANCE(TM)| BETHLEHEM, Pa.--(BUSINESS WIRE)--Dec. 20, 2005--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that it has taken
several actions in response to recent reports that specific clinical
sites in San Francisco and New York City and the L.A. Gay and Lesbian
Center have recently experienced an increased level of false positive
results using the Company's OraQuick(R) ADVANCE(TM) Rapid HIV-1/2
Antibody Test with oral fluid. The purpose of these actions has been
to ensure that custome... |
| | | 12/01/05 | OraSure Technologies Opens NASDAQ and Donates OraQuick(R) ADVANCE(TM) Tests in Recognition of World AIDS Day; OraSure Also Receives Red Ribbon Leadership Award| BETHLEHEM, Pa.--(BUSINESS WIRE)--Dec. 1, 2005--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, today announced it will participate in opening the NASDAQ
Stock Market and donate up to 100,000 OraQuick(R) ADVANCE(TM) Rapid
HIV-1/2 Antibody Test kits to several African countries and to India
in recognition of World AIDS Day, a global effort that is commemorated
annually on December 1st. OraSure President and CEO, Douglas A.
Michels will announce thi... |
| | | 11/30/05 | OraSure Launches OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test in Mexico; Event to Be Held at CENSIDA'S Ninth HIV/AIDS Conference on November 30th at 7:00 PM CST| BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 30, 2005--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, announced today the launch of its OraQuick(R) ADVANCE(TM)
Rapid HIV-1/2 Antibody test in Mexico. OraQuick(R) ADVANCE(TM) is the
only FDA approved and CLIA waived oral fluid rapid HIV-1/2 test
currently available in the United States, and will be the only oral
fluid rapid HIV test available in Mexico.
The OraQuick(R) ADVANCE(TM) test will be sold by... |
| | | 11/09/05 | OraSure Announces Record Third Quarter Financial Results; Increases Full-Year Earnings Guidance| BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 9, 2005--OraSure
Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid
diagnostics, today announced record revenues of $18.1 million for the
quarter ended September 30, 2005, representing a 28% increase over the
$14.2 million in revenues recorded for the comparable period in 2004.
The Company's net income was $3.8 million, or $0.08 per share on a
basic and fully-diluted basis, for the third quarter of 2005. These
results compare to a... |
| | | 10/24/05 | OraSure Technologies Quarterly Conference Call Invitation; 2005 Third Quarter Earnings Conference Call Wednesday November 9, 2005, 5:00 p.m. ET| BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 24, 2005--OraSure
Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular quarterly
earnings conference call covering 2005 third quarter financial results
for 5:00 pm ET (2:00 pm PT) on Wednesday, November 9, 2005.
November 9, 2005 Schedule
-------------------------
4:00 p.m. ET 2005 third quarter financial results will be
distributed by Business Wire
4:50 p.m. ET To parti... |
| | | 10/18/05 | OraSure Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 18, 2005--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the C.E. Unterberg, Towbin Emerging Growth
Life Sciences Conference in New York City. The conference will be
simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak on October 25, 2005, at
approximately 2:20 P.M. Eastern Time (11:20 A.M. Pacific Time).
... |
| | | 10/12/05 | OraSure Technologies to Present before the FDA Blood Products Advisory Committee on November 3, 2005| BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 12, 2005--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, announced today that it will present at a meeting of the
Blood Products Advisory Committee ("BPAC") of the U.S. Food and Drug
Administration ("FDA") in Gaithersburg, Maryland on November 3, 2005.
The public meeting will include an OraSure proposal for an
Over-the-Counter Home-Use Rapid HIV Test Kit.
The full BPAC meeting agenda for the November 3... |
| | | 09/26/05 | OraSure Technologies Appoints New Chief Science Officer| BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 26, 2005--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, today announced that Stephen R. Lee, Ph.D. has been named
as the Company's Executive Vice President and Chief Science Officer.
Dr. Lee joins OraSure Technologies with twenty years of experience
in the immunodiagnostic industry primarily with Ortho Clinical
Diagnostics, a Johnson & Johnson company. While at Ortho, Dr. Lee
served as Vice President, ... |
| | | 09/12/05 | OraSure Technologies to Present at UBS Global Life Sciences Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 12, 2005--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the UBS Global Life Sciences Conference in New
York City. The conference will be simultaneously webcast over the
Internet.
Mr. Michels is scheduled to speak on September 26, 2005, at
approximately 3:00 P.M. Eastern Time (12:00 P.M. Pacific Time).
Interested investors can ac... |
| | | 08/25/05 | OraSure Technologies to Present at Thomas Weisel Partners' Healthcare Tailwinds 2005 Conference| BETHLEHEM, Pa., Aug 25, 2005 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced
that Douglas A. Michels, President and Chief Executive Officer, and
Ronald H. Spair, Chief Financial Officer, will speak to the investment
community at the Thomas Weisel Partners' Healthcare Tailwinds 2005
Conference in Boston, Massachusetts, at approximately 10:55 am Eastern
Time (7:55 am Pacific Time) on September 7, 2005. The conference will
be simultaneously webcast over the Interne... |
| | | 08/24/05 | OraSure Technologies Sets 2006 Annual Meeting Date| BETHLEHEM, Pa., Aug 24, 2005 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced
that its 2006 Annual Meeting of Stockholders is scheduled to be held
on Tuesday, May 16, 2006, at the Historic Hotel Bethlehem, Bethlehem,
Pennsylvania. Stockholder proposals must be received no later than
December 9, 2005, in order to be considered for inclusion in the
Company's Proxy Statement under relevant Securities and Exchange
Commission rules and no later than February 15, 2006,... |
| | | 08/02/05 | OraSure Receives HCV Patent License from Ortho-Clinical Diagnostics and Chiron Corporation; OraSure to Develop and Commercialize Rapid HCV Test| BETHLEHEM, Pa.--(BUSINESS WIRE)--Aug. 2, 2005--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, announced today that it has received a worldwide,
non-exclusive license from Ortho-Clinical Diagnostics and Chiron
Corporation to patents relating to the hepatitis C ("HCV") virus.
Under the terms of the license, OraSure has obtained non-exclusive
rights to certain HCV patents from Ortho-Clinical Diagnostics and
Chiron Corporation, in exchange for the payme... |
| | | 08/02/05 | OraSure Announces Record Second Quarter Financial Results; Increases Full-Year Earnings Guidance| BETHLEHEM, Pa.--(BUSINESS WIRE)--Aug. 2, 2005--OraSure
Technologies, Inc. (Nasdaq NM:OSUR), a market leader in oral fluid
diagnostics, today announced record revenues of $17.4 million for the
quarter ended June 30, 2005, representing a 32% increase over the
$13.2 million in revenues recorded for the comparable period in 2004.
The Company's net income was $1.4 million, or $0.03 per share on a
basic and fully-diluted basis, for the second quarter of 2005. These
results compare to net ... |
| | | 07/14/05 | OraSure Technologies Quarterly Conference Call Invitation; 2005 Second Quarter Earnings Conference Call Tuesday August 2, 2005, 5:00 p.m. ET| BETHLEHEM, Pa., Jul 14, 2005 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled
its regular quarterly earnings conference call covering 2005 second
quarter financial results for 5:00 pm ET (2:00 pm PT) on Tuesday,
August 2, 2005.
August 2, 2005 Schedule
-----------------------
4:00 p.m. ET 2005 second quarter financial results will be
distributed by Business Wire
4:50 p.m. ET To participate in the conference cal... |
| | | 06/15/05 | The National Association of People with AIDS and OraSure Technologies Launch ''Mayors Campaign against HIV'' for National HIV Testing Day 2005; Campaign Urges Mayors across the U.S. to Promote HIV Testing and Prevention| BETHLEHEM, PA.--(BUSINESS WIRE)--June 15, 2005--OraSure
Technologies, Inc. (NASDAQ:OSUR) and the National Association of
People with AIDS (NAPWA) announced today the launch of the Mayors
Campaign Against HIV, a national campaign to encourage testing for HIV
and promote the benefits of knowing one's HIV status. The Campaign is
being sponsored by OraSure Technologies, the manufacturer of the
OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test, in observance of
National HIV Testing Day on Ju... |
| | | 06/02/05 | OraSure and SSL International to Launch Over-the-Counter Cryosurgical Wart Treatment Product in Europe, Australia and New Zealand; OraSure Increases Financial Guidance; SSL International to Distribute Product Under the Scholl Brand| BETHLEHEM, Pa., Jun 02, 2005 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) announced today
the execution of an exclusive agreement with SSL International plc
(LSE:SSL), under which OraSure will manufacture and supply, and SSL
will distribute, the Company's cryosurgical wart removal product in
the over-the-counter ("OTC") footcare market in Europe, Australia and
New Zealand. The product will be manufactured and sold under SSL
International's Scholl and Dr. Scholl trademarks, a... |
| | | 06/01/05 | OraSure Technologies to Present at Thomas Weisel Partners' Growth Forum 7.0 Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--June 1, 2005--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, and Ronald H. Spair,
Executive Vice President and Chief Financial Officer, will speak to
the investment community at the Thomas Weisel Partners' Growth Forum
7.0 Conference in San Francisco, California, at approximately 1:55 pm
Eastern Time (10:55 am Pacific Time) on June 15, 2005. The conference
will be simultaneously webc... |
| | | 05/11/05 | OraSure Technologies to Webcast Annual Meeting of Stockholders| BETHLEHEM, Pa.--(BUSINESS WIRE)--May 11, 2005--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, announced that it will webcast its 2005 Annual Meeting of
Stockholders beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific
Time) on Tuesday, May 17, 2005.
The formal portion of the meeting will be immediately followed by
a management presentation and a question and answer session. Persons
accessing the webcast who desire to ask questions will be p... |
| | | 05/03/05 | OraSure Technologies Announces 2005 First Quarter Results; Record Quarterly Revenues of $15.8 Million and Net Income of $1.6 Million; Increases Guidance for 2005 Net Income| BETHLEHEM, Pa.--(BUSINESS WIRE)--May 3, 2005--OraSure
Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid
diagnostics, today announced record revenues of $15.8 million for the
quarter ended March 31, 2005, representing a 28% increase over the
$12.4 million in revenues recorded for the comparable period in 2004.
Product revenues for the quarter were $15.7 million, also a 28%
increase over the first quarter of 2004.
The Company's net income was approximately $1.6 million, ... |
| | | 04/15/05 | OraSure Technologies Quarterly Conference Call Invitation; 2005 First Quarter Earnings Conference Call Tuesday May 3, 2005, 5:00 p.m. ET| BETHLEHEM, Pa., Apr 15, 2005 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled
its regular quarterly earnings conference call covering 2005 first
quarter financial results for 5:00 pm ET (2:00 pm PT) on Tuesday, May
3, 2005.
May 3, 2005 Schedule
4:00 p.m. ET 2005 first quarter financial results will be
distributed by Business Wire
4:50 p.m. ET To participate in the conference call, dial
... |
| | | 03/30/05 | OraSure Sponsors ''Road to Hope'' HIV/AIDS Awareness Tour; National Tour of 22 Colleges and Universities Urges HIV Awareness, Testing, Prevention| BETHLEHEM, Pa.--(BUSINESS WIRE)--March 30, 2005--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, announced today that it will be the presenting sponsor of
the 2005 Road to Hope Tour, a national HIV/AIDS awareness campaign.
The tour is being organized by Hope's Voice, a national HIV/AIDS
organization committed to promoting the education and prevention of
HIV/AIDS to young adults and the Student Global AIDS Campaign (SGAC),
a national HIV/AIDS advocacy... |
| | | 03/04/05 | OraSure Technologies to Present at SG Cowen's Health Care Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--March 4, 2005--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the SG Cowen Health Care Conference in Boston,
Massachusetts. The conference will be simultaneously webcast over the
Internet.
Mr. Michels is scheduled to speak on March 15, 2005, at
approximately 11:20 am Eastern Time (8:20 am Pacific Time). Interested
investors can access ... |
| | | 02/18/05 | OraSure Technologies to Present at Wells Fargo Securities' Healthcare Fireside Chats| BETHLEHEM, Pa., Feb 18, 2005 (BUSINESS WIRE) -- OraSure
Technologies, Inc. (NASDAQ:OSUR) announced today that Douglas A.
Michels, President and Chief Executive Officer, and Ronald H. Spair,
Executive Vice President and Chief Financial Officer, will speak to
the investment community at the Wells Fargo Securities' Health Care
Fireside Chats in New York, New York. The conference will be
simultaneously webcast over the Internet.
Mr. Michels and Mr. Spair are scheduled to speak on March 2,... |
| | | 02/14/05 | Abbott and OraSure Technologies Enter Agreement for OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Test|
Abbott Obtains Exclusive Distribution Rights for Hospitals and Non-Exclusive Rights to Physician Offices in the United States
ABBOTT PARK, Ill., and BETHLEHEM, Pa., Feb. 14 /PRNewswire-FirstCall/ --
Abbott (NYSE: ABT) and OraSure Technologies (Nasdaq: OSUR) today announced an
agreement for the distribution of OraSure Technologies' OraQuick(R)
ADVANCE(TM) rapid antibody test for the detection of antibodies to the Human
Immunodeficiency Virus Type 1 (HIV-1) and Type 2 (HIV-2). Under the... |
| | | 02/10/05 | OraSure Announces Record Financial Results| BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 10, 2005--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, today announced record revenues of $54.0 million and
$14.2 million for the year and quarter ended December 31, 2004,
respectively. Full year 2004 revenues represent a 34% increase from
the $40.5 million in revenues recorded for 2003. Revenues for the
quarter ended December 31, 2004 were 20% higher than those for the
same period of 2003.
The Company ... |
| | | 01/27/05 | OraSure Technologies Quarterly Conference Call Invitation; 2004 Fourth Quarter and Year End Earnings Conference Call Thursday, February 10, 2005, 5:00 p.m. ET| BETHLEHEM, Pa., Jan 27, 2005 /PRNewswire-FirstCall via COMTEX/ -- OraSure Technologies,
Inc. (Nasdaq: OSUR) has scheduled its regular quarterly earnings conference
call covering 2004 fourth quarter and full-year financial results for 5:00 pm
ET (2:00 pm PT) on Thursday, February 10, 2005.
February 10, 2005 Schedule
4:00 p.m. ET 2004 fourth quarter and full-year financial results will
be distributed by Business Wire
4:50 p.m. ET To participate in t... |
| | | 12/22/04 | CDC to Purchase $2.3 Million Worth of OraQuick ADVANCE Rapid HIV-1/2 Antibody Tests; Company Updates Financial Guidance for 2005| BETHLEHEM, Pa.--(BUSINESS WIRE)--Dec. 22, 2004--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, announced today that The Centers for Disease Control and
Prevention ("CDC") will purchase approximately $2.3 million of the
Company's OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Tests. The
CDC purchase is expected to be fulfilled by September 30, 2005.
This is the first bulk purchase of the OraQuick(R) ADVANCE(TM)
test. Two other bulk purchases of... |
| | | 12/01/04 | OraSure Technologies Opens NASDAQ Stock Market in Honor of World AIDS Day; Cities Across the U.S. Launch Rapid Oral Fluid HIV Testing with OraQuick ADVANCE| BETHLEHEM, Pa., Dec 1, 2004 (BUSINESS WIRE) -- OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, today opened The NASDAQ Stock Market in recognition of
World AIDS Day, commemorated annually on December 1. OraSure President
and CEO, Douglas A. Michels, presided over The NASDAQ Market Open
ceremony this morning in New York City.
This year's World AIDS Day is dedicated to women and girls. Nearly
half of the estimated 37.2 million adults living with HI... |
| | | 11/10/04 | OraQuick ADVANCE Rapid HIV-1/2 Antibody Test Receives Popular Science Magazine's '2004 Best of What's New' Award| BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 10, 2004--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, announced today that its OraQuick(R) ADVANCE Rapid
HIV-1/2 Antibody Test has been awarded a 2004 Best of What's New award
by Popular Science magazine in the Personal Health category. The award
was announced on November 9, 2004, at the Best of What's New Showcase
Event at Vanderbilt Hall in Grand Central Terminal in New York City.
The OraQuick(R) ADVA... |
| | | 11/02/04 | OraSure Announces 2004 Third Quarter Results; Company Reports Record Quarterly Revenues; Increases Full Year Revenue Estimate| BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 2, 2004--OraSure
Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid
diagnostics, today announced its financial results for the quarter and
nine months ended September 30, 2004.
Total revenues for the third quarter of 2004 increased 37% to
$14.2 million, compared to $10.3 million for the quarter ended
September 30, 2003. Product revenues for the third quarter increased
38% to $14.1 million, compared to $10.2 million in 2003. Both amo... |
| | | 10/22/04 | OraSure Technologies Quarterly Conference Call Invitation; 2004 Third Quarter Earnings Conference Call Tuesday, November 2, 2004, 5:00 p.m. ET| BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 22, 2004--OraSure
Technologies, Inc. (NASDAQ NM:OSUR) has scheduled its regular
quarterly earnings conference call covering third quarter 2004
financial results for 5:00 pm ET (2:00 pm PT) on Tuesday, November 2,
2004.
November 2, 2004 Schedule
-------------------------
4:00 p.m. ET Q3 2004 results will be distributed by Business Wire
4:50 p.m. ET To participate in the conference call, ... |
| | | 10/20/04 | OraSure Announces Launch of OraQuick ADVANCE Rapid HIV-1/2 Antibody Test; Initial Shipments Expected in Early November 2004| BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 20, 2004--OraSure
Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid
diagnostics, announced today that it is launching its OraQuick(R)
ADVANCE Rapid HIV-1/2 Antibody Test, the first and only U.S. Food and
Drug Administration ("FDA") approved and CLIA (Clinical Laboratory
Improvements Amendments Act of 1988) waived rapid point-of-care test
that provides accurate results for both HIV-1 and HIV-2 in 20 minutes,
using oral fluid, finger-sti... |
| | | 09/28/04 | Early Trial Set in OraSure Patent Infringement Lawsuit Against Schering-Plough| BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 28, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) today announced that an early
trial has been set in the Company's patent infringement lawsuit filed
against Schering-Plough Healthcare Products, Inc. (NYSE:SGP). As a
result, a final trial on the merits in this matter is expected to
occur in February 2005.
The trial will include an early final determination of the
Company's request for permanent injunctive relief, in lieu of its
prior reque... |
| | | 09/21/04 | OraSure Technologies to Present at UBS Global Life Sciences Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 21, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, will speak to the
investment community at the UBS Global Life Sciences Conference in New
York City. The conference will be simultaneously webcast over the
Internet.
Mr. Michels is scheduled to speak on September 28, 2004, at
approximately 12:00 P.M. Eastern Time (9:00 am Pacific Time).
Interested investors can a... |
| | | 09/01/04 | OraSure Technologies to Present at Thomas Weisel Partners' Healthcare Tailwinds 2004 Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 1, 2004--OraSure
Technologies, Inc. (NASDAQ NM:OSUR) today announced that Douglas A.
Michels, President and Chief Executive Officer, and Ronald H. Spair,
Chief Financial Officer, will speak to the investment community at the
Thomas Weisel Partners' Healthcare Tailwinds 2004 Conference in
Boston, Massachusetts, at approximately 4:25 pm Eastern Time (1:25 pm
Pacific Time) on September 8, 2004. The conference will be
simultaneously webcast over the Inte... |
| | | 08/11/04 | OraSure Technologies Sets 2005 Annual Meeting Date| BETHLEHEM, Pa.--(BUSINESS WIRE)--Aug. 11, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) today announced that its 2005
Annual Meeting of Stockholders is scheduled to be held on Tuesday, May
17, 2005, at the Radisson Hotel Bethlehem, Bethlehem, Pennsylvania,
18018. Stockholder proposals must be received no later than December
11, 2004, in order to be considered for inclusion in the Company's
Proxy Statement under relevant Securities and Exchange Commission
rules and no later than Februa... |
| | | 08/06/04 | OraSure Receives $4 Million Purchase Order from SAMHSA for OraQuick Rapid HIV Antibody Tests and HIV Confirmatory Test Services|
Tests to Be Deployed to over 22,000 Sites Throughout the U.S.
BETHLEHEM, Pa.--(BUSINESS WIRE)--Aug. 6, 2004-- OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in
oral fluid diagnostics, announced today that the Substance Abuse and
Mental Health Services Administration ("SAMHSA") has committed to
purchase $4 million of the Company's OraQuick(R) Rapid HIV Antibody
Tests and HIV confirmatory test services. The OraQuick(R) tests and
related confirmatory service... |
| | | 08/03/04 | OraSure Announces 2004 Second Quarter Results; Company Reports Net Profit for the Quarter; Increases Full Year Revenue Estimate| BETHLEHEM, Pa.--(BUSINESS WIRE)--Aug. 3, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR), a market leader in oral fluid
diagnostics, today announced its financial results for the quarter and
six months ended June 30, 2004.
Total revenues for the second quarter of 2004 increased 37% to
$13.2 million, compared to $9.6 million for the quarter ended June 30,
2003. Product revenues for the second quarter increased 39% to $13.1
million, compared to $9.4 million in 2003. Both amounts rep... |
| | | 07/26/04 | OraSure Technologies Sues Schering-Plough for Patent Infringement| BETHLEHEM, Pa.--(BUSINESS WIRE)--July 26, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) today announced that it has filed
a lawsuit against Schering-Plough Healthcare Products, Inc. (NYSE:SGP)
for infringement of several OraSure patents relating to the technology
for the cryosurgical removal (i.e., freezing) of warts and other
benign skin lesions.
The suit was commenced in the United States District Court for the
Eastern District of Pennsylvania, and alleges that Schering-Plough... |
| | | 07/22/04 | OraSure Technologies Quarterly Conference Call Invitation; 2004 Second Quarter Earnings Conference Call Tuesday, August 3, 2004, 5:00 p.m. ET| BETHLEHEM, Pa.--(BUSINESS WIRE)--July 22, 2004--OraSure
Technologies, Inc. (NASDAQ NM:OSUR) has scheduled its regular
quarterly earnings conference call covering second quarter 2004
financial results for 5:00 pm ET (2:00 pm PT) on Tuesday, August 3,
2004.
August 3, 2004 Schedule
-----------------------
4:00 p.m. ET Q2 2004 results will be distributed by Business Wire
4:50 p.m. ET To participate in the conference call,
... |
| | | 06/25/04 | OraSure Receives CLIA Waiver for OraQuick Rapid HIV-1/2 Antibody Test| BETHLEHEM, Pa.--(BUSINESS WIRE)--June 25, 2004--OraSure
Technologies, Inc. (NASDAQ NM:OSUR), the market leader in oral fluid
diagnostics, announced today that the U.S. Food and Drug
Administration ("FDA"), through its Center for Devices and
Radiological Health, has approved a waiver under the Clinical
Laboratory Improvements Amendments of 1988 ("CLIA") for the Company's
OraQuick(R) Rapid HIV-1/2 Antibody Test.
Specifically, the test has been waived for use in detecting HIV-1
and HI... |
| | | 06/23/04 | FDA Approves OraQuick HIV-1/2 Test to Detect HIV-2 in Oral Fluid| BETHLEHEM, Pa.--(BUSINESS WIRE)--June 23, 2004--OraSure
Technologies, Inc. (NASDAQ NM:OSUR), the market leader in oral fluid
diagnostics, announced today that it has received U.S. Food and Drug
Administration ("FDA") approval of its OraQuick(R) Rapid HIV-1/2
Antibody Test for use in detecting antibodies to the Human
Immunodeficiency Virus Type 2, or HIV-2, in oral fluid samples. With
this approval, the OraQuick(R) HIV-1/2 Test is the only rapid,
point-of-care test approved by the FDA for ... |
| | | 06/23/04 | OraSure Technologies Appoints New President and Chief Executive Officer; Conference Call/Webcast Scheduled For 1:00 PM Eastern Time Today| BETHLEHEM, Pa.--(BUSINESS WIRE)--June 23, 2004--OraSure
Technologies, Inc. (NASDAQ NM:OSUR), a market leader in oral fluid
diagnostics, today announced that Douglas A. Michels has been named
President and Chief Executive Officer and appointed to the Company's
Board of Directors. Mr. Michels will replace Mike Gausling, who has
been OraSure's President and Chief Executive Officer since January
2002 and a member of the Company's Board since September 2000. Mr.
Gausling had previously announc... |
| | | 06/22/04 | OraSure to Open NASDAQ Stock Market in Honor of National HIV Testing Day; Company Will Also Donate OraQuick Rapid HIV-1 Antibody Tests| BETHLEHEM, Pa.--(BUSINESS WIRE)--June 22, 2004--OraSure
Technologies, Inc. (NASDAQ NM:OSUR), the market leader in oral fluid
diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody
Test will be donated to numerous locations across the United States to
conduct free HIV testing in observance of National HIV Testing Day on
June 27, 2004. Additionally, in further recognition of this annual
observance, OraSure Technologies will preside over the opening of The
NASDAQ Stock Market... |
| | | 06/21/04 | OraSure Receives Rapid Test HIV-2 Patent Sublicense From Bio-Rad| Sublicense Enables OraSure To Market OraQuick(R) Rapid HIV-1/2
Antibody Test
BETHLEHEM, Pa.--(BUSINESS WIRE)--June 21, 2004--
OraSure Technologies, Inc. (NASDAQ NM:OSUR) announced today that
it has received a worldwide, non-exclusive sublicense from Bio-Rad
Laboratories (AMEX:BIO and BIOb) under patents relating to the Human
Immunodeficiency Virus, Type 2, or HIV-2. Bio-Rad is the exclusive
licensee of Institut Pasteur of Paris, France, under the H... |
| | | 06/08/04 | OraSure Technologies to Present at Thomas Weisel Partners' Growth Forum 6.0 Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--June 8, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) today announced that Mike
Gausling, President and Chief Executive Officer, and Ron Spair,
Executive Vice President and Chief Financial Officer, will speak to
the investment community at the Thomas Weisel Partners' Growth Forum
6.0 Conference in Laguna Beach, California, at approximately 6:30 pm
Eastern Time (3:30 pm Pacific Time) on June 15, 2004. The conference
will be simultaneously webcast over t... |
| | | 05/12/04 | OraSure Technologies to Webcast Annual Meeting of Stockholders| BETHLEHEM, Pa.--(BUSINESS WIRE)--May 12, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, announced that it will webcast its 2004 Annual Meeting of
Stockholders beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific
Time) on Tuesday, May 18, 2004.
The formal portion of the meeting will be immediately followed by
a management presentation and a question and answer session. Persons
accessing the webcast who desire to ask questions will b... |
| | | 05/04/04 | OraSure Technologies to Present at Rodman & Renshaw Techvest Global Healthcare Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--May 4, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) today announced that Mike
Gausling, President and Chief Executive Officer, and Ronald H. Spair,
Executive Vice President and Chief Financial Officer, will speak to
the investment community at the Rodman & Renshaw Techvest Global
Healthcare Conference in London, England. The conference will be
simultaneously webcast over the Internet.
Messrs. Gausling and Spair are scheduled to speak on May 13, ... |
| | | 04/27/04 | OraSure Technologies Announces 2004 First Quarter Results; Revenues Increase 44% to $12.4 Million| BETHLEHEM, Pa.--(BUSINESS WIRE)--April 27, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR), a market leader in oral fluid
diagnostics, today announced record revenues of $12.4 million for the
quarter ended March 31, 2004, representing a 44% increase over the
$8.6 million in revenues recorded for the comparable period in 2003.
Product revenues for the quarter were $12.3 million, a 47% increase
over the first quarter of 2003.
The Company's net loss was approximately $162,000, or $(0... |
| | | 04/20/04 | OraSure Technologies and Drager Safety Launch UPlink Oral Fluid Rapid Drug Detection System in Europe| BETHLEHEM, Pa.--(BUSINESS WIRE)--April 20, 2004--OraSure
Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid
diagnostics, in conjunction with its development and distribution
partner, Drager Safety AG & Co. KGaA, located in Lubeck, Germany,
today announced the European launch of the Company's UPlink(R) Oral
Fluid Rapid Drug Detection System. The UPlink(R) System is expected to
be initially used by law enforcement agencies primarily to test
operators and passengers of motor veh... |
| | | 04/14/04 | OraSure Technologies Invites You to Join Its 2004 First Quarter Financial Results Conference Call| BETHLEHEM, Pa.--(BUSINESS WIRE)--April 14, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) will host a conference call with
analysts and an audio webcast to discuss the Company's first quarter
2004 financial results beginning at 5:00 p.m. Eastern Time (2:00 p.m.
Pacific Time) on Tuesday, April 27 2004. The call will be preceded by
the release of the Company's 2004 first quarter financial results,
which will occur immediately after the market closes that day.
In order to listen to ... |
| | | 03/26/04 | OraSure Receives FDA Approval of OraQuick Oral Fluid and Plasma Claims; First and Only Oral Fluid Rapid HIV Test Approved in U.S. by the FDA|
Press Conference Footage and B-Roll Available via Satellite
Uplink, March 26, at 2 PM EST
BETHLEHEM, Pa.--(BUSINESS WIRE)--March 26, 2004--OraSure Technologies, Inc. (NasdaqNM:OSUR), the market leader in
oral fluid diagnostics, announced today that it has received U.S. Food
and Drug Administration ("FDA") approval of its OraQuick(R) Rapid HIV
Antibody Test for use with oral fluid -- making the test the first and
only rapid HIV test to be approved in the U.S. by the FDA for use... |
| | | 03/26/04 | OraSure Required to Submit Additional Data for FDA Clearance of UPlink Oral Fluid Rapid Drug Detection System| BETHLEHEM, Pa.--(BUSINESS WIRE)--March 26, 2004--OraSure
Technologies, Inc. (NASDAQNM:OSUR), a market leader in oral fluid
diagnostics, today announced that it will need to submit additional
performance data to the U.S. Food and Drug Administration ("FDA") in
order to obtain 510(k) clearance of its UPlink(R) Oral Fluid Drug
Detection System.
In September 2003, OraSure submitted an application with the FDA
for 510(k) clearance of its UPlink(R) analyzer and oral fluid assays
for the ... |
| | | 03/23/04 | OraSure Receives FDA Approval for Test to Detect HIV-2 Antibodies| BETHLEHEM, Pa.--(BUSINESS WIRE)--March 23, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) announced today that the U.S. Food
and Drug Administration ("FDA") has approved the Company's new
OraQuick(R) Rapid HIV-1/2 Antibody Test. This approval will allow the
simultaneous detection of antibodies to both the HIV-1 and HIV-2
viruses in finger stick and venipuncture whole blood specimens.
"Receiving FDA approval to test for HIV-2 is another significant
milestone," said Mike Gausling, ... |
| | | 03/17/04 | OraSure Technologies to Present at Wells Fargo Securities' Healthcare Fireside Chats| BETHLEHEM, Pa.--(BUSINESS WIRE)--March 17, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) announced today that Mike
Gausling, President and Chief Executive Officer, and Ron Spair,
Executive Vice President and Chief Financial Officer, will speak to
the investment community at the Wells Fargo Securities' Health Care
Fireside Chats in New York, New York. The conference will be
simultaneously webcast over the Internet.
Mr. Gausling and Mr. Spair are scheduled to speak on March 24,
2... |
| | | 03/10/04 | OraSure Receives FDA Approval to Transfer Manufacturing| BETHLEHEM, Pa.--(BUSINESS WIRE)--March 10, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, announced that the U.S. Food and Drug Administration
("FDA") has approved the transfer of manufacturing of its OraSure(R)
HIV-1 oral specimen collection device from Oregon to the Company's
Bethlehem, Pennsylvania facilities. In late 2003, the Company also
received approval to transfer manufacturing of its oral fluid Western
blot HIV-1 confirmatory test... |
| | | 03/08/04 | OraSure CEO To Retire By Year-End| BETHLEHEM, Penn.--(BUSINESS WIRE)--March 8, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) today announced that Mike
Gausling, the Company's President and Chief Executive Officer, will
retire from the Company and its Board of Directors by the end of 2004.
"After consultation with the Board of Directors, we have decided
that 2004 is an opportune time to transition the leadership of the
Company," said Mike Gausling. "I have served this Company with my best
efforts for 17 years and ... |
| | | 03/04/04 | CDC Reports That OraQuick Test Produces Fewer False Positive HIV-1 Results Than Other Available Tests| BETHLEHEM, Pa.--(BUSINESS WIRE)--March 4, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody
Test was reported to produce substantially fewer false-positive
results than traditional lab-based HIV tests or other U.S. Food and
Drug Administration ("FDA") approved rapid HIV tests when used in a
laboratory setting. This information is based on the results from
clinical trials submitted to th... |
| | | 03/03/04 | OraSure Technologies to Present at SG Cowen's Health Care Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--March 3, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) today announced that Mike
Gausling, President and Chief Executive Officer, will speak to the
investment community at the SG Cowen Health Care Conference in Boston,
Massachusetts. The conference will be simultaneously webcast over the
Internet.
Mr. Gausling is scheduled to speak on March 10, 2004, at
approximately 10:15 am Eastern Time (7:15 am Pacific Time). Interested
investors can access t... |
| | | 02/23/04 | OraSure Announces Resolution of Dispute with Abbott Laboratories| BETHLEHEM, Pa., Feb 23, 2004 (BUSINESS WIRE) -- OraSure
Technologies, Inc. (Nasdaq NM:OSUR) announced the receipt of an
arbitrator's decision resolving its dispute with Abbott Laboratories
under the parties' distribution agreement for the Company's
OraQuick(R) Rapid HIV-1 Antibody Test. The arbitrator ruled that the
agreement was not terminated and will remain in effect. In addition,
consistent with the arbitrator's rulings OraSure has notified Abbott
that the agreement has been converted... |
| | | 02/10/04 | OraSure Announces Record Financial Results| BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 10, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, today announced record revenues of $40.5 million and
$11.9 million for the year and quarter ended December 31, 2003,
respectively. Full year 2003 revenues represent a 26% increase from
the $32.0 million in revenues recorded for 2002. Revenues for the
quarter ended December 31, 2003, were 44% higher than those for the
same period of 2002.
The Comp... |
| | | 02/06/04 | OraSure Salutes National Black HIV/AIDS Awareness and Information Day with OraQuick Rapid Testing Initiative on February 7th| OraSure Partners with HIV Testing Sites Across the Country to
Encourage Rapid HIV Testing with OraQuick(R)
BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 6, 2004--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in
oral fluid diagnostics, announced today that its OraQuick(R) Rapid
HIV-1 Antibody Test will be utilized by numerous locations across the
United States to conduct free HIV testing in observance of National
Black HIV/AIDS Awareness and Information Day on February 7, 20... |
| | | 01/30/04 | OraSure to Receive New Patent Covering Lateral Flow Test for Oral Fluid and Other Specimens| BETHLEHEM, Pa., Jan 30, 2004 (BUSINESS WIRE) -- OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, announced today that it has received notice from the
United States Patent and Trademark Office that a new patent will be
issued with broad claims covering a lateral flow diagnostic test that
can be used to test oral fluid or other specimen types for the
presence of one or more antibodies or other analytes. The patent's
claims will cover the Company's cu... |
| | | 01/29/04 | OraSure Technologies Appoints New Director of Hospital Sales| BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 29, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, announced today the hiring of David G. Stevans as
Director, Hospital Sales. Mr. Stevans joins OraSure with extensive
sales and hospital management experience in the biopharmaceutical and
healthcare industries, with a specialization in HIV/AIDS and
infectious diseases. In his role at OraSure, he will be responsible
for directing the sales of the Company'... |
| | | 01/28/04 | OraSure Technologies Invites You To Join Its 2003 Fourth Quarter and Full-Year Financial Results Conference Call| BETHLEHEM, Penn.--(BUSINESS WIRE)--Jan. 28, 2004--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) will host a conference call with
analysts and an audio webcast to discuss the Company's 2003 fourth
quarter and full-year financial results, and 2004 guidance and major
business objectives, beginning at 5:00 p.m. Eastern Time (2:00 p.m.
Pacific Time) on Tuesday, February 10, 2004. The call will be preceded
by the release of the Company's 2003 financial results, which will
occur immediately after ... |
| | | 01/26/04 | OraQuick Rapid HIV-1 Antibody Test is Honored for Innovation with 2003 Circle of Excellence Award| BETHLEHEM, Pa., Jan 26, 2004 (BUSINESS WIRE) -- OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody
Test has received the prestigious 2003 Photonics Circle of Excellence
Award. This Award is bestowed annually on the 25 most technically
innovative new products of the year, as judged by members of the
Photonics Spectra magazine Editorial Advisory Board. The award was
announced today at the Photon... |
| | | 12/17/03 | FDA Completes Inspection of OraSure Manufacturing Facility; Manufacturing Consolidation Expected To Save $1 Million Annually| BETHLEHEM, Pa., Dec 17, 2003 (BUSINESS WIRE) -- OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, announced today that the U.S. Food and Drug
Administration ("FDA") has successfully completed a facility
inspection required for the transfer of the Company's in-house and
third party contract manufacturing operations from Oregon to
Bethlehem, Pennsylvania.
In August and October, 2003, the Company submitted pre-market
approval ("PMA") supplements t... |
| | | 12/15/03 | OraSure Submits Additional Data to FDA for OraQuick HIV-2 Claim| BETHLEHEM, Pa., Dec 15, 2003 (BUSINESS WIRE) -- OraSure
Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid
diagnostics, announced today that it has submitted the additional data
requested by the U.S. Food and Drug Administration ("FDA") in support
of an HIV-2 claim for its OraQuick(R) Rapid HIV-1 Antibody Test.
In June 2003, the Company submitted an application to the FDA for
approval of the OraQuick(R) test for use in detecting HIV-2
antibodies. On November 14, 2003, t... |
| | | 12/01/03 | CDC Commits Additional $2 Million for Purchase of OraQuick Rapid HIV-1 Antibody Tests| BETHLEHEM, Pa.--(BUSINESS WIRE)--Dec. 1, 2003--OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, announced today that The Centers for Disease Control and
Prevention ("CDC") has committed to purchase an additional 250,000
OraQuick(R) Rapid HIV-1 Antibody Tests for a total of $2 million. The
CDC purchase is expected to be fulfilled by September 1, 2004, and
further supports its four-part HIV prevention strategy, which was
previously announced on April... |
| | | 11/26/03 | OraSure Technologies to Open NASDAQ Stock Market on December 1, 2003 in Honor of World AIDS Day| BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 26, 2003--OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, announced today that in recognition of World AIDS Day,
OraSure Technologies will open the NASDAQ Stock Market on Monday,
December 1, 2003.
OraSure's President and Chief Executive Officer Mike Gausling will
preside over the NASDAQ Market Open ceremony beginning at 9:20 a.m.
OraSure has been recognized as a leader in HIV testing with the
intr... |
| | | 11/20/03 | OraSure Technologies Sets 2004 Annual Meeting Date| BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 20, 2003--OraSure
Technologies, Inc. (NasdaqNM:OSUR) today announced that its 2004
Annual Meeting of Stockholders is scheduled to be held on Tuesday, May
18, 2004, at the Radisson Hotel Bethlehem, Bethlehem, Pennsylvania,
18018. Stockholder proposals must be received no later than December
12, 2003, in order to be considered for inclusion in the Company's
Proxy Statement under relevant Securities and Exchange Commission
rules and no later than Februar... |
| | | 11/17/03 | OraSure To Submit Additional Data To FDA For OraQuick HIV-2 Claim| BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 17, 2003--OraSure
Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid
diagnostics, announced today that it will be submitting a small amount
of additional data to the U.S. Food and Drug Administration ("FDA") in
support of an HIV-2 claim for its OraQuick(R) Rapid HIV-1 Antibody
Test.
In June 2003, the Company submitted an application to the FDA for
approval of the OraQuick(R) test for use in detecting HIV-2
antibodies. In response... |
| | | 11/07/03 | OraQuick Rapid HIV-1 Antibody Test Receives Popular Science Magazine's '2003 Best of What's New' Award|
OraQuick(R) to be Featured in December 2003 Issue as Winner in
Personal Health Category
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 7, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in
oral fluid diagnostics, announced today that its OraQuick(R) Rapid
HIV-1 Antibody Test has been awarded a 2003 Best of What's New award
by Popular Science magazine in the Personal Health category. The award
was announced on November 6, 2003, at the Best of What's New Showcase
Ev... |
| | | 11/03/03 | OraSure Announces Exercise of Underwriters' Overallotment Option| BETHLEHEM, Pa., Nov 3, 2003 (BUSINESS WIRE) -- OraSure
Technologies, Inc. (Nasdaq:OSUR) today announced that the underwriters
of its recent public offering of 5,000,000 shares of common stock have
purchased an additional 311,000 shares pursuant to an overallotment
option granted in connection with the offering. This represents a
partial exercise of the option, which originally covered 750,000
shares of the Company's common stock. With the exercise of the
overallotment option, the offering... |
| | | 10/28/03 | OraSure Announces Record Revenues and Net Profit for Third Quarter 2003| BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 28, 2003--OraSure
Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid
diagnostics, today announced its financial results for the quarter and
nine months ended September 30, 2003, provided an update on its
strategy to distribute OraQuick(R) to the hospital market, and
reaffirmed its financial guidance for 2003 and 2004.
Total revenues for the third quarter of 2003 increased 27% to
$10.3 million, compared to $8.1 million for the quar... |
| | | 10/16/03 | OraSure Technologies Invites You to Join Its 2003 Third Quarter Financial Results Conference Call| BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 16, 2003--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) will host a conference call with
analysts and an audio webcast to discuss the Company's third quarter
2003 financial results beginning at 5:00 p.m. Eastern Time (2:00 p.m.
Pacific Time) on Tuesday, October 28, 2003. The call will be preceded
by the release of the Company's third quarter 2003 financial results,
which will occur immediately after the market closes that day.
In order to listen t... |
| | | 10/15/03 | OraSure Technologies to Present at Rodman & Renshaw Techvest Healthcare Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 15, 2003--OraSure
Technologies, Inc. (Nasdaq:OSUR) today announced that Mike Gausling,
President and Chief Executive Officer, and Ronald H. Spair, Executive
Vice President and Chief Financial Officer, will speak to the
investment community at the Rodman & Renshaw Techvest Healthcare
Conference in Boston, Massachusetts. The conference will be
simultaneously webcast over the Internet.
Messrs. Gausling and Spair are scheduled to speak on October 22... |
| | | 10/02/03 | OraSure Sells 5,000,000 Shares of Common Stock| BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 2, 2003--OraSure
Technologies, Inc. (Nasdaq:OSUR), today announced that it has entered
into an underwriting agreement for the sale by the Company of
5,000,000 shares of common stock in a public offering under its shelf
registration statement. Proceeds to the Company from the sale are
expected to be $45 million before underwriting discounts and
commissions and other offering expenses. The Company has also granted
to the underwriters an option to purcha... |
| | | 09/29/03 | OraSure Seeks FDA Approval of Oral Fluid and Plasma Claims for OraQuick Rapid HIV-1 Antibody Test| BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 29, 2003--OraSure
Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid
diagnostics, announced that it is filing an application today with the
U.S. Food and Drug Administration ("FDA") for pre-market approval of
its OraQuick(R) Rapid HIV-1 Antibody Test for use in detecting HIV-1
antibodies in both oral fluid, or saliva, and plasma samples. Under
applicable regulations, the FDA has 180 days to respond to the
submission.
"This filing ... |
| | | 09/22/03 | OraSure Technologies Seeks FDA Clearance for UPlink Oral Fluid NIDA-5 Drug Test System| BETHLEHEM, Pa., Sep 22, 2003 (BUSINESS WIRE) -- OraSure
Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid
diagnostics, today announced that it has filed an application for
510(k) clearance with the U.S. Food and Drug Administration ("FDA")
for its UPlink(R) analyzer and oral fluid assays for the rapid,
point-of-care detection of drugs of abuse commonly identified by the
National Institute for Drug Abuse ("NIDA") as the NIDA-5, i.e., -
cocaine, opiates, amphetamine/methamphet... |
| | | 09/17/03 | OraSure Technologies Renews Credit Facility with Comerica Bank| BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 17, 2003--OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, announced today the renewal of its existing credit
facility with Comerica Bank (NYSE:CMA).
In September 2002, Comerica's Technology and Life Sciences
Division provided OraSure with a $10.9 million credit facility,
composed of a $4 million line of credit for working capital, a $3
million term loan, a $3 million credit line for capital equipment
p... |
| | | 09/16/03 | CDC Study Finds That OraQuick Test Provides Fast Results During Labor and Delivery| BETHLEHEM, Pa., Sep 16, 2003 (BUSINESS WIRE) -- OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, announced today that the use of its OraQuick(R) Rapid
HIV-1 Antibody Test at the point of care was found to provide testing
results four-times faster than when the OraQuick(R) test was used in a
laboratory setting. These findings resulted from the Mother Infant
Rapid Intervention at Delivery (MIRIAD) study, which was conducted by
the Centers for Disease... |
| | | 09/10/03 | OraSure Technologies Announces Public Offering| BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 10, 2003--OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, today announced that it plans to publicly offer 5,000,000
shares of its common stock. The offering will be made pursuant to a
registration statement covering shares of common stock that became
effective on August 8, 2003. The Company will grant to the
underwriters an option to purchase an additional 750,000 shares of its
common stock not later than 30 ... |
| | | 09/09/03 | FDA Approves Venipuncture Whole Blood Claim for OraQuick Rapid HIV-1 Antibody Test| BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 9, 2003--OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody
Test has been approved by the U.S. Food and Drug Administration
("FDA") for use in detecting HIV-1 antibodies in venipuncture whole
blood specimens.
This is the second claim approved by the FDA for the OraQuick(R)
test. In November 2002, the Company received approval for use of the
OraQuic... |
| | | 09/02/03 | OraSure Technologies to Present at Thomas Weisel Partners' Healthcare Tailwinds 2003 Conference| BETHLEHEM, Pa.--(BUSINESS WIRE)--Sept. 2, 2003--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) today announced that Mike
Gausling, President and Chief Executive Officer, will speak to the
investment community at the Thomas Weisel Partners' Healthcare
Tailwinds 2003 Conference in Boston, Massachusetts, at approximately
10:00 am Eastern Time (7:00 am Pacific Time) on September 5, 2003. The
conference will be simultaneously webcast over the Internet.
Interested investors can access the li... |
| | | 07/29/03 | OraSure Technologies Announces Record 2003 Second Quarter Results| BETHLEHEM, Pa.--(BUSINESS WIRE)--July 29, 2003--OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, today announced its financial results for the quarter and
six months ended June 30, 2003.
Total revenues for the quarter increased 21% to $9.6 million,
compared to $7.9 million for the quarter ended June 30, 2002. Product
revenues for the second quarter of 2003 increased 20% to $9.4 million,
compared to $7.9 million in 2002. Both amounts represent... |
| | | 07/29/03 | OraSure Receives Approval to Distribute OraQuick Rapid HIV-1 Antibody Test in Mexico; Approval Includes Oral Fluid Testing| BETHLEHEM, Pa., Jul 29, 2003 (BUSINESS WIRE) -- OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, announced today that it has received approval from the
Ministry of Health in Mexico for its OraQuick (R)Rapid HIV-1 Antibody
Test. Pursuant to this approval, the Company can distribute the
OraQuick(R) test to healthcare professionals in Mexico for the
detection of HIV-1 antibodies in both finger-stick whole blood and
oral fluid samples.
The approva... |
| | | 07/17/03 | OraSure Ships over $1 Million of New Compound W Freeze Off Cryosurgical Wart Treatment Product| BETHLEHEM, Pa.--(BUSINESS WIRE)--July 17, 2003--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) announced today that it has
shipped more than $1 million of its cryosurgical wart treatment
product to Medtech Products, Inc., for distribution in the
over-the-counter ("OTC") market in the United States. The shipment was
completed in June 2003. The product will be sold under Medtech's
Compound W(R) brand name and Freeze Off(TM) trademark, and is expected
to be available for retail purchase in drug... |
| | | 07/15/03 | OraSure Technologies Invites You To Join Its 2003 Second Quarter Financial Results Conference Call| BETHLEHEM, Penn.--(BUSINESS WIRE)--July 15, 2003--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) will host a conference call with
analysts and an audio webcast to discuss the Company's second quarter
2003 financial results beginning at 5:00 p.m. Eastern Time (2:00 p.m.
Pacific Time) on Tuesday, July 29, 2003. The call will be preceded by
the release of the Company's second quarter 2003 financial results and
certain business developments, which will occur immediately after the
market closes t... |
| | | 07/03/03 | OraSure Technologies Files Universal Shelf Registration Statement| BETHLEHEM, Pa.--(BUSINESS WIRE)--July 3, 2003--OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, today announced that it has filed a universal shelf
registration statement on Form S-3 with the Securities and Exchange
Commission ("SEC") for the registration and potential issuance of up
to $75 million of OraSure securities.
The securities covered by the universal shelf, which may include
common stock, preferred stock or debt securities, are bein... |
| | | 06/26/03 | CDC Commits $2 Million for Purchase Of OraQuick Rapid HIV-1 Antibody Tests| Press Conference Footage and B-Roll Available via Satellite
Uplink, Thursday, June 26 at 3:15 PM EDT
WASHINGTON & BETHLEHEM, Pa., Jun 26, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in
oral fluid diagnostics, announced today that The Centers for Disease
Control and Prevention ("CDC") has committed to a purchase of 250,000
OraQuick(R) Rapid HIV-1 Antibody Tests along with OraQuick(R) training
materials and services for 50 locations across the Uni... |
| | | 06/25/03 | ADVISORY/Orasure Technologies and Senator Specter to Announce Major Initiative in Conjunction with CDC On Rapid HIV-1 Antibody Testing| Press Conference - Thursday, June 26 on Capitol Hill, Washington,
D.C.
--(BUSINESS WIRE)-- National HIV Testing Day Satellite Uplink Feed - 2:00 PM EDT,
Today, June 25
EVENT:
Senator Arlen Specter (R-PA), Chairman of the Labor,
Health and Human Services, and Education Appropriations
Subcommittee, along with OraSure Technologies, Inc.
(Nasdaq:OSUR), and other federal government officials
will announce a major initiative between OraSure and the
Centers for Disease Contro... |
| | | 06/24/03 | OraSure to Donate OraQuick Rapid HIV-1 Antibody Test for National HIV Testing Day on June 27th; Interview Footage and B-Roll Available via Satellite Uplink Wednesday, June 25| BETHLEHEM, Pa.--(BUSINESS WIRE)--June 24, 2003--OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody
Test will be donated to numerous locations across the United States to
conduct free HIV testing in observance of National HIV Testing Day on
June 27, 2003. This will mark the first time in the history of
National HIV Testing Day that a rapid, point-of-care HIV test will be
made available for this... |
| | | 06/06/03 | OraQuick Rapid HIV-1 Antibody Test Receives Gold Medical Design Excellence Award| BETHLEHEM, Pa.--(BUSINESS WIRE)--June 6, 2003--OraSure
Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid
diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody
Test has received the Gold Medical Design Excellence Award in the "In
Vitro Diagnostics" category in the sixth annual Medical Design
Excellence Awards (MDEA) competition. The Gold Award, a top award in
its category, was announced on June 3, 2003, at the Medical Design &
Manufacturing East Exposition ... |
| | | 05/15/03 | OraSure Technologies to Host HHS Deputy Secretary Claude Allen at Event on HIV Testing and Prevention| BETHLEHEM, Pa.--(BUSINESS WIRE)--May 15, 2003--Claude Allen,
Deputy Secretary of the U.S. Department of Health and Human Services,
and other leading federal healthcare officials will offer remarks on
HIV testing and prevention strategies in the United States and abroad,
on Monday, May 19, 2003, from noon to 1:00 p.m. EDT, at the
headquarters of OraSure Technologies, Inc. (Nasdaq:OSUR) in Bethlehem,
PA.
The event, hosted by OraSure in recognition of the FDA's recent
approval of its ... |
| | | 05/13/03 | OraSure Technologies Appoints New Director| BETHLEHEM, Pa.--(BUSINESS WIRE)--May 13, 2003--OraSure
Technologies, Inc. (NasdaqNM:OSUR), the market leader in oral fluid
diagnostics, today announced the appointment of Ronny B. Lancaster to
the Company's Board of Directors.
Mr. Lancaster has extensive experience in the medical and public
health fields, particularly in the development of public health policy
and promotion of health education. Since March 1996, Mr. Lancaster has
served as Senior Vice President for Management and Polic... |
| | | 05/12/03 | OraSure Technologies To Webcast Annual Stockholders' Meeting| BETHLEHEM, Pa., May 12, 2003 (BUSINESS WIRE) -- OraSure
Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid
diagnostics, announced that it will webcast its 2003 Annual Meeting of
Stockholders beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific
Time) on Tuesday, May 20, 2003.
The formal portion of the meeting will be immediately followed by
a management presentation and a question and answer session. Persons
accessing the webcast who desire to ask questions will be pe... |
| | | 04/29/03 | OraSure Technologies Announces 2003 First Quarter Results| BETHLEHEM, Pa.--(BUSINESS WIRE)--April 29, 2003--OraSure
Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid
diagnostics, today announced its financial results for the quarter
ended March 31, 2003.
Total revenues for the quarter increased approximately 11% to $8.6
million, compared to $7.7 million for the quarter ended March 31,
2002. Product revenues for the first quarter of 2003 increased
approximately 12% to $8.3 million, compared to $7.5 million in 2002.
Both amou... |
| | | 04/28/03 | OraQuick Rapid HIV-1 Antibody Test is Highlighted in New CDC HIV Prevention Initiative|
-CDC Recommends Use of Rapid Testing as Part of
Comprehensive HIV Testing Strategy-
BETHLEHEM, Pa.--(BUSINESS WIRE)--April 28, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in
oral fluid diagnostics, announced today that the Centers for Disease
Control and Prevention ("CDC") stated that simple, rapid HIV testing
would be a key component to its new HIV testing initiative announced
by the CDC on Thursday, April 17, 2003, in the CDC's Morbidity an... |
| | | 04/25/03 | OraSure Expands Sales Into the Over-the-Counter Market; Cryosurgical Wart Treatment to Be Available Under Compound W Trademark| BETHLEHEM, Pa.--(BUSINESS WIRE)--April 25, 2003--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) announced today the execution of
an exclusive distribution agreement with Medtech Holdings, Inc.
pursuant to which OraSure will manufacture and supply, and Medtech
will purchase, the Company's cryosurgical wart removal product for
distribution in the over-the-counter ("OTC") market in the United
States and Canada.
The product will be manufactured and sold under Medtech's Compound
W(R) and F... |
| | | 04/22/03 | OraSure Technologies Invites You To Join Its 2003 First Quarter Financial Results Conference Call| BETHLEHEM, Pa.--(BUSINESS WIRE)--April 22, 2003--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) will host a conference call with
analysts and an audio webcast to discuss the Company's first quarter
2003 financial results beginning at 5:00 p.m. Eastern Time (2:00 p.m.
Pacific Time) on Tuesday, April 29, 2003. The call will be preceded by
the release of the Company's 2002 financial results, which will occur
immediately after the market closes that day.
In order to listen to the conferenc... |
| | | 03/10/03 | OraSure Technologies to Present at SG Cowen's Health Care Conference| BETHLEHEM, Pa., Mar 10, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc.
(Nasdaq:OSUR) today announced that Mike Gausling, President and Chief Executive
Officer, will speak to the investment community at the SG Cowen Health Care
Conference in Boston, Massachusetts. The conference will be simultaneously
webcast over the Internet.
Mr. Gausling is scheduled to speak on March 20, 2003, at approximately 10:15 am
and again at 11:15 am Eastern Time (7:15 am and 8:15 am Pacific Time).
Intere... |
| | | 03/03/03 | OraSure Appoints Chairman| BETHLEHEM, Pa., Mar 3, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that
Douglas G. Watson has been appointed Chairman of the Company's Board of
Directors. He is replacing William W. Crouse, who is retiring from the Board.
Mr. Watson joined OraSure's Board in May 2002, after a distinguished career in
the pharmaceutical industry, spanning 33 years. Prior to his retirement in May
1999, he served as President... |
| | | 02/11/03 | OraSure Announces Senior Management Promotions| BETHLEHEM, Pa., Feb 11, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), today announced the promotion of several members of its senior
management team.
P. Michael Formica has been promoted to Executive Vice President, Operations of
the Company. Mr. Formica served as OraSure's Senior Vice President, Operations
since May 2000, and has recently assumed overall supervisory responsibility for
the Company's Regulatory Affairs and Quality Assurance Departments.
Mr. Formic... |
| | | 02/07/03 | OraSure to Participate with Penn in Oral Fluid Research Grant| BETHLEHEM, Pa., Feb 7, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that
it will participate in a $4.2 million four-year grant for research and
development of saliva/oral fluid-based diagnostic technologies, awarded by the
National Institutes of Health to the University of Pennsylvania.
The grant will fund work by a multidisciplinary group of scientists from OraSure
and the University's School of Dental Me... |
| | | 02/05/03 | OraSure Technologies Announces 2002 Results| BETHLEHEM, Pa., Feb 5, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced
total revenues of $32.0 million for the full year 2002 and $8.25 million for the
quarter ended December 31, 2002. Full year 2002 revenues reflect a 2% decline
from the $32.6 million in revenues recorded for 2001. Revenues for the quarter
ended December 31, 2002, were 2% higher than those for the same period of 2001.
The Company's net loss ... |
| | | 02/03/03 | U.S. Navy Purchases OraQuick HIV-1 Test; Part of Smallpox Vaccination Program| BETHLEHEM, Pa., Feb 3, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced that the
United States Navy Military Sealift Command has purchased 10,000 OraQuick(R)
Rapid HIV-1 Antibody Tests to screen its personnel participating in the smallpox
vaccination program directed by the Federal government.
OraQuick(R) is a finger-stick whole blood test and the first FDA-approved,
CLIA-waived, rapid point-of-care test designed to... |
| | | 01/31/03 | OraSure Receives CLIA Waiver for OraQuick Rapid HIV-1 Antibody Test| BETHLEHEM, Pa., Jan 31, 2003 (BUSINESS WIRE) -- OraSure Technologies, Inc.
(NasdaqNM:OSUR), the market leader in oral fluid diagnostics, announced today
that the U.S. Food and Drug Administration (FDA), through its Center for Devices
and Radiological Health, has approved a waiver under the Clinical Laboratory
Improvements Amendments of 1988 (CLIA) for the Company's OraQuick(R) Rapid HIV-1
Antibody Test.
This waiver was granted on the basis of information contained in the Company's
appl... |
| | | 01/31/03 | OraSure Applies for CLIA Waiver on OraQuick Rapid HIV-1 Antibody Test|
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 31, 2003--OraSure
Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid
diagnostics, announced today that it has submitted to the U.S. Food
and Drug Administration (FDA) an application for a waiver under the
Clinical Laboratory Improvements Amendments of 1988 (CLIA) for its
OraQuick(R) Rapid HIV-1 Antibody Test. With an approved CLIA waiver,
the OraQuick(R) test, which provides HIV-1 test results in just 20
minutes, would ... |
| | | 01/28/03 | OraSure Technologies Appoints New Vice President, Sales|
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 28, 2003--OraSure
Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid
diagnostics, today announced the hiring of Susan Schiller as Vice
President, Sales. Ms. Schiller joins OraSure Technologies with
extensive sales management experience in the biopharmaceutical and
healthcare industries.
Ms. Schiller comes to OraSure most recently from Viropharma,
Incorporated, a developer and manufacturer of antiviral therapies.
U... |
| | | 01/27/03 | OraSure Technologies Invites You To Join Its 2002 Fourth Quarter and Full-Year Financial Results Conference Call|
BETHLEHEM, Penn.--(BUSINESS WIRE)--Jan. 27, 2003--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) will host a conference call with
analysts and an audio webcast to discuss the Company's 2002 fourth
quarter and full-year financial results, certain financial
expectations for 2003, and certain business developments, beginning at
5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Wednesday, February
5, 2003. The call will be preceded by the release of the Company's
2002 financial re... |
| | | 01/07/03 | OraSure Begins Shipment of OraQuick Rapid HIV-1 Antibody Test; OraSure Fills Initial Stocking Order to Abbott Laboratories|
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 7, 2003--OraSure
Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid
diagnostics, announced today that it has shipped more than 50,000
OraQuick(R) Rapid HIV-1 Antibody Tests to Abbott Laboratories.
This order was completed in late December 2002, and represents the
first sale of OraQuick(R) tests under OraSure's agreement with Abbott,
which is the Company's co-exclusive distributor of OraQuick(R) in the
United Stat... |
| | | 12/20/02 | Intercept Oral Fluid Drug Test Equivalent to Urine Drug Testing; Landmark Study Published in the Journal of Analytical Toxicology|
BETHLEHEM, Pa.--(BUSINESS WIRE)--Dec. 20, 2002--OraSure
Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid
diagnostics, announced today the publication of results of the first
large-scale study of oral fluid drug testing in private industry with
its Intercept(R) oral fluid drug testing system.
The results from the study demonstrate that oral fluid drug
testing produces equivalent results to urine drug testing.
This study, entitled "Oral Flu... |
| | | 11/14/02 | OraSure Technologies Sets Annual Meeting Date|
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 14, 2002--OraSure
Technologies, Inc. (Nasdaq:OSUR) today announced that its 2003 Annual
Meeting of Stockholders is scheduled to be held on Tuesday, May 20,
2003, at the Radisson Hotel Bethlehem, Bethlehem, Pennsylvania, 18018.
Stockholder proposals must be received no later than December 13,
2002, in order to be considered for inclusion in the Company's Proxy
Statement under relevant Securities and Exchange Commission rules and
no later ... |
| | | 11/07/02 | Multimedia Available: Image of OraQuick Rapid HIV-1 Test and OraSure Technologies Logo|
ADVISORY...for Thursday (Nov. 7)
NOTE TO EDITORS: Multimedia Assets Available With This Story
Include Logos, Photos, Text News Releases
--(BUSINESS WIRE)--
OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in
oral fluid diagnostics, announced today that it has received approval
from the U.S. Food and Drug Administration ("FDA") for its OraQuick(R)
Rapid HIV-1 Antibody Test. Pursuant to this approval, the C... |
| | | 11/07/02 | Image of OraQuick Rapid HIV-1 Test and OraSure Technologies Logo|
NOTE TO MEDIA: Multimedia assets available
A photo is available at URL:
http://www.businesswire.com/cgi-bin/photo.cgi?pw.110702/bb12
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 7, 2002--OraSure
Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid
diagnostics, announced today that it has received approval from the
U.S. Food and Drug Administration ("FDA") for its OraQuick(R) Rapid
HIV-1 Antibody Test. Pursuant to this approval, the Compan... |
| | | 11/07/02 | OraSure Receives FDA Approval for OraQuick Rapid HIV-1 Test; Investor Conference Call and Press Conference at 2:15 P.M. Eastern Time|
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 7, 2002--OraSure
Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid
diagnostics, announced today that it has received approval from the
U.S. Food and Drug Administration ("FDA") for its OraQuick(R) Rapid
HIV-1 Antibody Test.
Pursuant to this approval, the Company can manufacture and market
the OraQuick(R) test in the United States for the detection of HIV-1
antibodies in finger-stick whole blood samples.
... |
| | | 10/28/02 | OraSure Technologies Reports 2002 Third Quarter Results; - $3 Million Increase In Cash Flow From Operations -| BETHLEHEM, Pa., Oct 28, 2002 (BUSINESS WIRE) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced that
it had revenues of $8.1 million for the three months ended September 30, 2002,
down 6% when compared to revenues of $8.6 million for the three months ended
September 30, 2001. The Company also recorded a net loss of $387,000, or ($0.01)
per share, for the three months ended September 30, 2002. This compares to a net
profit of $16,000 fo... |
| | | 10/23/02 | OraSure Technologies to Participate in U.S. Trade Mission to Africa; -OraSure to Highlight OraQuick Rapid HIV Antibody Test-| BETHLEHEM, Pa., Oct 23, 2002 (BUSINESS WIRE) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that
the Company was selected by the United States Department of Commerce to join a
business development mission to Ghana and South Africa, on November 12-15.
Secretary of Commerce, Donald L. Evans, will lead a delegation of 12 U.S. firms
that represent a variety of business sectors capable of assisting with Africa's
infrastructure needs.
... |
| | | 10/15/02 | OraSure Technologies Invites You To Join Its 2002 Third Quarter Financial Results Conference Call| BETHLEHEM, Pa., Oct 15, 2002 (BUSINESS WIRE) -- OraSure Technologies, Inc.
(Nasdaq NM:OSUR) will host a conference call with analysts and an audio webcast
to discuss the Company's third quarter 2002 financial results and certain
business developments beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific
Time) on Monday, October 28, 2002. The call will be preceded by the release of
the Company's financial results, which will occur immediately after the market
closes that day.
In order ... |
| | | 10/07/02 | OraSure Technologies to Present at UBS Warburg Global Life Sciences Conference| BETHLEHEM, Pa., Oct 7, 2002 (BUSINESS WIRE) -- OraSure Technologies, Inc.
(Nasdaq:OSUR) today announced that Mike Gausling, President and Chief Executive
Officer, will speak to the investment community at the UBS Warburg Global Life
Sciences Conference in New York City.
The conference will be simultaneously webcast over the Internet.
Mr. Gausling is scheduled to speak on October 10, 2002, at approximately 10:30
am Eastern Time (7:30 am Pacific Time). Interested investors can access t... |
| | | 09/16/02 | OraSure Technologies Receives $10.9 Million Credit Facility From Comerica| PHILADELPHIA and BETHLEHEM, Pa., Sep 16, 2002 /PRNewswire/
-- Comerica (NYSE: CMA), a leading financial services company, and OraSure
Technologies, Inc. (Nasdaq: OSUR), the market leader in oral fluid diagnostics,
announced today that Comerica's Technology and Life Sciences Division has
provided OraSure with a $10.9 million credit facility, composed of a $4 million
line of credit for working capital, a $3 million term loan, a $3 million credit
line for capital equipment purchases and expan... |
| | | 09/12/02 | OraSure Appoints New Executive Vice President, Marketing and Sales| BETHLEHEM, Pa., Sep 12, 2002 (BUSINESS WIRE) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced the
hiring of Joseph E. Zack as Executive Vice President, Marketing and Sales.
Mr. Zack joins OraSure Technologies with extensive marketing and sales
experience in the medical product and pharmaceutical industries.
Since 1998, Mr. Zack served as Vice President, Marketing and Sales for
OraPharma, Inc., a specialty public pharmaceutical ... |
| | | 08/28/02 | OraSure Technologies to Present At Wells Fargo Securities' Class of 2002 Conference| BETHLEHEM, Pa., Aug 28, 2002 (BUSINESS WIRE) -- OraSure Technologies, Inc.
(Nasdaq:OSUR) today announced that Mike Gausling, President and Chief Executive
Officer, will speak to the investment community at the Wells Fargo Securities'
Class of 2002 Conference in San Francisco, California.
The conference will be simultaneously webcast over the Internet.
Mr. Gausling is scheduled to speak on September 4, 2002, at approximately 3:30
p.m. Eastern Time (12:30 pm Pacific Time). Interested i... |
| | | 07/29/02 | OraSure Technologies Reports 2002 Second Quarter Results| BETHLEHEM, Pa., Jul 29, 2002 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced
that, consistent with its previous forecast, it had revenues of approximately
$7.9 million for the three months ended June 30, 2002, down 7% when compared to
revenues of $8.5 million for the three months ended June 30, 2001.
The Company also recorded a net loss of approximately $1.3 million, or ($0.03)
per share, for the three months ende... |
| | | 07/19/02 | OraSure Technologies Invites You to Join Its 2002 Second Quarter Financial Results Conference Call| BETHLEHEM, Pa., Jul 19, 2002 (BUSINESS WIRE) -- OraSure Technologies, Inc.
(Nasdaq NM:OSUR) will host a conference call with analysts and an audio webcast
to discuss the Company's second quarter 2002 financial results and certain
business developments beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific
Time) on Monday, July 29, 2002. The call will be preceded by the release of the
Company's financial results, which will occur immediately after the market
closes that day.
In order to... |
| | | 06/17/02 | Abbott And OraSure Technologies Enter Distribution Agreement For OraQuick(R) Rapid HIV-1 Test In The United States|
- Abbott To Focus On Hospital And Physician's Office Laboratory Markets; OraSure Also Sublicenses Certain Lateral-Flow Patents - ABBOTT PARK, Ill., and BETHLEHAM, Pa., Jun 17, 2002 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) and OraSure Technologies (Nasdaq:
OSUR) today announced agreements for the co-exclusive distribution of OraSure
Technologies' OraQuick(R) rapid test for the detection of antibodies to the
Human Immunodeficiency Virus Type 1 (HIV-1) and for a non-exclusive subl... |
| | | 05/20/02 | OraSure Appoints Two New Directors| BETHLEHEM, Pa., May 20, 2002 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced the
appointment of Richard J. Lane and Douglas G. Watson to the Company's Board of
Directors.
Mr. Lane has enjoyed a distinguished career in the pharmaceutical industry. Most
recently, he was Executive Vice President of Bristol-Myers Squibb and President
of its Worldwide Medicines Group, with responsibility for worldwide
pharmaceutical o... |
| | | 05/15/02 | OraSure Technologies to Webcast Annual Stockholders' Meeting| BETHLEHEM, Pa., May 15, 2002 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced that it
will webcast its 2002 Annual Meeting of Stockholders beginning at 10:00 a.m.
Eastern Time (7:00 a.m. Pacific Time) on Monday, May 20, 2002.
The formal portion of the meeting will be immediately followed by a management
presentation and a question and answer session. Persons accessing the webcast
who desire to ask questions will be permi... |
| | | 05/13/02 | OraSure Receives FDA Approvable Letter for OraQuick HIV-1 Test| BETHLEHEM, Pa., May 13, 2002 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that
it has received notification from the U.S. Food and Drug Administration ("FDA")
that the OraQuick(R) Rapid HIV-1 Antibody Test is approvable, subject to the
Company meeting certain conditions.
The OraQuick(R) test is intended to detect HIV-1 antibodies in finger stick
whole blood within 20 minutes.
Sam Niedbala, OraSure's Chief S... |
| | | 04/30/02 | OraSure Technologies Announces 2002 First Quarter Results| BETHLEHEM, Pa., Apr 30, 2002 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced its
financial results for the quarter ended March 31, 2002.
Total revenues for the quarter increased approximately 4% to $7.7 million
compared to $7.4 million for the quarter ended March 31, 2001. Product revenues
for the first quarter of 2002 increased approximately 8% to $7.5 million
compared to $6.9 million in 2001.
The Company rec... |
| | | 04/29/02 | OraSure Technologies Appoints New Vice President, Strategic Marketing| BETHLEHEM, Pa., Apr 29, 2002 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced the
hiring of William F. Bruckner as Vice President, Strategic Marketing.
Mr. Bruckner joins OraSure Technologies with extensive experience in strategic
marketing and product management. Since 2000, Mr. Bruckner served as Senior
Managing Director, Head of Marketing for Shaklee Corporation, a diversified
global consumer products company, w... |
| | | 04/19/02 | OraSure Technologies Receives FDA Clearance for Ninth Intercept Oral Fluid Drug Test| BETHLEHEM, Pa., Apr 19, 2002 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced that
it has received 510(k) clearance from the FDA for a test for detecting
benzodiazepines in oral fluid specimens, which will be available as part of the
Company's Intercept(R) laboratory-based drug testing service.
Benzodiazepines are a commonly prescribed class of tranquilizers and one of the
most frequently abused prescription drugs.... |
| | | 04/18/02 | OraSure Technologies Invites You to Join Its 2002 First Quarter Financial Results Conference Call| BETHLEHEM, Pa., Apr 18, 2002 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, will host a
conference call with analysts and an audio webcast to discuss the Company's
first quarter 2002 financial results beginning at 11:00 a.m. Eastern Time (8:00
a.m. Pacific Time) on Tuesday, April 30, 2002.
On the call will be Mike Gausling, Chief Executive Officer, Ronald H. Spair,
Chief Financial Officer, and R. Sam Niedbala, Chief Science Offi... |
| | | 04/08/02 | OraSure Technologies Receives FDA Clearance for UPlink Test System|
First FDA-Cleared Oral Fluid Point-of-Care Test -
Conference Call and Webcast Scheduled for April 11, 2002 -
BETHLEHEM, Pa.--(BW HealthWire)--April 8, 2002-- OraSure Technologies, Inc. (Nasdaq NM:OSUR), today announced that
it has received 510(k) clearance from the U.S. Food and Drug
Administration ("FDA") for its UPlink(TM) test system to detect
opiates in oral fluid.
This clearance is based on data submitted by the Company
dem... |
| | | 02/15/02 | OraSure Technologies Announces 2001 Financial Results| BETHLEHEM, Pa., Feb 15, 2002 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced revenues
of $32.6 million for the full year 2001 and $8.1 million for the quarter ended
December 31, 2001. After excluding revenues in 2000 from the discontinued Serum
Western Blot product, these amounts represent increases of 20 percent and 9
percent, respectively, over revenues reported for the same periods a year ago.
The Company's net loss ... |
| | | 02/12/02 | OraSure Technologies Invites You to Join Its 2001 Fourth Quarter and Full-Year Results Conference Call| BETHLEHEM, Pa., Feb 12, 2002 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, will host a
conference call with analysts and an audio webcast to discuss the Company's
fourth quarter and full-year financial results beginning at 11:00 a.m. Eastern
Time (8:00 a.m. Pacific Time) on Friday, February 15, 2002.
On the call will be Mike Gausling, Chief Executive Officer, Ronald H. Spair,
Chief Financial Officer, and R. Sam Niedbala, Chief ... |
| | | 02/07/02 | OraSure Technologies Submits UPlink Oral Fluid Point-Of-Care Drug Test Data To The FDA| BETHLEHEM, Pa., Feb 7, 2002 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, today announced that
it has resubmitted a 510(k) application with the U.S. Food and Drug
Administration (FDA) for its UPlink(TM) reader and related opiates oral fluid
test.
This application was filed in order to provide certain additional data requested
by the FDA in response to the Company's June 2001 510(k) submission for the
UPlink(TM) reader and five... |
| | | 02/01/02 | OraSure Technologies to Present At Emerald Groundhog Day Investment Forum| BETHLEHEM, Pa., Feb 1, 2002 (BW HealthWire) -- OraSure Technologies Inc.
(Nasdaq:OSUR) today announced that Mike Gausling, Chief Executive Officer, will
be presenting at the Ninth Annual Emerald Groundhog Day Investment Forum,
scheduled for Tuesday, February 5, 2002, at the Wyndham Franklin Plaza Hotel in
Philadelphia.
Emerald will be providing an audio feed of the entire Forum via their Internet
Web site at www.teamemerald.com/. All company presentations will be broadcast
live and wil... |
| | | 01/31/02 | Michael Gausling New OraSure Technologies CEO| BETHLEHEM, Pa., Jan 31, 2002 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, appointed Michael
Gausling as Chief Executive Officer.
He replaces Robert D. Thompson who resigned his positions as CEO and a member of
OraSure's Board of Directors to pursue other opportunities.
In addition to being named CEO, Mr. Gausling will continue as President and a
member of OraSure's Board of Directors. Mr. Gausling was a Founder and CEO o... |
| | | 01/30/02 | OraSure Technologies Announces Intercept Oral Fluid Drug Testing Solution to be Marketed by Quest Diagnostics| BETHLEHEM, Pa., Jan 30, 2002 (BW HealthWire) -- OraSure Technologies Inc.
(Nasdaq:OSUR) announced today that Quest Diagnostics, Inc. (NYSE:DGX), the
nation's leading provider of diagnostic testing, information and services, has
signed an agreement to market Intercept(R), OraSure Technologies' oral fluid
drug testing solution.
Terms of the agreement were not disclosed.
Quest Diagnostics is the nations leading provider of drugs of abuse testing,
performing more than eight million drug... |
| | | 01/25/02 | OraSure Technologies Reschedules Annual Meeting Date| BETHLEHEM, Pa., Jan 25, 2002 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq:OSUR) today announced that its 2002 Annual Meeting of Stockholders has
been rescheduled and will now be held on May 20, 2002, in Bethlehem,
Pennsylvania.
A specific meeting site will be communicated to stockholders in the proxy
materials distributed for the annual meeting. As previously announced,
stockholder proposals had to be received no later than December 20, 2001, in
order to be considered for incl... |
| | | 01/18/02 | OraSure Technologies Announces Preliminary Fourth Quarter and Full Year 2001 Results| BETHLEHEM, Pa., Jan 18, 2002 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced
preliminary revenues of approximately $8.1 million for the quarter ended
December 31, 2001, and $32.6 million for the full year 2001, which after
excluding revenues in 2000 from discontinued products, represent increases of 9
percent and 20 percent, respectively, over revenues reported for the same
periods a year ago. The Company also expects to r... |
| | | 12/07/01 | OraSure Technologies Appoints Carter H. Eckert to Board of Directors| BETHLEHEM, Pa., Dec 7, 2001 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq:OSUR) today announced the appointment of Carter H. Eckert to the
Company's Board of Directors.
This appointment increases the size of OraSure's Board to eight members.
Mr. Eckert has enjoyed a distinguished career in the pharmaceutical industry
spanning four decades. Most recently, Mr. Eckert was President and Chief
Executive Officer of Knoll Pharmaceutical Company and President of the Americas
for Kno... |
| | | 11/01/01 | OraSure Technologies Appoints New Chief Financial Officer|
BETHLEHEM, Pa.--(BW HealthWire)--Nov. 1, 2001--OraSure
Technologies, Inc. (Nasdaq:OSUR) today announced the appointment of
Ronald H. Spair to the position of Executive Vice President and Chief
Financial Officer.
Mr. Spair joins OraSure Technologies with extensive senior
financial experience in the pharmaceutical and biotechnology
industries. Mr. Spair has held the position of Chief Financial Officer
with several pharmaceutical or biotechnology companies - Delsys
Pharmaceu... |
| | | 10/26/01 | OraSure Technologies Sets Annual Meeting Date|
BETHLEHEM, Pa.--(BW HealthWire)--Oct. 26, 2001--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) today announced that its 2002
Annual Meeting of Stockholders is scheduled to be held on May 9, 2002,
in Bethlehem, Pennsylvania.
A specific meeting site will be communicated to stockholders in
the proxy materials distributed for the annual meeting.
Stockholder proposals must be received no later than December 20,
2001, in order to be considered for inclusion in the Compa... |
| | | 10/24/01 | Orasure Technologies Reports Profit On Record Revenues|
BETHLEHEM, Pa., Oct 24, 2001 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq NM:OSUR), the market leader for oral fluid diagnostics, today announced
record third quarter revenues of $8.6 million, a 19 percent increase over the
$7.2 million reported in the same period a year ago.
The net profit for the quarter was $16,000, an improvement of $7.9 million over
the third quarter of 2000, which included a one-time charge of $5.9 million for
merger-related expenses. Excluding revenu... |
| | | 10/17/01 | OraSure Technologies Invites You to Join Its Third Quarter 2001 Financial Results Conference Call on the Web, Wednesday, October 24, 2001, at 11:00 a.m. ET, 8 a.m. PT|
BETHLEHEM, Pa.--(BW HealthWire)--Oct. 17, 2001--OraSure
Technologies, Inc. (Nasdaq:OSUR) will hold a conference call with
financial analysts on Wednesday, October 24, 2001, at 11:00 a.m.
Eastern Time (8:00 a.m. Pacific), to discuss its 2001 third quarter
financial results and other matters, including certain forward-looking
statements.
On the call will be Robert Thompson, Chief Executive Officer, Mike
Gausling, President and Chief Operating Officer, Rich Hooper, Chief
Fin... |
| | | 10/05/01 | OraSure Technologies to Present at UBS Warburg Global Life Sciences Conference|
BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 5, 2001--OraSure
Technologies, Inc. (Nasdaq:OSUR) today announced that Robert D.
Thompson, Chief Executive Officer, will be presenting at the UBS
Warburg Global Life Sciences Conference on Monday, October 8, at 11:30
a.m. (Eastern).
This conference will be held at the Pierre Hotel, New York, New
York.
UBS Warburg will be providing listen-only dial-in conference lines
for public access to the presentation. Additionally, the c... |
| | | 08/31/01 | OraSure Technologies Announces Significant Additions to Management Team| BETHLEHEM, Pa., Aug 31, 2001 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq NM: OSUR) today announced two key additions to its management team - -
Salvatore Salamone as Senior Vice President, Development, and Eve Damiano as
Vice President, Regulatory Affairs.
Dr. Salamone joins OraSure Technologies with 17 years of research and
development experience at Roche Diagnostics. Dr. Salamone's most recent position
at Roche was Vice President, Research and Development, where he was respo... |
| | | 08/14/01 | CDC Selects OraSure Technologies' OraQuick as the Exclusive Rapid HIV Test for the MIRIAD Project| BETHLEHEM, Pa., Aug 14, 2001 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq NM:OSUR), announced that the Centers for Disease Control and Prevention
(CDC) has selected the OraQuick(R) rapid HIV test to be used to provide results
to pregnant women as part of the CDC funded clinical study, the Maternal Infant
Rapid Intervention at Delivery (MIRIAD) Project.
Robert D. Thompson, Chief Executive Officer of OraSure Technologies, Inc.,
stated, "We are pleased to have been chosen once aga... |
| | | 08/07/01 | OraSure Announces Rule 10b5-1 Sales Plans|
BETHLEHEM, Pa.--(BW HealthWire)--Aug. 7, 2001--OraSure
Technologies, Inc. (Nasdaq:OSUR) today announced that several
executive officers of the Company have entered into predetermined
sales plans for the purpose of selling limited amounts of their
Company stock holdings.
The plans, which were entered into pursuant to Rule 10b5-1 under
the Securities Exchange Act of 1934, will enable these officers to
diversify a small portion of their stockholdings in OraSure
Technologies,... |
| | | 07/27/01 | OraSure Technologies Reports Record Revenues|
BETHLEHEM, Pa.--(BW HealthWire)--July 27, 2001--
-Revenues Increase by 19%-
-Operating Loss Improves by $540,000-
OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader for
oral fluid diagnostics of infectious disease and drugs of abuse, today
announced record revenues for the second quarter of approximately $8.5
million compared to $7.2 million for the same period a year ago, a 19%
increase. This record was achie... |
| | | 07/20/01 | OraSure Technologies Invites You to Join Its Second Quarter 2001 Financial Results Conference Call on the Web, Friday, July 27, 2001, at 11:00 a.m. ET, 8 a.m. PT|
BETHLEHEM, Pa.--(BUSINESS WIRE)--July 20, 2001--OraSure
Technologies, Inc. (Nasdaq:OSUR) will hold its quarterly conference
call with financial analysts to discuss second quarter 2001 financial
results on Friday, July 27, 2001, at 11:00 a.m. Eastern Time (8:00
a.m. Pacific).
The call will be preceded by the release of the Company's results,
which will occur before the market opens on that day.
On the call will be Robert Thompson, Chief Executive Officer, Mike
G... |
| | | 07/13/01 | OraSure Technologies Seeks FDA Clearance for UPlink Point-of-Care Reader and Expanded Oral Fluid Drugs of Abuse Test Panel|
BETHLEHEM, Pa.--(BW HealthWire)--July 13, 2001--OraSure
Technologies, Inc. (NASDAQ NM:OSUR) today announced that it filed a
510(k) application with the U.S. Food and Drug Administration (FDA)
for its UPlink(TM) reader and six oral fluid drugs of abuse assays -
cocaine, opiates, amphetamine, methamphetamine, PCP, and marijuana.
UPlink will deliver rapid drug screen results in less than ten minutes
at the point-of-care on an oral fluid specimen. This application
supersedes the applica... |
| | | 07/11/01 | OraSure Technologies Files for Pre-Market Approval of OraQuick Rapid HIV Test|
BETHLEHEM, Pa.--(BW HealthWire)--July 11, 2001--OraSure
Technologies, Inc. (NASDAQ:OSUR) today announced that it filed
with the U.S. Food and Drug Administration (FDA) for Pre-Market
Approval of its OraQuick(R) HIV test.
OraQuick is a rapid test device that can detect antibodies to the
HIV disease within 20 minutes, and is the only rapid device in the
world designed to use oral fluid, whole blood, serum or plasma
samples.
The submittal, which is for serum and w... |
| | | 06/25/01 | OraSure Technologies and Drager Successfully Conduct First UPlink Roadside Drugs of Abuse Test in Germany| BETHLEHEM, Penn., Jun 25, 2001 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq:OSUR) headquartered in Bethlehem, Pennsylvania, and Drager
Sicherheitstechnik GmbH, located in Lubeck, Germany, today jointly announced
successful execution of the first large scale field trial of OraSure
Technologies' UPlink(TM) Drugs of Abuse Testing System in a roadside setting.
This new platform technology is the first practical test platform for on-site,
oral fluid drug testing for roadside testing... |
| | | 06/20/01 | OraSure Technologies Announces Inclusion in the Russell 3000 Index| BETHLEHEM, Pa., Jun 20, 2001 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq:OSUR) today announced that its stock has recently been included in the
Russell 3000(R) Index.
This index is compiled by the Frank Russell Company and is a ranking of the
3,000 largest U.S. stocks by market capitalization. At the close of trading on
May 31, 2001, OraSure's market capitalization was approximately $413.9 million.
"We're pleased to be included in this widely recognized market index," said
... |
| | | 06/07/01 | OraSure Technologies Announces First Preview of Uplink Technology at 2001 American Society of Microbiology Meeting| BETHLEHEM, Pa., Jun 7, 2001 (BW HealthWire) -- OraSure Technologies, Inc.
(Nasdaq:OSUR) and its partner, Meridian Bioscience, Inc., Cincinnati, Ohio
(Nasdaq:VIVO) today announced the demonstration, for the first time, of the
unique abilities of the phosphor-based UPlink(TM) technology in the detection of
infectious disease.
The results were previewed in a poster session at the 2001 American Society for
Microbiology Conference, held in Orlando, Fla.
The initial product concept, UPlin... |
| | | 05/16/01 | OraSure Technologies Announces New Intercept Drug Testing Partner|
BETHLEHEM, Penn.--(BW HealthWire)--May 16, 2001--
Deal Marks Growing Acceptance of Oral Fluid Drug Testing in
Criminal Justice and Drug Rehabilitation Markets
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that
it has signed an agreement with Comprehensive Toxicology Services
(CTS) of Tacoma, Washington, for its Intercept(TM) Oral Fluid Drug
Testing Service.
The account is expected to reach over $750,000 in annual sales for
OraSur... |
| | | 05/08/01 | OraSure Technologies Presentation At Deutsche Banc Alex. Brown Conference to be Webcast Live|
BETHLEHEM, Pa.--(BW HealthWire)--May 8, 2001--OraSure
Technologies, Inc. (Nasdaq:OSUR) today announced that Robert D.
Thompson, Chief Executive Officer of OraSure, will speak to the
investment community at Deutsche Banc Alex. Brown's 2001 Health Care
Conference in Baltimore, Maryland.
Thompson is scheduled to speak on May 10, 2001, at 8:00 a.m.
Eastern Time. Interested investors can access a live audio webcast of
the presentation and slide materials at http://www.db.com/co... |
| | | 04/30/01 | OraSure Technologies Announces First Quarter Results|
BETHLEHEM, Penn.--(BW HealthWire)--April 30, 2001--
Loss Narrows to $547,000 Excluding Non-Recurring Charges;
Manufacturing Realignment Substantially Complete
OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader for
oral fluid diagnostics of infectious disease and drugs-of-abuse, today
announced its financial results for the quarter ended March 31, 2001.
Total revenue for the quarter ended March 31, 2001, rose
approximately 12% to $7.4 m... |
| | | 04/25/01 | OraSure Technologies Appoints Gregory B. Lawless to Board of Directors|
BETHLEHEM, Pa.--(BW HealthWire)--April 25, 2001--OraSure
Technologies, Inc. (Nasdaq:OSUR) today announced the appointment of
Gregory B. Lawless to the Company's Board of Directors. This
appointment increases the size of OraSure's Board to seven members.
Since 1998, Dr. Lawless has been the Managing Partner of Collins
Mabry & Co., a strategic advisory firm for the life sciences industry,
which he co-founded. From 1992 to 1998, Dr. Lawless served as
President and Chief Execu... |
| | | 04/20/01 | OraSure Technologies Invites You to Join Its First Quarter 2001 Financial Results Conference Call on the Web, Monday, April 30, 2001, at 11:00 a.m. ET, 8:00 a.m. PT|
BETHLEHEM, Pa.--(BUSINESS WIRE)--April 20, 2001--OraSure
Technologies, Inc. (Nasdaq:OSUR) will hold its quarterly conference
call with financial analysts to discuss first quarter results for 2001
on Monday, April 30, 2001, at 11:00 a.m. Eastern Time (8:00 a.m.
Pacific). The call will be preceded by the release of the company's
results, which will occur before the market opens on that day. In
addition to the company's financial performance, the call will cover
business developments a... |
| | | 04/05/01 | OraSure Technologies Announces Large Commitment From Major Retailer For Intercept Drugs of Abuse System; Retailer To Use Oral Fluid Specimens For Workplace Drug Testing|
BETHLEHEM, Pa.--(BW HealthWire)--April 5, 2001--OraSure
Technologies, Inc. (Nasdaq:OSUR) today announced that a major retailer
has committed to use the Company's Intercept(TM) Drugs of Abuse
product.
With thousands of locations nationwide, the account is expected to
generate approximately $1.2 million in annual sales for OraSure
Technologies once the program is fully implemented.
The retailer has indicated that it will immediately begin to use
Intercept to test ... |
| | | 04/04/01 | OraSure Technologies Receives Order from Centers for Disease Control; OraQuick Device To Be Used As Part of LIFE Initiative|
BETHLEHEM, Penn.--(BW HealthWire)--April 4, 2001--OraSure
Technologies, Inc. (Nasdaq:OSUR) announced that the company has
received an initial order from the Centers for Disease Control for
118,000 OraQuick(R) HIV-1/2 devices, in conjunction with the LIFE
(Leadership and Investment in Fighting an Epidemic) Initiative.
OraQuick HIV-1/2 is a rapid test device that can detect antibodies
to the HIV disease within 20 minutes, and is the only rapid device in
the world that uses e... |
| | | 03/15/01 | CDC Selects OraQuick as One of Two Rapid HIV Tests for Treatment Investigational Device Exemption Submittal|
BETHLEHEM, Pa.--(BW HealthWire)--March 15, 2001--
OraQuick Selected After Accuracy Validated in Studies
Conducted by CDC Over Past Year
OraSure Technologies, Inc. (Nasdaq:OSUR), announced that the
Centers for Disease Control and Prevention (CDC) has selected the
OraQuick HIV-1/2 rapid HIV test to be used in the CDC sponsored
Treatment Investigational Device Exemption (IDE).
Under federal regulations, the FDA can authorize th... |
| | | 03/12/01 | OraSure Technologies UPT Technology Published in March Issue of Nature Biotechnology|
BETHLEHEM, Pa.--(BW HealthWire)--March 12, 2001--OraSure
Technologies, Inc. (Nasdaq:OSUR), announced that an article was
published in the March edition of Nature Biotechnology, which
describes the use of the Company's proprietary Up-Converting Phosphor
Technology (UPT(TM)) particles to detect DNA in microchips.
UPT particles are used to amplify and make easier the detection of
biological materials such as DNA, infectious disease markers and drugs
of abuse. In this article ... |
| | | 03/07/01 | OraSure Technologies Invites You to Join Its Discussion Regarding Recent Publication on the Company's UPT Technology, Monday, March 12, 2001, at 11:00 a.m. ET|
BETHLEHEM, Pa.--(BUSINESS WIRE)----March 7, 2001--OraSure
Technologies Inc. (NasdaqNM:OSUR) will hold a conference call to
discuss the recently published research report about OraSure
Technologies' UPT(TM) technology called, "Up-converting phosphor
reporters for nucleic acid microarrays." The article was published in
Nature Biotechnology, the premier magazine for the biotechnology
industry. Due to the important findings of this article and the
complex nature of the subject matter, O... |
| | | 02/26/01 | OraSure Technologies Announces Fourth Quarter and Year-end 2000 Results|
BETHLEHEM, Pa.--(BW HealthWire)--Feb. 26, 2001--
-- Product Revenue Up 20% --
-- First International OraQuick Shipments Initiated --
-- UPlink System FDA Submission --
OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader for
oral fluid diagnostics of infectious disease and drugs-of-abuse, today
announced its fourth quarter and full-year financial results for 2000.
OraSure Technologies was for... |
| | | 02/21/01 | OraSure Technologies Invites You to Join Its Fourth Quarter and Year-End Results Conference Call on the Web|
BETHLEHEM, Pa--(BUSINESS WIRE)--Feb. 21, 2001--OraSure
Technologies, Inc., (Nasdaq:OSUR) will hold its quarterly conference
call with financial analysts to discuss fourth quarter and full year
results for 2000 on Monday, February 26, 2001, at 11:00 a.m. Eastern
Time (8:00 a.m. Pacific). The call will be preceded by the release of
the company's results, which will occur before the market opens on
that day. In addition to the company's financial performance, the call
will cover busine... |
| | | 02/15/01 | OraSure Technologies Seeks FDA Clearance for UPlink Point-of-Care Reader|
BETHLEHEM, Pa.--(BW HealthWire)--Feb. 15, 2001--OraSure
Technologies, Inc., (Nasdaq:OSUR) today announced that it has filed a
510(k) application with the U.S. Food and Drug Administration (FDA)
for its UPlink(TM) reader and three oral fluid drugs-of-abuse assays
cocaine, opiates and amphetamines.
Two additional drugs-of-abuse assays, marijuana and PCP, are
expected to be submitted within the next two months. UPlink is
designed to be a highly sensitive, point-of-care diagnostic sys... |
| | | 02/02/01 | OraSure Technologies Appoints New Officers|
BETHLEHEM, Pa.--(BW HealthWire)--Feb. 2, 2001--OraSure
Technologies, Inc. (Nasdaq:OSUR) today announced the appointment
of Richard D. Hooper, 37, as the company's Chief Financial Officer.
Mr. Hooper's appointment follows the retirement of Charles E.
Bergeron in connection with the recent merger of Epitope, Inc., and
STC Technologies, Inc., into the Company. The Company has also named
Jack E. Jerrett as Secretary, Mark L. Kuna as Controller, and Michelle
M. Sells as Manager... |
| | | 02/01/01 | OraSure Technologies Announces Plans to Realign its Global Manufacturing Operations; Company to Relocate and Expand Manufacturing of OraQuick Product|
BETHLEHEM, Pa.--(BW HealthWire)--Feb. 1, 2001--OraSure
Technologies, Inc. (Nasdaq:OSUR) today announced plans to realign
its global manufacturing operations to maximize the operating
strengths of its facilities in the United States and add capacity
overseas.
Implementation of this strategy will result in the elimination of
the manufacturing of its OraQuick product line in the Beaverton,
Oregon facility, the installation of automated manufacturing equipment
for OraQuick in... |
| | | 01/26/01 | OraSure Announces New Intercept Drug Testing Partner; Company Also Receives FDA Clearance of Oral Fluid Assays for Barbiturates and Methadone|
BETHLEHEM, Pa.--(BW HealthWire)--Jan. 26, 2001--OraSure
Technologies, Inc. (Nasdaq:OSUR) today announced that it has signed an
agreement with a new lab partner, Bendiner & Schlesinger, Inc., of New
York, N.Y., which will offer its Intercept(TM) Oral Fluid Drug Testing
Service to the drug rehabilitation market in the New York metropolitan
area.
OraSure Technologies will be providing a turnkey solution of oral
fluid collection devices and assays to Bendiner & Schlesinger, wi... |
| | | 01/17/01 | OraSure Receives ISO Certification and CE Mark|
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 17, 2001--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) today announced that its Bethlehem
facility has received formal certification to ISO 9001, EN 46001 and
ISO 13485 standards from TUV Rheinland of North America, Inc.
TUV also granted approval for the Medical Device Directive
93/42/EEC, thereby authorizing CE Mark for the Histofreezer(R) product
line.
ISO is the recognized name for an international quality agency
working t... |
| | | 12/14/00 | OraSure Technologies Sets Annual Meeting Date|
BEAVERTON, Ore.--(BW HealthWire)--Dec. 15, 2000--OraSure
Technologies, Inc. (Nasdaq NM:OSUR) today announced that as a result
of changing from a fiscal year to a calendar year ending Dec. 31
for financial reporting purposes, the Company has changed the date set
for its next annual meeting of stockholders to June 14, 2001.
The meeting will take place in Bethlehem, Penn., which is now the
location of the executive offices for OraSure. A specific meeting site
will be communic... |
| | | 12/06/00 | OraSure Technologies Announces Another Distribution Arrangement for OraQuick Rapid HIV Test; Minimum Purchase of Over $5 Million of OraQuick Devices in the First Year|
BEAVERTON, Ore.--(BW HealthWire)--Dec. 6, 2000--OraSure
Technologies, Inc. (Nasdaq/NM:OSUR) today announced that Edison
Africa, its distributor for the OraQuick HIV device in sub-Saharan
Africa, signed an agreement with the UCB Group of Brussels, Belgium to
act as a distribution agent for this product in the physician and
family care markets in that territory.
The initial order of 100,000 units of OraQuick HIV will begin
shipping this month to Edison Africa to assist in th... |
| | | 11/08/00 | OraSure Technologies Announces Phase II Funding for Syphilis Project; NIH Approves Nearly $1 Million in Added Funding for Oral Fluid Syphilis Test|
BEAVERTON, Ore.--(BW HealthWire)--Nov. 8, 2000--OraSure
Technologies, Inc. (Nasdaq:OSUR), the market leader for oral fluid
diagnostics of infectious disease and drugs-of-abuse, today announced
that the National Institutes of Health (NIH) has approved a grant of
nearly $1 million to fund Phase II of the Company's project to develop
a test for syphilis using either blood or oral fluid samples.
This "fast-track" grant came after OraSure Technologies reached
specific milestone... |
| | | 10/30/00 | OraSure Technologies, Inc. Announces First Combined Results; Merger of Epitope, Inc. and STC Technologies Completed in the Quarter|
BEAVERTON, Ore.--(BW HealthWire)--Oct. 30, 2000--OraSure
Technologies, Inc. (Nasdaq:OSUR), the market leader for oral fluid
diagnostics of infectious disease and drugs-of-abuse, today announced
financial results for the third quarter and first nine months of
fiscal year 2000, as well as financial objectives for 2001.
Quarterly revenues of $7.2 million represent a 9.3 percent
increase over the prior year's comparable quarter of $6.6 million.
Revenues for the first nine mont... |
| | | 10/23/00 | OraSure Technologies Announces First International Order for OraQuick Rapid HIV Test| First Clinical Trial Results Available
BEAVERTON, Ore.--(BW HealthWire)--Oct. 23, 2000--OraSure Technologies, Inc. (Nasdaq:OSUR - news) today announced its first international order for the unique OraQuick® HIV-1/2 rapid test.
The OraQuick product detects HIV disease from an oral fluid sample within 20 minutes after collection.
The initial order of 100,000 units came from Edison Africa (S.A.) (Pty) Ltd., OraSure Technologies' new distributor in South Africa. OraSure Technologies exp... |
| | | 10/06/00 | OraSure Technologies Appoints Alan ''Kip'' Whitefield New Vice President, Insurance Sales| Whitefield to Lead Company's Sales and Marketing Efforts to Insurance Industry
BEAVERTON, Ore.--(BW HealthWire)--Oct. 6, 2000--OraSure Technologies, Inc. (Nasdaq:OSUR - news) today announced that Alan ``Kip'' Whitefield has been appointed Vice President, Insurance Sales, effective October 16, 2000.
Whitefield brings 35 years of experience in the insurance-related services industry to his new position at OraSure. He will be responsible for sales and marketing of OraSure products to the do... |
| | | 09/29/00 | Epitope and STC Technologies Merger Approved| New Company Created -- OraSure Technologies, Inc.
BEAVERTON, Ore.--(BW HealthWire)--Sept. 29, 2000--Epitope, Inc. (Nasdaq:EPTO) today completed its merger with STC Technologies, Inc. (STC), a closely held private company based in Bethlehem, Pennsylvania, as stockholders of both companies voted in favor of the merger in separate meetings.
The agreement, which was approved by the board of directors of both companies and announced in May of this year, is a $260 million, all-stock deal which... |
| | | 08/31/00 | Epitope's Merger Partner STC Technologies Signs With Meridian Diagnostics to Commercialize Rapid Infectious Disease Tests| BEAVERTON, Ore.--(BW HealthWire)--Aug. 31, 2000--Epitope, Inc., (Nasdaq:EPTO) its proposed merger partner, STC Technologies, Inc., and Meridian Diagnostics, Inc. (Nasdaq:KITS) announced today that they have entered into multi-year, multi-million dollar exclusive Research and Supply Agreements to develop, manufacture, and sell a broad range of point-of-care tests for the rapid detection of parasites, gastrointestinal, and upper respiratory diseases.
The tests will utilize Up-Converting Phosp... |
| |
|
Print Page | 
E-mail Page | 
RSS Feeds | 
E-mail Alerts | 
IR Contacts | 
Financial Tear Sheet